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ABSTRACT OF THE DISSERTATION
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Professor Jeffrey I. Gordon, Chair
Undernutrition is a pressing and pervasive global health problem. The pathogenesis of this dis-
ease remains unclear, but epidemiologic studies indicate that it is not due to food insecurity alone. 
dependent studies have demonstrated that the normal postnatal pattern of gut microbiota develop-
ment is disrupted in children with undernutrition, leading to the proposal that perturbations in gut 
microbiota development impairs healthy growth of the host. Human breast milk contains a diverse 
repertoire of free and conjugated human milk oligosaccharides (HMOs) frequently decorated with 
fucose and/or sialic acid moieties. HMOs are not absorbed in the proximal gut and function as 
prebiotics that promote colonization of the infant gut with bacterial strains associated with numer-
improved vaccine responses). To date, the relationships between the overall abundance of breast 
milk HMOs, development of a healthy gut microbiota, and the growth phenotypes of infants and 
children have not been well characterized. The central hypotheses of my thesis are that (i) the gut 
microbiota plays a key role in supporting healthy growth and metabolism in infants and children, 
(ii) perturbations in microbiota function are causally related to undernutrition in infants and chil-
xii
dren, (iii) the representation of HMO species in mothers’ milk is significantly correlated with the 
nutritional status and growth outcomes of their offspring (as defined by anthropometry), and (iv) 
HMOs promote growth and modulate metabolism through microbiota-dependent mechanisms and 
may yield new therapeutic agents for treating and ultimately preventing undernutrition. My thesis 
is presented in four chapters.
The first chapter is presented as a perspective, describing the relationship between pertur-
bations in postnatal development/maturation of the gut microbiota and childhood undernutrition. 
This chapter describes hypotheses and experimental models for performing proof-of-concept ex-
periments that test the causal role of the gut microbiota, milk glycans, and interactions between 
these components in modulating host metabolism and growth.
Chapter two describes a set of experiments that involve transplanting fecal microbiota from 
Malawian infants and children (manifesting healthy growth or varying degrees of undernutrition) 
into young germ-free mice fed a representative Malawian diet. These studies revealed that imma-
ture microbiota from severely stunted/underweight donors transmit impaired growth phenotypes 
as compared to microbiota from healthy donors. The representation of several taxa in the micro-
biota of recipient animals correlated with lean body mass gain, bone morphology, and metabolic 
phenotypes in liver, muscle, and brain. Furthermore, co-housing these ‘humanized’ gnotobiotic 
mice shortly after colonization revealed that invasion of bacterial taxa from mice harboring a 
healthy infant’s microbiota to cagemates harboring an immature microbiota from a stunted/under-
weight donor ameliorated growth faltering. These results indicate that gut microbiota immaturity 
is causally related to undernutrition.
The third chapter begins by defining the relationship between infant growth outcomes and 
breast milk HMO content in two independent Malawian birth cohorts. Analysis of human milk 
oligosaccharides from 6-month postpartum Malawian mothers revealed that sialylated HMOs are 
significantly less abundant in milk from mothers with severely stunted infants. This chapter then 
describes the effects of sialylated milk oligosaccharides on growth and metabolism using young 
xiii
gnotobiotic mice and newborn gnotobiotic piglets. In both cases, animals were colonized with a 
sequenced bacterial culture collection generated from a severely stunted Malawian infant, and 
fed a prototypic Malawian diet with and without supplementation using a purified preparation of 
sialylated bovine milk oligosaccharides (S-BMO). S-BMO produced a microbiota-dependent aug-
mentation of body weight and lean body mass gain, changed bone morphology, and altered liver, 
muscle, and brain metabolism in ways indicative of a greater ability to utilize nutrients for anabo-
lism. These two preclinical models establish a causal microbiota-dependent relationship between 
S-BMO and growth promotion.
Chapter four details future research directions, including experimental approaches for de-
termining the microbial dependencies of S-BMO mediated growth and identifying bioactive struc-
tures present in S-BMO. Finally, this chapter describes the potential for and challenges facing the 
use of dietary milk oligosaccharide supplements to treat childhood undernutrition.
1Chapter 1
Introduction
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Cultivating Healthy Growth and Nutrition through the Gut Microbiota
Sathish Subramanian1,2, Laura V. Blanton1,2, Steven A. Frese3, Mark Charbonneau1,2, David A. 
Mills3, Jeffrey I. Gordon1,2
1Center for Genome Sciences and Systems Biology, Washington University School of Medicine, 
St. Louis, MO 63108, USA
2Center for Gut Microbiome and Nutrition Research, Washington University School of Medicine, 
St. Louis, MO 63108, USA
3Departments of Food Science & Technology and Viticulture & Enology, University of California, 
Davis, Davis, CA 95616, USA
This chapter corresponds to the complete and accepted version of a manuscript published as:
Subramanian, S. et al. Cultivating Healthy Growth and Nutrition through the Gut Microbiota. Cell 
161, 36–48 (2015).
3Abstract
Microbiota assembly is perturbed in children with undernutrition, resulting in persistent micro-
biota immaturity that is not rescued by current nutritional interventions. Evidence is accumulat-
ing that this immaturity is causally related to the pathogenesis of undernutrition and its lingering 
sequelae. Preclinical models in which human gut communities are replicated in gnotobiotic mice 
have provided an opportunity to identify and predict the effects of different dietary ingredients on 
microbiota structure, expressed functions, and host biology. This capacity sets the stage for proof-
of-concept tests designed to deliberately shape the developmental trajectory and configurations of 
microbiota in children representing different geographies, cultural traditions, and states of health. 
Developing these capabilities for microbial stewardship is timely given the global health burden of 
childhood undernutrition, the effects of changing eating practices brought about by globalization, 
and the realization that affordable nutritious foods need to be developed to enhance our capacity to 
cultivate healthier microbiota in populations at risk for poor nutrition.
Introduction
Understanding the determinants of the nutritional value of different foods has never been more 
important, with population stabilization being unlikely this century (Gerland et al., 2014) and 
growing challenges related to sustainable agriculture. An integral part of understanding how best 
to deliver nutritious food to a burgeoning population is understanding how the microbial commu-
nity in our gut (the microbiota) is shaped by what we eat and how that community in turn shapes 
our development and health. Nowhere will this kind of insight be more crucial than in raising the 
world’s children.
Current obstacles to achieving healthy and productive lives and societies are reflected in 
the United Nations’ millennium development goals that include reductions in child mortality and 
hunger and improvements in maternal health (http://www.un.org/millenniumgoals/). The scope of 
the problem of childhood undernutrition is described by parameters such as the International Food 
Policy Research Institute’s Global Hunger Index (http://www.ifpri.org/publication/2014-global-
4hunger-index), which is an aggregate measure of calorie intake plus the rates of children being 
underweight and childhood mortality within a given region or country.
Much has been said about how changing patterns of food preferences brought about by 
economic development, globalization, and changes in food technology and food distribution sys-
tems are producing dramatic changes in how, what, and when we eat. These changes, combined 
with rapid population expansion and issues related to sustainable agriculture, create the need and 
the opportunity to drive innovation in the area of identifying new, affordable, and nutritious foods. 
Here, we focus on the importance of understanding the postnatal developmental biology of our 
gut microbial community—a highly adaptable microbial “organ” that is critically involved in the 
biotransformation of foods to products that can shape many aspects of human biology. In our view, 
studies of human gut microbial communities will markedly revise current thinking about many as-
pects of human nutrition. The knowledge gained could and should catalyze efforts to integrate ag-
ricultural policies, food production, and nutritional recommendations for consumers representing 
different ages, cultural traditions, and geographies. Preclinical research platforms are now avail-
able to evaluate the effects of foods that we currently consume and those that we envision creating 
in the future on the gut microbial community and host biology in ways that can inform clinical 
studies. Furthermore, studies of children with undernutrition are highlighting the importance of 
postnatal development of the gut microbiota for achieving healthy growth and providing us with a 
new set of metrics to define the efficacy of nutritional recommendations and interventions directed 
at infants, the maternal-infant dyad, and children. Finally, we emphasize the importance of ad-
dressing ethical, social, and regulatory issues related to research in this area now rather than later.
Defining Human Postnatal Development from a Microbial Perspective
The human gut microbiota is composed of all three domains of life; Bacteria, which predominate, 
Archaea, and Eukarya, plus viruses. The gut microbiota is composed of relatively few bacterial 
phyla compared to communities in other body habitats and is notable for its strain-level diversity. 
Application of low-error sequencing methods to PCR amplicons generated from the bacterial phy-
5logenetic marker gene encoding the principal RNA in the small subunit of ribosomes (16S rRNA) 
has indicated that, once acquired, the majority of bacterial strains in a healthy adult are retained for 
long periods of time (Faith et al., 2013). Thus, early colonizers, once established in the gut ecosys-
tem, have the potential to exert their effects on our biological features and health status for most 
and perhaps all of our adult lives. This latter finding emphasizes the importance of understand-
ing whether there is a definable program of community assembly in healthy infants/children and 
whether such a program is shared or varies considerably across populations with distinct dietary 
habits and culinary traditions residing in different geographic locations. If such a developmental 
program were definable and a significant contributor to healthy growth, fostering its proper and 
full execution could represent the basis of an arm of preventive medicine designed to ensure long-
term health through informed microbial stewardship.
Food is a major factor that shapes the proportional representation of microorganisms pres-
ent in the gut microbiota and the relative abundance of its genes (the microbiome). Reciprocally, 
the configuration of the microbiota/microbiome influences the nutritional value of food. One il-
lustration of this interrelationship comes from a culture-independent metagenomic analysis of the 
gut microbiomes of infants, children, and adults belonging to 150 families living in three countries 
located on three different continents (metropolitan areas of the USA plus rural villages in southern 
Malawi and the Amazonas state of Venezuela). The results revealed that the relative abundances 
of genes in the microbiome that are related to vitamin biosynthesis (e.g., folate, cobalamin, thia-
mine, and biotin), amino acid metabolism, and processing of complex polysaccharides change in 
an identifiable sequence during the postnatal period (Yatsunenko et al., 2012). In addition, differ-
ences between Westernized (USA) and non-Westernized populations were evident, with breastfed 
Malawian and Amerindian babies having higher relative abundances of microbial genes encoding 
enzymes involved in carbohydrate metabolism, vitamin biosynthesis (e.g., components of the bio-
synthetic pathway for riboflavin, a component of breast milk, dairy products, and meat), and ure-
ase (Yatsunenko et al., 2012). Urea represents up to 15% of breast milk nitrogen; its degradation 
to ammonia can be used for microbial biosynthesis of essential amino acids, potentially benefiting 
6both the microbiota and host when diets are deficient in protein. Significant differences in microbi-
ome configuration were also observed between breast-fed and formula-fed infants, with the latter 
showing increased representation of genes involved in various aspects of carbohydrate and amino 
acid metabolism and cobalamin (vitamin B12) biosynthesis (Yatsunenko et al., 2012). Cobalamin 
is not only important for the host; the ability to transport cobalamin and other substituted corrins is 
an important determinant of survival for members of the microbiota (Degnan et al., 2014).
Together, these findings suggested that the gut community should be considered when 
assessing the nutritional requirements at different stages of the human life cycle and in different 
geographic/cultural settings. They also raised the question of whether perturbations in the func-
tional development of the microbiota/microbiome were related to childhood undernutrition, the 
major cause of childhood deaths worldwide and a manifestation of a complex set of still poorly 
understood intra- and intergenerational factors, rather than food insecurity alone (Lazzerini et al., 
2013, Caulfield et al., 2014 and Richard et al., 2014).
Undernutrition and Gut Microbiota Immaturity
The World Health Organization’s (WHO) Multi-Center Growth Reference Study (http://www.
who.int.beckerproxy.wustl.edu/childgrowth/mgrs/en/) defines three anthropometric (physical) pa-
rameters (weight-for-age, height-for-age, and weight-for-height Z scores) to describe normal early 
childhood growth and nutritional status from its evaluation of 8,440 infants and children living in 
six distinct sites around the world (USA, Oman, Norway, Brazil, Ghana, and India). A recent study 
provided another definition of healthy growth but from a microbial perspective (Subramanian 
et al., 2014). It did so by examining gut microbiota assembly in 50 children residing in Dhaka, 
Bangladesh whose anthropometry during their first 2 years of life indicated healthy growth. Fecal 
samples were collected monthly from birth through the end of the second postnatal year, and the 
relative abundances of bacterial strains were analyzed by 16S rRNA amplicon sequencing. The re-
sults revealed that interpersonal variation in the bacterial component of their gut communities was 
significantly smaller than the variation associated with age. Applying Random Forests, a machine-
7learning method, to regress relative abundances of bacterial taxa across these children revealed 
age-discriminatory bacterial strains. Separating these 50 children into training and validation co-
horts, the regression was optimized to include the most informative taxa for accurate prediction of 
microbiota “age.” The results were formally validated to prevent over-fitting and over-estimation 
of generalizability and produced a sparse model composed of 24 strains that could be used in ag-
gregate as a microbial signature for describing a shared program of microbiota development in 
healthy individuals and two derived metrics for defining deviations from that normal program: 
“relative microbiota maturity” and “microbiota-for-age” Z (MAZ) score (Figure 1).
Severe acute malnutrition (SAM) is defined by weight-for-height Z (WHZ) scores more 
than 3 SDs below the median of children in the WHO reference cohort. Application of this sparse 
model to 64 Bangladeshi children with SAM (WHZ −4.2 ± 0.72 [SD]) revealed they had gut mi-
crobiota that appeared significantly “younger” than their chronological age (relative microbiota 
maturity of −6 ± 0.7 months and MAZ scores of −1.7 ± 0.2). Moreover, this immaturity was in-
completely and only transiently rescued following a customary period of administration of either 
one of two types of ready-to-use therapeutic foods (RUTFs; typically given for 2 weeks until a 
15% increase in weight gain is achieved; http://www.ClinicalTrials.gov, number NCT01331044). 
Bangladeshi children with moderate acute malnutrition (WHZ between −3 and −2) also exhibited 
significant microbiota immaturity, although less severe than children with SAM (Subramanian et 
al., 2014). These results indicate that children with SAM have a persistent developmental abnor-
mality affecting their gut microbial “organ” that is not durably repaired with existing therapy.
These observations raise a critical question: is microbiota immaturity a cause or an effect of 
childhood undernutrition? Many studies have shown that, although current protocols for treating 
children with (acute) undernutrition reduce mortality, they do not rescue its long-term morbidi-
ties, including stunting, immune dysfunction, and neurodevelopmental abnormalities (Victora et 
al., 2008, Gaayeb et al., 2014, Kosek et al., 2013 and Galler et al., 2012). For example, given the 
remarkable metabolic requirements of the neonatal brain, alterations in the normal postnatal de-
8velopment of the gut microbiota may trigger marked impairments in brain development and lead 
to persistent disorders of cognition.
Support for a causal role for the gut microbiota in SAM comes from studies of gnotobi-
otic mice. In recent years, methods have been developed for transplanting previously frozen fecal 
samples from human donors into groups of germ-free mice at a selected stage of their lives (e.g., 
young, rapidly-growing animals that have been recently weaned or older animals) and with a 
designated genetic background. If the human microbiota sample is frozen shortly after it is pro-
duced and maintained at −80°C, the bacterial strains represented in the donor’s community can be 
transmitted efficiently and reproducibly to recipient mice (e.g., Turnbaugh et al., 2009a, Smith et 
al., 2013, Ridaura et al., 2013, Palm et al., 2014 and Kau et al., 2015). The recipient mice can be 
fed diets that contain ingredients used in foods consumed by the microbiota donor. Moreover, the 
ingredients and methods for preparing (cooking) such diets can be varied systematically. This ap-
proach allows myriad types of models to be constructed for studying the interaction of foods and 
the human gut microbiota in vivo. For example, diets can be given that are representative of those 
consumed by populations other than those of the donor to anticipate the effects of changes in food 
consumption patterns associated with Westernization or composed of ingredients that represent 
new potential sources of affordable, nutritious foods such as landraces and waste streams from cur-
rent food manufacturing processes. Critically, these preclinical gnotobiotic animal models allow 
proof-of-concept tests of whether a donor phenotype is transmissible via his/her gut microbiota, 
the extent to which phenotypic transmission generalizes across different donor microbiota, and 
the sensitivity or robustness of phenotypic transmission to diet type. These preclinical models also 
permit simulations of existing or anticipated therapeutic interventions, including the opportunity 
to “randomize” a given individual’s microbiota to not just one but multiple treatment arms in order 
to directly compare the effect (and effect size) of the treatments on both the microbiota and host, to 
characterize underlying mechanisms, and to identify surrogate- or mechanism-based biomarkers 
that could be translatable to the microbiota donor or donor population (Figure 2).
Transplanting fecal microbiota from same-gender Malawian twins discordant for kwashior-
kor, a form of SAM, into separate groups of adult germ-free mice and feeding the recipient animals 
9a representative micro- and macronutrient-deficient Malawian diet disclosed that the healthy and 
kwashiorkor co-twins’ microbiota transmitted discordant weight loss and metabolic phenotypes 
(as well as an enteropathy characterized by disruption of the small intestinal and colonic epithelial 
barrier in animals harboring kwashiorkor but not healthy microbiota) (Smith et al., 2013 and Kau 
et al., 2015). Unlike the transplanted healthy co-twins’ microbiota, the kwashiorkor microbiota 
was structurally and metabolically labile, reconfiguring itself upon exposure to a peanut-based 
RUTF, but not in a sustained way when animals were returned to the Malawian diet. The combina-
tion of a nutrient-deficient Malawian diet and a kwashiorkor microbiota was required to produce 
pathology in the recipient “humanized” mice, including inhibition of steps within the tricarboxylic 
acid cycle in host cells (Smith et al., 2013). These findings not only provided evidence for a causal 
relationship between the gut microbiota and SAM but also highlighted the importance of diet-by-
microbiota interactions in disease pathogenesis.
If we consider children with persistent microbiota immaturity from the perspective of de-
velopmental biology, we can pose a number of basic and applied scientific questions. One question 
is whether the developmental program defined in Bangladeshi infants and children is generalizable 
to other populations representing different geographic and cultural settings. If so, it would reveal a 
fundamental shared aspect of postnatal human development and raise mechanistic questions about 
the factors that specify a healthy microbial community “fate.” Initial support for generalizability 
comes from an analysis of concordant healthy Malawian twin pairs, which showed that a number 
of the age-discriminatory bacterial strains with the highest feature importance scores in the Ban-
gladeshi Random Forests model are also represented in the Malawian population (Subramanian 
et al., 2014 and Yatsunenko et al., 2012). The designation “same strain” was based on the same 
16S rRNA sequence; whole-genome sequencing of a given age-discriminatory strain identified by 
its 16S rRNA sequence will be needed to determine its degree of gene conservation across dif-
ferent Bangladeshi and Malawian hosts. Bacterial 16S rRNA analyses of fecal samples obtained 
at monthly intervals from infants and children with healthy growth phenotypes enrolled in birth 
cohorts living at multiple low-income countries allow country/community site-specific, Random-
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Forests-based models of microbiota maturation to be constructed, as well as an aggregate model 
representing data pooled from all sites. “Generalizability” can be established through reciprocal 
tests of the accuracy of the site-specific models (and aggregate model) for healthy individuals 
living at the different sites and whether these models reveal similar relationships between anthro-
pometry and relative microbiota maturity/MAZ scores for undernourished children living at each 
of these sites.
A second question has to do with the relationship between microbiota development, en-
teropathogen load, and environmental enteric dysfunction (EED, also known as environmental en-
teropathy), an enigmatic and as-yet incompletely defined disorder of gut barrier function (Keusch 
et al., 2014 and Kosek et al., 2014). Does a primary failure to execute normal maturation of the 
microbiota directly influence risk for enteropathogen invasion, perturbations in development of 
mucosal immune system, and abnormalities in nutrient processing and absorption that ultimately 
results in growth faltering? Alternatively, is a holistic view required that considers each of these 
features of enteric biology as intimately and integrally related to one another? Large birth cohort 
studies such as MAL-ED and GEMS have provided an opportunity to measure the contributions 
of enteropathogen load/carriage and diarrheal incidence to growth faltering (MAL-ED Network 
Investigators, 2014, Platts-Mills et al., 2014 and Kotloff et al., 2013). Evidence is emerging that 
some of the age-discriminatory taxa that define normal microbiota maturation also protect the host 
from enteropathogen infection. Intriguingly, studies of Bangladeshi adults with acute cholera have 
shown that recovery from the diarrheal phase involves recapitulation of the sequence of appear-
ance of the same age-discriminatory bacterial strains that define the normal pattern of assembly 
of the microbiota in healthy Bangladeshi infants/children, suggesting that an essential set of rules 
governs this assembly (successional) process (Hsiao et al., 2014). For example, Ruminococcus 
obeum, a bacterium that directly correlates with recovery from Vibrio cholerae infection in adult 
Bangladeshi subjects and defines later stages of normal gut microbiota maturation in healthy Ban-
gladeshi children, restricts V. cholerae colonization of gnotobiotic mice harboring a representative 
human gut microbiota. Its mechanism involves production of an autoinducer-2 (AI-2) that causes 
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quorum-sensing mediated repression of V. cholerae colonization and virulence factor expression 
(Hsiao et al., 2014).
A third related question is the manner in which the mucosal immune system and the micro-
biota co-develop. How do these complex organs talk to and educate each other? The answers could 
help identify factors that legislate a normal developmental trajectory for a gut community and how 
developmental arrest of the microbiota could be become fixed and difficult to overcome/advance. 
Immaturity of the microbiota may be associated with relative immaturity of mucosal immunity in 
ways that impede responsiveness to vaccines or enteropathogens. If so, can we use members of the 
microbiota as next-generation adjuvants to prime the immune system in the context of a defined 
antigen (Yilmaz et al., 2014)? One way to characterize maturation of the mucosal immune system 
is to use fluorescence-activated cell sorting (FACS) to identify microbial taxa targeted by its IgA re-
sponses as a function of chronologic age in hosts with healthy growth phenotypes and in those with 
undernutrition (critically, IgA targeting is not simply a reflection of the abundances of organisms 
in the gut community; Kau et al., 2015). This method, named BugFACS, has identified bacterial 
targets of gut mucosal IgA responses using fecal samples from children with healthy growth phe-
notypes or those with varying degrees of undernutrition, as well as fecal samples harvested from 
gnotobiotic mice harboring transplanted microbiota from healthy and undernourished donors fed 
diets representative of those that these children consume. BugFACS-purified viable IgA-targeted 
bacterial taxa were subsequently introduced into germ-free animals fed nutrient-deficient or -suf-
ficient diets to characterize their functional properties. The results disclosed that IgA responses to 
members of the microbiota can be used as biomarkers of growth faltering, that they are influenced 
by enteropathogen load, and that they mediate a diet-dependent enteropathy characterized by small 
intestinal and colonic epithelial barrier disruption. Moreover, treatment with IgA-targeted bacterial 
strains purified from healthy donor microbiota can prevent development of the enteropathy (Kau et 
al., 2015), indicating that this approach may have utility that extends beyond diagnostics to thera-
peutic lead discovery and defining mechanisms underlying EED pathogenesis.
A fourth and critical question is whether age-discriminatory taxa are not only just bio-
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markers but also effectors of growth. If so, they become potential therapeutic agents and targets 
for manipulation, including food-based manipulations that allow for their establishment in an in-
dividual or population at the time of presentation with manifest disease or prior to that time. One 
way we are currently determining whether age-indicative taxa are also growth indicative is by 
transplanting microbial communities from children exhibiting varying degrees of growth falter-
ing (defined by anthropometry), representing a particular geographic region, into young, actively 
growing germ-free animals fed diets representative of the donor population and then defining the 
effects of the different transplanted communities on the growth, metabolic and immunologic phe-
notypes of recipient gnotobiotic mice (Figure 2). 16S rRNA data sets generated from the animals’ 
fecal samples can be used to correlate strain abundances to these phenotypes. These strains can 
then be cultured from the microbiota of different donor populations. Determining the effects of 
subsequently introducing these strains—singly or as components of defined consortia—into young 
gnotobiotic mice harboring microbiota from different undernourished donors represents a way to 
address several challenges that would be faced when designing and interpreting a clinical study. 
For example, these preclinical studies could help to (1) define criteria used to select strains beyond 
their feature importance scores in the Random Forests models and cultivability (e.g., the extent 
of representation of virulence determinants in their genomes); (2) assess how to encapsulate these 
organisms, including anaerobes, in ways that permit their long-term storage and viability; (3) de-
termine the extent to which consortia can invade and establish themselves in different microbiota 
representing individuals from a given population or different populations; (4) assess the nature of 
their effects on growth (e.g., gain of lean body mass), metabolism, and gut barrier function as a 
function of the degree of donor undernutrition and microbiota immaturity; and (5) ascertain the 
degree to which invasion and establishment of these strains in the targeted microbiota and their 
host effects are impacted by diet. Determining whether these strains are interchangeable between 
countries will influence the generalizability of microbial interventions or whether there would 
have to be local sourcing of these biological resources by or for the communities who are them-
selves afflicted by undernutrition.
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Establishing Microbiota and the Maternal Influence
The origins of the microbes that colonize an infant’s gastrointestinal tract are complex, given that 
infants are exposed to different environmental sources. A major source is the mother and includes 
microbes from her vagina, skin, gut, and as some have reported, breast milk and possibly the pla-
centa (Dominguez-Bello et al., 2010, Hunt et al., 2011, Grönlund et al., 2011, Cabrera-Rubio et al., 
2012 and Aagaard et al., 2014).
A key knowledge gap relates to the “anthropology of microbes”: knowing how practices 
associated with pregnancy, including micronutrient supplementation, as well as traditional (and 
changing) societal “prescriptions” for dietary practices, impact a mother’s microbial ecology prior 
to and following parturition and how this may impact transmission of her microbes to her infant. 
A study of 91 pregnant Finnish women showed that the maternal microbiota changes between the 
first and third trimester (Koren et al., 2012) (Figure 3). Another analysis of Bangladeshi mothers 
revealed marked changes in their gut microbiota in the first month post-partum, followed by less 
substantial changes in the ensuing nine months (Subramanian et al., 2014). One testable hypoth-
esis is that the maternal microbiota, much like the infant microbiota, undergoes stereotypical al-
terations during normal pregnancy designed to enhance maternal health and to promote transfer of 
strains to the infant. Testing this hypothesis will require detailed time series sampling of maternal 
microbiota throughout pregnancy and of the maternal-infant dyad, plus other environmental sourc-
es, including other family members and caregivers. If a program of pregnancy-associated changes 
in the maternal gut microbiota can be identified using approaches analogous to those described 
above to characterize maturation of the infant microbiota, it could provide an opportunity to use 
the most indicative or transmissible taxa as biomarkers of nutritional status and as reporters of the 
effects of different dietary practices or the efficacy of prescribed prenatal nutritional interventions.
Pregnancy is also a time of increased susceptibility to infection. Rowe et al. (2011) demon-
strated that pregnant mice show increased bacterial burden in models of Listeria monocytogenes 
and Salmonella typhimurium infection, mediated via active immune suppression by a population 
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of FoxP3+ regulatory T cells (Tregs). Moreover, ablation of the Treg compartment resulted in 
near-complete resorption of fetuses, indicating a delicate balance between immunological toler-
ance of the fetus and defense against enteropathogens (Rowe et al., 2011). It is not known how this 
period of deliberate immune suppression impacts the maternal microbiota and, in turn, transfer of 
pathogens (and other microbial community members) to the infant.
The Impact of First Foods
Breast Milk
The association between healthy postnatal growth and exclusive breastfeeding has led to the 
WHO’s recommendation for a minimum of six months of exclusive breastfeeding (Kramer and 
Kakuma, 2002). Human milk is composed of lipids (tri-, di-, and monoglycerides, phospholipids, 
glycolipids, and free fatty acids), protein components (including immunoglobulins, lactoferrin, 
lysozyme, and cytokines), and a large repertoire of human milk oligosaccharides (HMOs). Over 
time, this composition changes from colostrum, which is HMO rich, to mature milk, which con-
tains fewer HMOs and protein while the fat content remains relatively stable (Coppa et al., 1993 
and Lemons et al., 1982).
HMOs and other milk glycoconjugates pass undigested through the proximal gut (Engfer 
et al., 2000) and serve as nutrient substrates for saccharolytic microbiota in the colon. The micro-
biota of healthy exclusively breastfed infants is dominated by members of the genus Bifidobac-
terium (Figure 1; Yatsunenko et al., 2012 and Subramanian et al., 2014). These infant-associated 
bifidobacteria, notably Bifidobacterium longum subsp. infantis, possess a suite of genes involved 
in importing complex fucosylated and sialylated milk glycans, their further degradation, and sub-
sequent utilization (Sela et al., 2008). The functions encoded by this suite of genes allow them to 
outcompete other saccharolytic taxa (Marcobal et al., 2010). Bifidobacteria also actively reshape 
milk composition. For example, they release N-linked glycans conjugated to milk glycoproteins 
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for use as a growth substrate. However, the effect of deglycosylation on milk protein digestibility 
and function is as-yet unknown (Garrido et al., 2012 and Garrido et al., 2013).
Colonization by Bifidobacterium species during nursing is associated with a range of ben-
efits, including improved vaccine responses (Huda et al., 2014) and enhanced gut barrier function 
(Ewaschuk et al., 2008 and Weng et al., 2014), including stabilized epithelial tight junctions noted 
in both animal models (Bergmann et al., 2013) and human cell lines (Chichlowski et al., 2012). 
Recent work has shown that infants with high Bifidobacterium population densities exhibit a cor-
responding decrease in fecal milk glycans (De Leoz et al., 2015 and Wang et al., 2015), a relation-
ship that could serve as the basis for developing inexpensive diagnostics to monitor development 
of a healthy gut microbiota in nursing infants.
Development of a healthy infant gut microbiota can be threatened by maternal undernutri-
tion and premature birth. Maternal undernutrition during pregnancy increases risk for underweight 
and preterm births (Kramer et al., 1992). Children of undernourished mothers receive substantially 
less than the recommended intake of priority micronutrients during lactation (Allen, 2005). Forti-
fied milk obtained from donors who have had a full-term pregnancy likely does not provide suf-
ficient protein to preterm infants (Arslanoglu et al., 2009). Even when mothers of preterm infants 
can produce sufficient milk, alterations in milk fat, protein, oligosaccharide content (Weber et al., 
2001 and De Leoz et al., 2012), and the repertoire of immunoactive components (Castellote et al., 
2011) are observed, leading to a call for identifying additional elements for nutritional support of 
these infants (Gabrielli et al., 2011 and De Leoz et al., 2012).
A vicious cycle of maternal undernutrition and poor infant nutritional status can reflect 
alterations in the immune, HMO, and/or other components of mother’s milk. This has critical 
implications for infant health. Poor maternal health is associated with variations in breast milk im-
munoglobulins and glycoprotein structures during lactation (Smilowitz et al., 2013) and with de-
creased lactoferrin, a protein with antimicrobial activities (Hennart et al., 1991). Parasite-specific 
breast milk IgA titers to Entamoeba histolytica and Cryptosporidium spp. correlate with nutritional 
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status in a Bangladeshi infant population in which the burden of infection with these enteropatho-
gens is very high (Korpe et al., 2013). Preterm delivery is associated with atypical variations in 
milk glycan structures (De Leoz et al., 2012), which poses additional risks. As HMOs have struc-
tural similarities to epithelial cell surface and mucus glycans, they can have anti-adhesive effects 
on enteropathogens. Sialic acid or fucose moieties are key determinants of this activity. Thus, 
variations in fucosylated HMOs associated with preterm birth may reduce the efficacy of milk 
oligosaccharides as anti-adhesive decoy molecules for pathogens (Ruiz-Palacios et al., 2003 and 
Jantscher-Krenn et al., 2012).
Understanding how breast milk glycan repertoires correlate with normal microbiota as-
sembly and with impaired microbiota maturation and undernutrition provides an opportunity to 
identify new glycan streams that could be used to treat undernourished infants. Commercial pre-
biotics are commonly added to infant formula, where they increase Bifidobacteria titers in infant 
feces (Haarman and Knol, 2005, Knol et al., 2005 and Boehm et al., 2002) and lower the incidence 
of pathogens (Knol et al., 2005). However, current prebiotics, namely fructooligosaccharides and 
galactooligosaccharides, do not represent the constellation of complex glycan structures delivered 
in human milk. Moreover, their consumption is not restricted to the population of microbes that 
define normal gut microbiota maturation (Everard et al., 2014 and Dewulf et al., 2013). Numerous 
efforts to recreate the glycan landscape present in human milk are underway. The technology for 
chemical and chemoenzymatic construction of complex “milk” oligosaccharides has advanced 
tremendously, enabling wholesale construction of a limited number of HMO-like structures pres-
ent in milk (Muthana et al., 2009). Alternatively, purification from animal milks presents another 
opportunity for rapid and large-scale acquisition of milk oligosaccharides and glycoconjugates. At 
present, a number of enriched or purified bovine milk glycoproteins, including immunoglobins, 
lactoferrin, glycomacropeptide, and glycolipids are commercially available or could be readily 
produced at scale for use in preclinical and clinical studies. Bovine milk contains a relatively low 
concentration of free oligosaccharides, but the distribution of structures observed roughly matches 
the most abundant species present in HMOs (Aldredge et al., 2013). Importantly, bovine milk 
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oligosaccharides (BMOs) can be sourced from numerous points in dairy processing, including 
cheese whey, suggesting an opportunity for large-scale production of fractions enriched for given 
(or similar) structures (Zivkovic and Barile, 2011).
Serial Introduction of Complementary Foods in Ways that Promote Maturation of the Gut 
Microbiota
A recent study compared the microbiota and immune system in bottle-fed versus breastfed ma-
caques. The results showed that breastfed infant macaques develop more robust TH17 cells in the 
memory pool, suggesting that the timing and trajectory of dietary exposures during early life may 
have lasting functional consequences beyond that period (Ardeshir et al., 2014). In breastfed hu-
mans, the transition to formula feeding and family foods (complementary feeding practices) varies 
considerably in terms of which food types are consumed, the order of their presentation, and the 
duration of their consumption. Documenting which foods growing infants consume and in what 
quantities has required innovative approaches, particularly in low-income countries where under-
nutrition is prevalent (Caulfield et al., 2014) (Figure 3). For example, data collection protocols 
across eight different countries have been harmonized to enable quantification of variations in 
child feeding practices in the MAL-ED consortium (Caulfield et al., 2014).
The co-linearity between the introduction of various types of solid foods, reduction in 
breast milk consumption, and maturation of the gut microbiota makes it challenging to identi-
fy causal relationships between specific ingredients and the representation of specific microbes 
through human studies. However, studies in gnotobiotic mice colonized with defined collections 
of cultured (and sequenced) human gut-derived bacteria have been successful in interrogating 
specific food-microbe associations (Faith et. al., 2011). These relationships were identified us-
ing an experimental design in which a given gnotobiotic animal harboring a defined microbial 
consortium received a sequence of diets, composed of several different combinations of foods, 
whose concentrations are intentionally varied between diets. The order of presentation of the dif-
ferent diets was also varied between different mice in order to limit confounding from hysteresis 
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effects. This approach has identified associations between various commercially available foods 
given in the USA during the complementary feeding period and specific microbes independent of 
their order of presentation, which would be virtually impossible to identify in clinical studies of 
developing human infants (Faith et al., 2011). This approach can be applied to young mice colo-
nized with the age- and healthy growth-associated bacterial strains identified using the methods 
described above to determine which complementary foods promote their representation and ex-
pressed functional features. The results could lead to a recommended sequence of complementary 
feeding that reflects local food availability, affordability, and cultural practices and that sponsors 
healthy microbiota maturation. This information would advance current recommendations, which 
are not microbiota based and quite general (Kleinman, 2000).
Additional Considerations Regarding the Developmental Biology of the Gut Microbiota
Obesity
Although we have emphasized the global challenge of undernutrition in children, another vexing 
global health problem is the growing burden of obesity and associated metabolic dysfunction in 
children. Increasing attention is being paid to delineating differences in the gut microbiota of chil-
dren who become obese in the hopes that early recognition of perturbed microbiota development 
may permit early interventions in at risk populations. For example, a recent culture-independent 
study of a Singaporean birth cohort disclosed that precocious maturation of the microbiota dur-
ing the first 6 months of postnatal life was associated with significantly increased adiposity at 18 
months (Dogra et al., 2015). Specifically, an unsupervised clustering approach based on bacterial 
16S rRNA sequence data sets revealed three clusters of fecal microbiota configurations. The num-
ber of samples that binned into one of these clusters (cluster 3), which is characterized by high 
levels of Bifidobacteria and Collinsella and low levels of Streptococcus and Enterobacteriaceae, 
increased with age. A faster time to achieving a cluster 3 configuration was associated with signifi-
cantly greater adiposity measured at age 18 months. Given the rapid rate of change in eating prac-
tices and incidence of childhood obesity, longitudinal studies of this type are timely. They should 
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be strategically applied to populations representing different manifestations of these economic, 
anthropologic, and epidemiologic transitions and accompanied by comprehensive, quantitative as-
sessments of food consumption during the pre-weaning, weaning, and postweaning periods.
Obesity is associated with reduced organismal and genetic diversity in the gut microbiota/
microbiome of adults (Turnbaugh et al., 2009b and Le Chatelier et al., 2013). Transplantation of 
intact fecal microbiota samples, or derived culture collections, from adult twins stably discordant 
for obesity into germ-free mice transmitted the donors’ discordant adiposity phenotypes, as well 
as obesity-associated metabolic dysfunction (Ridaura et al., 2013). Co-housing mice just after 
they received the obese donor’s (Ob) microbiota with mice just after they received the lean co-
twin’s (Ln) microbiota, before their discordant adiposity/metabolic phenotypes became evident, 
prevented development of obesity and metabolic abnormalities in the Ob cagemate. This preven-
tion was associated with unidirectional invasion of bacteria from the Ln cagemate’s gut commu-
nity to the Ob cagemate’s microbiota. Invasion was diet dependent, occurring in mice fed a human 
diet formulated to reflect the lower third of saturated fat and upper third of fruit and vegetable 
consumption in the USA, but not when animals received an unhealthy diet representing the upper 
third of saturated fat and lower third of fruit and vegetable consumption (Ridaura et al., 2013). 
These results illustrate how niches can be filled in the Ob microbiota by Ln-derived bacterial taxa 
to prevent disease and how important diet is to the installation of these health-promoting strains. 
The results raise important questions about the origins of the reduced bacterial diversity observed 
in Ob microbiota.
Impact of Antibiotics
One active area of investigation is the role of frequent consumption of broad-spectrum antibiot-
ics in determining the diversity and functional features of the developing microbiota. Studies in 
conventionally raised mice treated with low-dose penicillin from birth to 4, 8, or 28 weeks of age 
revealed that early and brief exposure was sufficient to produce durable changes in body com-
position (Cox et al., 2014). Practical issues (in many parts of the world, antibiotic consumption 
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in children is pervasive and poorly documented), ethical considerations, and the identification of 
suitable controls all confound the design of human studies that would seek to determine the effects 
of antibiotic administration on the developmental biology of the human infant gut microbiota and 
growth. In principle, pre-clinical tests that administer various classes of antibiotics in varying dos-
es—together with representative human diets to gnotobiotic mice harboring transplanted micro-
biota from infants and children living in various parts of the world—followed by transplantation of 
their antibiotic-treated microbiota to a next generation of (antibiotic-free) gnotobiotic recipients, 
would provide one way to explore these questions.
Affordable Nutritious Foods: Societal Implications and Challenges
An imbalance of carbohydrate, fat, and protein consumption, food insecurity, and changing diets in 
low-income countries brought about by globalization, increases in food prices at the point of retail, 
and a global protein supply that needs to double by 2050 are some of the drivers for developing 
new types of affordable nutritious foods that are culturally acceptable, suitable for storage, and 
distributable given current and envisioned future infrastructure. A sustainable economic model in 
which local economies benefit from producing and/or distributing foods is also required to ensure 
long-term supplies. Moreover, there is a paucity of generally accepted metrics for defining foods 
that provide optimal nutrition at affordable cost (e.g., see the “nutrient-rich foods index” devel-
oped based on FDA recommendations; Drewnowski, 2010).
We propose that the gut microbiota provides a parameter that needs to be considered when 
developing nutrition options and that the type of preclinical gnotobiotic models described above 
will be useful for testing and defining dietary parameters. Studies with mice and other species pro-
vide means for characterizing interactions between food ingredients (at different levels of ingredi-
ent resolution and including culturally relevant spices and sweeteners), their methods of prepara-
tion and preservation, the gut microbiota of various consumer populations, and human metabolic, 
immunologic, and other physiologic features. These research platforms offer the promise of yield-
ing next-generation foods designed to be satiating, delicious, nutritious, and able to manipulate 
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microbiota and host properties in ways that promote healthy growth and wellness. However, ful-
filling this promise demands a holistic view of the nexus of human gut microbial ecology research, 
agricultural practices, food production, evolving consumer tastes in an era of rapid globalization, 
envisioned commercialization strategies, current regulatory structures/practices, ethical issues, 
and public education. For example, there is a need to more thoroughly and rapidly characterize, 
through readily searchable, accessible, well-annotated databases, emerging food consumption pat-
terns in countries representing different cultural traditions, stages of economic development, and 
land/water resources. At the commercial level, there is an opportunity to define and differentiate 
foods based on their effects on different consumer populations with distinct biological phenotypes 
and with different gut microbial community configurations. There is an accompanying need to 
frame intellectual property laws in ways that provide appropriate incentives for private investment 
while protecting the public good.
To effectively and responsibly apply this knowledge in ways that benefit society, there is 
a need to work with government agencies to provide efficient and sensible regulatory schemes. 
These regulatory frameworks vary between nations and are evolving. Currently, the US Food and 
Drug Administration (FDA) defines “medical foods” as foods that make medical claims. A “di-
etary supplement” is a product intended for ingestion that contains a dietary ingredient designed 
to add further nutritional value to a diet. Dietary supplements can only contain ingredients that are 
“generally regarded as safe” (GRAS) or approved as food additives by the FDA after filing a “new 
dietary ingredient” (NDI) notification with full description of the ingredient and product in which 
it will be marketed, the basis for the manufacturer’s conclusion that it is an NDI, recommended use 
and proposed labeling, plus a history of its use and evidence of its safety to support the proposed 
use. Probiotics have been defined in various ways, including “live microorganisms that, when 
administered in adequate amounts, confer a health benefit on the host” (Joint FAO/WHO Expert 
Consultation on Evaluation of Health and Nutritional Properties of Probiotics, 2001), whereas pre-
biotics have been considered to be “a selectively fermented ingredient that allows specific changes 
both in the composition and/or activity of the gastrointestinal microbiota that confer benefits upon 
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host well-being and health” (Roberfroid, 2007). Synbiotics are combinations of prebiotics and pro-
biotics. Regulation of prebiotics, probiotics, and synbiotics remains a work in progress, although 
any health claims they make will likely require a clinical development pathway that is the same as 
that employed for biologics.
Opening the Public Discussion
For public acceptance and societal benefit, a thoughtful proactive, science-based, educational out-
reach is needed with an understandable vocabulary tailored to targeted consumer populations and 
respectful of their cultural traditions. The goal would be to objectively describe the extent to which 
the nutritional value of food is related to a consumer’s microbiota and how food ingredients, food 
choices, and the microbiota are connected to health benefits.
We suggest that one way of framing a public discussion regarding the impact of human gut 
microbiome research on the nexus of food, agriculture, and nutrition is to divide it into three “sec-
tors”: science and technology, ethics, and policy and governance.
Science and Technology
Ongoing and new studies will help to define (1) methods for selection and production of new food 
sources, (2) design of new foods/diets, (3) definitions of nutritional value and benefit and metrics 
for differentiation of foods, and (4) the role of the gut microbiota in determining nutritional status 
in pregnant women, infants and children, and adults throughout the course of their lives.
Ethics
The impact of gut microbiota research extends beyond conceptions of health to human rights. Key 
issues include (1) concepts of self and ownership of microbes and the shaping of these views by 
cultural, religious, socio-economic, educational, and political factors; (2) use of a person’s mi-
crobes to improve nutritional status within and beyond family, community, and country; (3) strate-
gies for responsible stewardship of our (human) microbial resources; and (4) personal, familial, 
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and societal impact (and shared benefit) of methods envisioned to promote intergenerational trans-
mission of beneficial microbes and to effect durable repair of defective gut microbial community 
development early in life or functional restoration later in life.
Policy and Governance
Advances in gut microbiota research will have long-term impact on regulatory and other govern-
mental policies and agencies as they relate to agriculture, food, and nutritional health. These ef-
fects include (1) definitions of food safety, including the products of microbial biotransformation 
of food ingredients; (2) definitions of nutritional benefit within and outside of the context of specif-
ic human health claims; (3) laws concerning ownership of microbial strains and their distribution 
within and across national borders (for example, in October 2014, the Convention on Biological 
Diversity/Nagoya Protocol on Access to Genetic Resources and the Fair and Equitable Sharing of 
Benefits from their Utilization entered into international force “stringent requirements for prior 
informed consent and benefit sharing for research and commercial activities involving genetic 
resources from plants, animals, and microorganisms” [http://www.cbd.int/abs/]); (4) laws concern-
ing intellectual property related to microbes, microbial consortia, and the products of microbial 
interactions with food ingredients, including diagnostics and therapeutics; (5) policies related to 
standards of manufacture, purity, and composition of probiotics and synbiotics; and (6) incentives 
for linking plans for food production and distribution with gut microbiota health. A key challenge 
is how to construe (1)–(6) in the context of a reference set of “representative” countries.
Closing Thoughts
Given the intricate links between first foods and long-term human health, ensuring availability of 
appropriate food sources is of high priority. Because undernutrition is such a widespread afflic-
tion, it is critical to consider how to categorize the targeted populations, the cost and economic 
sustainability, the efficacy (effect size and durability), and the cultural acceptability of various 
therapeutic or preventative approaches, as well as the generalizability of both food-based and 
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microbial interventions to large populations within and across national/societal boundaries. One 
way of conceptualizing this complex set of challenges for treatment and prevention is to place, 
on one end of the spectrum of undernutrition, children with already manifest SAM and signifi-
cant microbiota immaturity who could be treated with locally produced, readily and reproducibly 
manufactured, affordable and safe, culturally acceptable next-generation RUTFs, with or without 
microbial interventions of the type described above. Moving along this continuum, another group 
would consist of individuals who manifest growth faltering (stunting) in the first 1,000 days after 
conception, where the envisioned targets for interventions are pregnant and lactating women and 
their infants. At the other end of the continuum is a third group that are the targets of locally pro-
duced, consumer-focused, affordable nutrition products designed to improve dietary quality and 
increase the diversity of food choices.
Looking back over 800 million years of metazoan evolution, we appreciate more now than 
ever before the splendid innovation of having a gut that assembles microbial resources that enable 
efficient utilization of available nutrients (McFall-Ngai et al., 2013). We, humans, are now in a 
position to not only understand but to deliberately influence this process of microbial community 
acquisition in order to ensure its optimal execution. The challenges we face in designing and im-
proving food systems and nutritional health are great and pressing. Hopefully, our gut instinct will 
be to honor and harness the intimate interrelationship between foods and “our” microbes in an 
attempt to address this challenge now and throughout the course of this defining century for our 
species and planet.
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Figure Legends
Figure 1. Developing metrics for describing gut microbial community development. (a) Bac-
terial taxa that discriminate different stages of development were identified by a machine learning-
based (Random Forests) regression of 16S rRNA datasets produced from monthly fecal samples 
collected from anthropometrically healthy infants and children living in an urban slum in Dhaka, 
Bangladesh during their first two years of postnatal life to their respective chronologic ages at the 
time of sample collection (Subramanian et. al, 2014). Shown are depictions of the typical distri-
butions of these age-discriminatory taxa across the population. Taxa were selected based on their 
relative importance to the accuracy of the Random Forests model using a permutation-based ‘fea-
ture importance’. (b) The most discriminatory taxa, as defined by their feature importance, were 
used as inputs into a sparse 24-taxon model whose output (‘microbiota age’) is a microbiota-based 
prediction of the chronologic age of a healthy child. The plot on the left of the panel shows mi-
crobiota age against chronologic age of healthy children used as a training set to fit the regression 
(each dot is a fecal sample from an individual child). The plot on the right of the panel shows ap-
plication of the sparse model to a validation set composed of a different group of children living in 
the same location that were not used to train the model. Applying the model to a separate validation 
set controls for over-fitting of the model to the training set, and ensures its wider usability. (c) Two 
metrics of microbiota maturation based on application of the model to two separate validation sets 
of singletons and a separate study of Bangladeshi twins/triplets. ‘Relative microbiota maturity’ is 
the deviation, in months, from a smooth-spline fit of microbiota age values with respect to chrono-
logic age, fitted using the validation datasets (see black dashed curve). The red dot represents a 
fecal sample collected from a focus child that is 11 months below the spline fit, indicating negative 
relative microbiota maturity (i.e., an immature microbiota). A microbiota-for-age Z score (MAZ) 
is computed by dividing the difference between the focal child’s microbiota age and the median 
microbiota age of healthy controls in the same monthly chronologic age bin over the standard 
deviation within the same age bin. The median and standard deviation of each bin are computed 
using the validation datasets. The distribution of microbiota maturity and MAZ scores in birth-co-
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hort studies have been studied using linear mixed models that take into account random variation 
specific to each serially-sampled child and family while estimating the fixed variation attributable 
to a factor observed across different children (e.g., diarrheal episodes) (Subramanian et al., 2014).
Note that using Random Forests to study microbiota maturation is advantageous because of its 
non-parametric assumptions and utility in the context of high dimensional datasets (large num-
bers of predictors). Nonetheless, it is one of several methods that can be useful. For example, the 
rank-order Spearman correlation metric has been applied to infant microbiome datasets to detect 
monotonic relationships between microbiome-encoded functions/bacterial taxa and postnatal age 
(Yatsunenko et. al, 2012).
Figure 2. Integration of existing clinical observational and interventional studies into gnoto-
biotic mouse models to identify interactions between the gut microbiota, food, and host biol-
ogy. The discovery process depicted by the left circle illustrates how gnotobiotic animal models 
colonized with human donor microbiota and fed human diets can lead to a greater understanding of 
how diet-by-microbiota interactions are causally related to healthy growth and to phenotypes as-
sociated with undernutrition: e.g., immune system development, brain development and host and 
microbial community metabolism. New surrogate- or mechanism-based biomarkers of nutritional 
state emanating from these gnotobiotic models can be validated using biospecimens collected from 
the donors used to construct these gnotobiotic models, as well as from other members of the study 
population. The discovery/development process depicted on the right illustrates how dietary and 
microbial ‘leads’ can be tested in the context of humanized gnotobiotic animals to assess how they 
modulate biological processes already known, discovered or postulated to be involved in healthy 
growth and/or the pathogenesis of undernutrition. The downward pointing arrow in the middle 
of the figure points to next steps in clinical translation. See the main text for a discussion of the 
regulatory, ethical, societal and commercial implications of these efforts. Abbreviation: IND, In-
vestigational New Drug.
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Figure 3. Co-variation in gut microbiota assembly/maturation, dietary patterns and other 
facets of human postnatal development. (a) Illustration of the rate of change occurring in gut 
microbiota structure of both mother and child. Note that infant variation curves are known from 
both longitudinal and cross-sectional study designs (Yatsunenko et al., 2012, Subramanian et al., 
2014). In the case of mothers, the curve is interpolated based on studies of pregnant Finnish moth-
ers prior to delivery (Koren et al., 2012) and Bangladeshi mothers following parturition (Subra-
manian et al., 2014). (b) The food consumption pattern shown is at a population level and does not 
depict the great deal of temporal variation observed in food consumption patterns within a given 
child. Depicting the fractional contribution of each food to the consumption patterns of children in 
Bangladesh underscores how dietary changes occur simultaneously (lowering of breast-milk and 
increase in legumes and cow’s milk) and not in an orderly fashion (small fluctuations from month-
to-month; re-entry and dropout of certain foods). It also underscores the challenge encountered 
in ascertaining how food and the microbiota interact to effect maturation of the community. (c) 
Major processes related to growth and how they vary in rate and magnitude over time. Curves are 
adapted from Bogin (1999). Note that the newborn brain represents 12% of body weight (a value 
six times greater than in adults). By the end of the first decade, the brain represents 6% of body 
weight and consumes twice the amount of glucose and 1.5 times the amount of oxygen as the adult 
brain. Approximately 30% of the glucose consumed by the infant brain is accounted for by aerobic 
glycolysis (versus 12% in adults) (Goyal et al., 2014). The dramatic changes in brain metabolism 
that occur over the first two decades of life coincide with the initial proliferation and then pruning 
of synapses to adult levels. Central questions that need to be addressed in this area include the bio-
logical effects of the gut microbial community on neurogenesis, synaptic connectivity, gliogenesis 
and glial-neuron interactions, neural circuit function and higher cognitive processes in the context 
of healthy growth versus undernutrition, and whether/how the gut-brain axis operates to influence/
regulate other aspects of host physiology, metabolism and immunity in the infant/child. More-
over, if persistent immaturity of the gut microbiota is causally related to undernutrition and its 
long-term sequelae, including neurodevelopmental abnormalities, does durable repair of this im-
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maturity require that nutritional interventions be administered earlier before disease becomes fully 
manifest (and the microbial ecosystem is so perturbed that restoration becomes very difficult)? Do 
nutritional interventions need to be applied for more sustained periods of time? Do new types of 
therapeutic foods need to be developed or is a microbial intervention also needed?
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Abstract
Children with undernutrition exhibit impaired normal gut microbial community development. 
Transplanting fecal microbiota from 6- and 18-month-old Malawian donors manifesting healthy 
growth or varying degrees of undernutrition into recently weaned germ-free mice fed a represen-
tative Malawian diet revealed that immature microbiota transmit impaired growth phenotypes, 
with the representation of several age-discriminatory taxa in the microbiota of recipient animals 
correlating with lean body mass gain, metabolic phenotypes in liver, muscle, and brain, plus bone 
morphology. Co-housing mice shortly after they received microbiota from healthy (H) or severely 
stunted/underweight (Un) infants demonstrated that invasion of age-/growth-discriminatory taxa 
from H to Un cagemates’ microbiota ameliorates growth faltering. Adding two invasive species, 
Ruminococcus gnavus and Clostridium symbiosum, to the Un microbiota also produced ameliora-
tion of growth and metabolic abnormalities. These results indicate that gut microbiota immaturity 
is causally related to undernutrition, and reveal bacterial strains that are potential therapeutic tar-
gets and agents.
One sentence summary: Gnotobiotic mice provide evidence that delayed development of the hu-
man gut microbiota is not only associated with childhood undernutrition but causally related to it.
Main Text
Undernutrition is a leading cause of infant and childhood mortality worldwide (1-5). The mecha-
nisms that underlie disease pathogenesis, including the persistent abnormalities in growth, im-
mune function, and cognition, remain obscure. There is accumulating evidence that childhood 
undernutrition is not due to food insecurity alone, but also results from a combination of factors 
including diets with low nutrient density/bioavailability, pathogen burden and gut mucosal barrier 
dysfunction (6-10).
The World Health Organization (WHO) has developed anthropometric standards to define 
nutritional status [weight-for-height Z-Score (WHZ), weight-for-age Z-Score (WAZ), and height-
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for-age Z-Score (HAZ)] (11, 12). A recent study of infants and children with healthy growth phe-
notypes living in Mirpur, an urban slum in Dhaka, Bangladesh, involved monthly fecal collection 
from birth through the end of the second year of life; 16S rRNA analysis of bacterial membership 
in their gut microbiota and application of a machine learning method [Random Forests (6)] yielded 
a model composed of 24 ‘age-discriminatory’ strains whose changes in relative abundance over 
time defined a program of normal ‘maturation’ of the microbiota across biologically unrelated 
individuals (6). This model served as the basis for computing two related metrics, ‘relative mi-
crobiota maturity’ and microbiota-for-age Z-score (MAZ), that significantly correlated with the 
chronological age of children with healthy growth phenotypes. Applying these metrics revealed 
that children living in Mirpur with moderate acute malnutrition (MAM) or severe acute malnutri-
tion (SAM) have significant gut microbiota immaturity compared to age-matched children from 
the same locale, with the degree of immaturity being greater in SAM than MAM (13). Moreover, 
treatment of children with SAM with either one of two ready-to-use therapeutic foods (RUTFs) 
produced incomplete and only transient improvement in this immaturity, and no improvement in 
their HAZ scores (13).
These findings raise several key questions. To what extent are these age-discriminatory 
strains also indicative of the normal development of the gut microbiota of infants and children 
representing other populations living in geographically distinct areas of the world with differ-
ent cultural traditions and diets? Are these age-discriminatory strains simply biomarkers of gut 
microbiota development or are they critical mediators of healthy growth? If they are mediators of 
healthy growth, can their introduction into immature microbiota prevent disease?
A Malawian model of gut microbiota development
To address these questions, we first developed a Random Forests-based model of gut microbial 
community development from a cohort of Malawian twins concordant for healthy growth and then 
applied the model to serially sampled Malawian infants/children in order to define the degree of 
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correlation between nutritional status and microbiota maturation and ascertain whether an MAZ 
score could predict future growth performance.
We previously followed a cohort of 317 twin pairs and three sets of triplets, living in five 
rural villages in southern Malawi from birth to 36 months of age, with periodic sampling of their 
fecal microbiota (14). To define healthy microbiota development in this population, we sequenced 
PCR amplicons generated from variable region 4 (V4) of bacterial 16S rRNA genes represented in 
238 fecal samples collected from 27 twin pairs and two sets of triplets whose serial anthropometric 
measurements were indicative of consistently healthy growth [WHZ 0.09±0.93; fecal collection 
over an age range of 0.6 to 33.5 months; 3.96±1.6 samples (mean±SD)/individual; see Tables S1A 
and S2A for microbiota donor characteristics and a summary of sequencing datasets]. V4-16S 
rRNA reads with ≥97% nucleotide sequence identity were grouped into operational taxonomic 
units (97%ID OTUs) and taxonomic assignments were made as described in Materials and Meth-
ods.
We modeled microbiota maturation in these healthy Malawian infants/children by regress-
ing OTUs against chronological age using Random Forests [training subset, 121 fecal samples 
from 14 twin pairs and 1 set of triplets; test subset, 117 samples from 13 twin pairs and 1 set of 
triplets; see Fig. S1 which shows that the age distribution of infants/children at the time of sample 
collection in each subset are not significantly different (p=0.51, Kolmogorov-Smirov test)]. Ap-
plication of the training subset-based model to the test subset yielded a positive and significant 
correlation between host chronological age and predicted microbiota age (r2=0.78, p<0.0001). 
Random Forests assigns a mean squared error (MSE), or feature importance score, to each OTU 
that indicates the extent to which each OTU contributes to the accuracy of the model. The 25 most 
age-discriminatory taxa, ranked by MSE, yielded a sparse model that predicted microbiota age 
and accounted for ~80% of the observed variance in the healthy cohort (Fig. 1A-C, see Table 
S3A for a complete list of OTUs and MSE values). Remarkably, multiple OTUs from the sparse 
Malawian model had ≥97% sequence identity to OTUs in the sparse Bangladeshi model (Fig. 1A, 
Table S3B).
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We used the Malawian Random Forests-derived model to analyze the relationship between 
microbiota maturity and growth/nutritional status in children enrolled in a randomized nutritional 
interventional trial at 6, 12, and 18 months of age (iLiNS-DYAD-M) (15) that took place in the 
Mangochi district of southern Malawi (see Materials and Methods). There was a significant posi-
tive correlation between MAZ and WHZ (ρ=0.1664, p=0.0073, Spearman’s rank correlation) and 
MAZ and WAZ (ρ=0.1715, p=0.0056) but not HAZ (ρ=0.1022, p=0.1 for HAZ) at 18 months 
of age in the group of 259 iLiNS-DYAD-M enrollees who had fewer than three reported days 
of antibiotic consumption during the previous 12 months (Table S2B). Remarkably, there was 
a significant correlation between MAZ at 12 months and growth at 18 months [Spearman’s rank 
correlation ρ=0.1406 (p=0.02) for WHZ and ρ=0.1373 (p=0.02) for WAZ] [Note that ρ=0.1184 
(p=0.05) for HAZ]. These results suggest that MAZ may be useful for predicting future (ponderal) 
growth. Further studies and analyses are required to discern the effects of a number of variables, 
such as duration of prior antibiotic use, enteropathogen load, number of diarrheal days, geography, 
and various nutritional interventions, on the relationship between MAZ measurements at various 
postnatal ages, anthropometry and other metrics of healthy growth (e.g., cognitive testing and im-
munization responses).
Identification of age-discriminatory taxa that are also growth-discriminatory
To establish a causal relationship between microbiota maturity and growth, we selected fecal 
samples from 19 Malawian infants representing either healthy or undernourished growth pheno-
types for transplantation into young, actively growing germ-free C57Bl/6J mice. Of the 19 donor 
samples, nine were from 6-month-old infants [four classified as healthy with WHZ 1.45±0.57 
(mean±SD), WAZ 1.75±0.56, and HAZ 1.27±0.45, and five moderately or severely underweight 
and stunted (WHZ -1.27±0.49, WAZ -3.90±1.82 and HAZ -4.36 ±2.07)]. Ten samples were from 
18-month-old children, four with healthy weights (WHZ 1.44±0.08, WAZ -0.3±0.57 and HAZ 
-2.84±0.99; note that all 18-month-old donors were members of twin pairs where HAZ scores 
are typically lower than in singletons), and six who were moderately or severely underweight 
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and stunted (WHZ -1.75±0.17, WAZ -2.88±0.42 and HAZ -3.28±0.82) (see Table S4A for MAZ 
metrics). Fecal samples from the 18-month-old children were from the Malawi twin cohort while 
the 6-month-old microbiota donors were members of the iLiNS-DYAD-M study who had not yet 
received a nutritional supplement.
Each microbiota sample was transplanted into a separate group of 5-week old male germ-
free mice (n=5 animals/sample). Three days before transplantation, all mice were switched onto 
a sterile (irradiated) Malawian diet formulated based on the results of a dietary survey of the 
complementary feeding practices of 9-month-old Malawian children enrolled in the iLiNS-DOSE 
study (#NCT00945698) that took place in the Mangochi district. We selected eight ingredients to 
produce a cooked, representative Malawian diet consumed by children (‘M8’; see Materials and 
Methods); its micro- and macronutrient content does not fulfill the needs of humans or mice (see 
Table S5A,B for a list of ingredients and the results of a direct nutritional analysis).
Following a single gavage of the donor microbiota, recipient mice were followed for 4-5 
weeks (see Fig. 2A for experimental design). Fecal samples were collected weekly for bacterial 
V4-16S rRNA analysis. Growth was monitored by serial measurements of total body weight and 
body composition [lean mass and fat mass as defined by quantitative magnetic resonance (qMR)] 
while femurs were removed for micro-computed tomographic (micro-CT) characterization of 
bone morphology.
Mice harboring donor microbiota from healthy infants gained significantly more weight 
(p<0.0001; 2-way ANOVA) and lean body mass (p=0.0001; 2-way ANOVA) than mice colonized 
with microbiota from undernourished donors (Tables S6A,B), yet there was no significant dif-
ference in food consumption between groups (p>0.05, Student’s t-test, Table S7). 16S rRNA se-
quencing of fecal samples obtained from recipient mice revealed variable transplantation efficien-
cy. Of the 19 donor samples, eight produced transplantation efficiencies of ≥50% [i.e., ≥50% of the 
97%ID OTUs represented in the input community, weighted to relative abundance, were detect-
able in recipient mice throughout the course of the experiment; see Table S4B. Note that bacterial 
50
viability, as quantified by the number of colony forming units 24 hours after plating onto rich me-
dium, was significantly greater (p<3.2x10-6; Student’s t-test) in the case of fecal samples from the 
twins, which had been flash frozen in liquid nitrogen within 5-10 min after they were produced. In 
iLiNS-DYAD-M, the time to freezing was often several hours]. When we restricted our analysis to 
the eight donor samples producing >50% transplantation efficiency [four six-month-old singleton 
infants from iLiNS-DYAD-M (two healthy, two undernourished) and four from 18-month-old co-
twins from the Malawian twin study (one healthy, three undernourished)] the discordant growth 
phenotypes between recipients of healthy versus undernourished microbiota became even more 
pronounced (weight gain, p<0.0001; lean mass gain, p=0.0005; 2-way ANOVA). Importantly, 
there was no significant difference in fat mass gain (p=0.78, 2-way ANOVA, Table S6B) or food 
consumption (p>0.05, Student’s t-test; Fig. 2B,C; Tables S6A,B, and S7) between the groups.
For both the 6-month and 18-month age bins, mice colonized with healthy donor micro-
biota gained significantly more total body weight and lean mass than those colonized with un-
dernourished donor microbiota (weight for recipients of the 6- and 18-month donor microbiota, 
p=0.0003 and p=0.0043, respectively; lean body mass, p=0.03 and p=0.0013, respectively; 2-way 
ANOVA; Table S6A,B). Intriguingly, recipients of the healthy and undernourished 6-month-old 
donors’ fecal samples grew more than recipients of the corresponding 18-month-old healthy and 
undernourished donor microbiota (p<0.0001 for healthy; p<0.0001 for undernourished, based on 
lean mass gain; 2-way ANOVA).
Growth over the course of the 5-week experiment in the 19 different groups of recipient 
mice ranged from 105% to 152% of starting weight (averaged per group; Table S6A). There was 
no significant relationship between growth phenotypes and bacterial diversity in the fecal micro-
biota of recipient animals (Spearman’s rank correlation ρ=0.1, p=0.3275 for Shannon Index versus 
lean body mass gain at day 28 following gavage of the donors’ microbiota). We applied Random 
Forests to regress the growth phenotypes of recipient gnotobiotic mice against 97%ID OTUs iden-
tified in their fecal microbiota. Two models were generated, one based on weight gain, the other 
based on lean body mass gain (see Fig. 2D and Fig. S2, respectively, plus Table S8A,B). The 
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weight and lean body mass gain models explained ~66% and ~58% of the observed phenotypic 
variance, respectively (p<0.0001, permutation test; 999 permutations). Remarkably, two of the 
growth discriminatory species represented in the weight and lean mass gain Random Forests-based 
models, Bifidobacterium longum and Faecalibacterium prausnitzii, have high feature importance 
scores in the sparse 25 OTU Malawian and sparse 24 OTU Bangladeshi Random Forests-derived 
models of age-discriminatory taxa [ranked 1st and 8th, respectively, in the Malawian model shown 
in Fig. 1A, and 5th and 1st in the Bangladeshi model (13)]. B. longum is an early colonizer while 
F. prausnitzii becomes more prominent at later times in the healthy Malawian and Bangladeshi 
populations used to create these models (see Fig. 1B, (13)).
The relative abundances of 13 and seven of the OTUs with significant positive monotonic 
correlations to body weight and lean mass gain, respectively, also had significant correlations to 
chronological age in concordant healthy Malawian twins/triplets, including three OTUs for F. 
prausnitzii (p<0.0001; see Fig. 2D, Fig. S2, plus Table S9 for a complete list of OTUs with their 
Spearman’s rank correlation r-values). Moreover, 15 and 11 OTUs with significant positive corre-
lations to weight and lean mass gain, respectively, were also significantly correlated with chrono-
logical age for the 259 infants/children from iLiNS-DYAD-M, including the same three OTUs for 
F. prausnitzii that were significantly correlated with age in the cohort of healthy Malawian twins 
and triplets (p<0.0001 for all correlations; Spearman’s rank correlation; see Table S9).
The relationship between age- and growth-discriminatory taxa and femoral phenotypes
We used micro-CT to assay morphological parameters in cancellous and cortical regions of femurs 
obtained at the time of sacrifice from mice harboring the eight donor microbiota that exhibited 
>50% transplantation efficiency. There were strong trends to higher femoral cortical BV/TV and 
volumetric bone mineral density (vBMD) in recipients of undernourished donor gut microbial 
communities (p=0.05, p=0.07, respectively, Mann-Whitney test). Differences between mice har-
boring microbiota from 6- and 18-month-old donors were evident in cancellous rather than cortical 
bone, regardless of donor nutritional status; mice colonized with 6-month-old donor communities 
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had significantly higher BMD, BV/TV, trabecular connectivity and number, and significantly low-
er trabecular spacing irrespective of their nutritional status (Fig. S3, Mann-Whitney test, p<0.001 
for all bone metrics).
We extended our Random Forests and ranked Spearman correlation analyses to identify 
OTUs that discriminate these femoral bone phenotypes (Fig. S4, Table S10). Six of the OTUs rep-
resented in both of the growth discriminatory Random Forests models, including one assigned to 
B. longum, were also represented among the top 20 most discriminatory features in at least three of 
the five Random Forests-based models of bone metrics (Fig. S4). The B. longum OTU (72820) is 
also a member of the sparse Malawian Random Forests-derived model of age-discriminatory taxa. 
Moreover, an F. prausnitzii OTU (265871) was ranked within the top 40 taxa in all of the Random 
Forests models based on bone metrics as well as the lean mass gain model. Together, these results 
provide evidence for microbiota-dependent regulation of bone morphology (17) and that these ef-
fects are influenced by the age and nutritional status of the donor.
Effects of gut microbiota immaturity on host metabolism
We selected gnotobiotic recipients of two 6-month-old donor microbiota that transmitted the most 
discordant growth phenotypes in the initial screen of 19 microbiota to characterize the effects of 
microbiota immaturity on host metabolism (Fig. S5A). One was a healthy infant from Mangochi 
(HAZ 1.49, WAZ 1.43, WHZ 0.9) with age appropriate microbiota maturity (microbiota age of 
6.7 months); the other was a severely stunted and underweight infant (HAZ -3.35, WAZ -3.08, 
WHZ -0.79) from Malindi (located 20km from Mangochi) with microbiota immaturity (micro-
biota age of 4.6 months). The configurations of these transplanted microbiota were quite distinct: 
mice colonized with the healthy donor community were dominated by F. prausnitzii (33±19% rela-
tive abundance) while mice colonized with the undernourished donor microbiota were dominated 
by Clostridium neonatale (37±11% relative abundance) (n=5 mice/donor microbiota). Of the 27 
species (66 97%ID OTUs) present in recipients of the healthy donor community and the 22 spe-
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cies (33 OTUs) present in recipients of the undernourished immature donor microbiota, 13 OTUs, 
representing 13 different species were present in both (see Fig. S5B and Table S11).
In follow-up confirmatory experiments, mice received the same donor microbiota; serum, 
liver, gastrocnemius muscle, and brain were obtained at the time of euthanasia three weeks after 
gavage of these microbial communities, and analyzed by targeted mass spectrometry (n=5-6 mice/
treatment group). The two donors’ microbiota conferred distinct metabolic phenotypes with the 
major differences involving fatty acid and amino acid metabolism; mice colonized with the healthy 
donor’s microbiota had significantly higher concentrations of long chain acylcarnitines in their se-
rum and liver and significantly decreased concentrations of a number of amino acids in their gas-
trocnemius muscle (and cecal contents) (p<0.05; Student’s t-test; Fig. 3; Table S12). These data 
support the notion that the two microbial communities may regulate the manner in which amino 
acids are utilized, such that mice colonized with the healthy donor microbiota funnel amino acids 
into new protein synthesis and lean body mass, whereas those colonized with the undernourished 
donor microbiota preserve the amino acid pools for oxidation and energy production. Consistent 
with this idea, increased levels of the branched-chain amino acids Val and Leu/Ile in the gastroc-
nemius muscle of mice colonized with undernourished donor microbiota were accompanied by an 
increase in a metabolite produced by their oxidation, C3 (propionyl) acylcarnitine (Table S12).
These differences in metabolic profiles extended to the brain (Fig. S6; Table S12). Echo-
ing results from serum and liver, levels of long chain acylcarnitines were significantly elevated in 
the cerebral cortex of mice harboring the healthy donor microbiota compared to the undernour-
ished donor microbiota (p<0.05; Student’s t-test). Amino acid metabolism was also impacted with 
concentrations of histidine, proline, glycine, arginine, and citrulline being significantly higher in 
the brains of mice with the healthy donor’s microbiota. Additionally, there was evidence of per-
turbations in the TCA cycle, with citrate levels being significantly higher in animals harboring 
the undernourished infant’s gut community. The resource demands of the brain in children are 
prodigious: e.g., at the end of the first decade of postnatal life, a child’s brain consumes twice the 
amount of glucose and 1.5 times the amount of oxygen per gram of tissue as an adult’s brain, and 
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accounts for up to 50% of the body’s total basal metabolic rate (16-18). During this period there 
is an explosive growth of synapses. The differences in brain metabolism that are evident within 
three weeks after transplantation of undernourished versus healthy infant microbiota into young 
gnotobiotic mice fed the same prototypic, nutrient deficient Malawian diet provide preclinical 
evidence that brain development needs to be viewed in the context of the developmental biology 
of the microbiota and its capacity to metabolize components of the diets consumed by children.
There were strong correlations between the relative abundances of bacterial species in the 
fecal microbiota of gnotobiotic mice and serum C10, C12, and C14 acylcarnitine levels, as well 
as levels of amino acids in gastrocnemius muscle. Species enriched in the healthy community 
that significantly correlated to serum acylcarnitines and amino acids included taxa that were also 
weight- and/or lean mass gain-discriminatory: R. gnavus (C10:2, C12, C12-OH/C10-DC acylcar-
nitines; valine, leucine/isoleucine, and methionine), Dorea formicigenerans (C10, C10:1, C12, 
C12-OH/C10-DC , C14, C14:2 acylcarnitines; methionine), F. prausnitzii (C12-OH/C10-DC, 
C14 acylcarnitines, leucine/isoleucine), and Clostridium symbiosum (C10:1, C12, C12-OH/C10-
DC, C14 acylcarnitines; and 11 amino acids including valine, leucine/isoleucine, and methionine) 
(p<0.05, see Figs. 2, S2, and S7A,B; plus Table S13 for a complete list with Spearman’s ranked 
correlation ρ-values). B. longum and F. prausnitzii, the two age- and growth-discriminatory spe-
cies, were also correlated with hepatic levels of the TCA cycle intermediate citrate (p<0.05; see 
Fig. S7C, Table S13).
While these two donors’ microbiota transmitted discordant weight, lean mass gain and 
metabolic phenotypes, they did not transmit discordant bone morphometric phenotypes (p>0.05 
on all metrics; Student’s t-test). This implies, perhaps not surprisingly, that ‘anthropometrically 
undernourished’ and ‘anthropometrically healthy’ donor microbiota do not transmit discrete sets 
of effects, but may produce overlapping phenotypes, each component of which may vary in its 
degree of discordance from donor to donor. A corollary is that different host phenotypes need to 
be assayed to obtain a more robust functional classification of ‘healthy’ versus ‘undernourished’ 
microbiota.
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Repairing impaired growth phenotypes with age- and growth-discriminatory strains present 
in a healthy donor microbiota
We next determined whether age- and growth-discriminatory bacterial species were capable of 
invading the stunted/underweight microbiota and repairing the growth abnormalities that this mi-
crobial community transmitted to mice. Taking advantage of the coprophagic behavior of mice, 
we gavaged 5-week-old male germ-free C57BL/6J animals with either the healthy or stunted/
underweight donor’s microbiota. Four days later, before phenotypic differences were apparent, we 
dually housed mice with the healthy (H) donor microbiota (H-H controls) and dually housed mice 
with the undernourished (Un) donor community (Un-Un controls) (n=3 cages of each control/ex-
periment). In addition, H and Un mice were co-housed with one another (HCH-UnCH) (n=6 cages/
experiment; n=2 independent experiments) (see Fig. 4A). All animals were fed the M8 diet begin-
ning three days before colonization and throughout the course of the 3-week experiment. Animals 
were weighed twice a week while body composition and fecal samples were assayed once a week.
HCH and UnCH cagemates both gained significantly more lean mass compared to Un-Un 
controls (Fig. 4B; UnCH p=0.0121; HCH p=0.0447, Mann-Whitney test), but had no significant 
difference to lean mass gain in H-H controls. We proceeded to characterize invasion using a pre-
viously described approach (19) that employs Microbial SourceTracker to estimate the posterior 
probability that every species-level taxon or 97%ID OTU is derived from each of a set of source 
communities (7). The fecal microbiota of H-H or Un-Un controls sampled 4 days after gavage (just 
prior to co-housing) were used as source communities. The fecal communities belonging to each 
HCH and UnCH mouse were then traced to these sources. We defined the direction of invasion by 
calculating the log odds ratio of the probability of a H origin (PH) or an Un origin (PUn) for each 
species-level taxon or 97%ID OTU, i:
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A positive log odds ratio indicates that a species or 97%ID OTU is derived from an H 
source, while a negative log odds ratio indicates a Un source. An invasion score is calculated to 
quantify the success of invasion of each species or 97%ID OTU, i, into each co-housing group, j:
where  is the average relative abundance of taxon i in all fecal samples collected from group 
j after cohousing, and  is its relative abundance in all samples from that group prior to initia-
tion of cohousing.
The mean of the distribution of invasion scores for UnCH animals was significantly higher 
than that for Un-Un controls (p≤0.0085, Welch’s two-sample t-test). This was not the case for HCH 
animals compared to H-H controls (p>0.05), indicating that there was significant invasion of mem-
bers of the HCH microbiota into the microbiota of UnCH cagemates, but not vice versa.
To quantify invasion further, we used the mean and standard deviation of the null distribu-
tion of invasion scores (defined as the scores from recipients of the H or Un microbiota that had 
never been co-housed with each other) to calculate a z-value and a Benjamini-Hochberg adjusted 
p-value for the invasion score of each species in HCH and UnCH mice. We defined a taxon as a suc-
cessful invader if it (i) had a Benjamini-Hochberg adjusted p≤0.05, and (ii) had a relative abun-
dance of ≤0.05% before cohousing and ≥0.5% in the fecal microbiota at the time of sacrifice. Fig. 
4C and Table S14 provide information about the direction and success of invasion. We identified 
nine OTUs from the HCH cagemate microbiota that consistently invaded the microbiota of cage-
mates with the stunted/underweight donor microbiota (total of 12 co-housed mice). These nine 
OTUs together comprised 58.7±14.2% (mean±SD) of the fecal microbiota of UnCH animals (data 
averaged throughout the 17 day cohousing period) and 67.7±6.7% on the day of sacrifice. Based 
on the rank order of their invasion scores, the two most successful invaders were F. prausnitzii, 
an age- and growth-discriminatory taxon in the Random Forests models and the most abundant 
OTU in the fecal microbiota of UnCH mice at the conclusion of the co-housing experiment, and R. 
gnavus, a growth-discriminatory taxon. In contrast, only two OTUs from the stunted/underweight 
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microbial community successfully invaded the gut community of HCH mice; these two OTUs, 
one assigned to Enterococcus and the other to Eubacterium limosum represented 2.7±1.7% of the 
community after co-housing [note that the Enterococcus OTU 4316566 had a significant nega-
tive correlation to lean mass gain in the initial screen of 19 donor microbiota (ρ=-0.14, p=0.0065; 
Spearman’s rank correlation)].
Culturing invasive growth- and age-discriminatory taxa and characterizing their effects on 
growth
Acquisition of HCH-derived bacterial taxa in the microbiota of UnCH cagemates was accompanied 
by reductions in the relative abundances of 19 OTUs, six of which were below the limits of detec-
tion (<0.01%) by the end of the co-housing experiment. These observations raised two key ques-
tions. Which member or members of the group of invasive OTUs mediated the observed effects on 
growth phenotypes? To what extent was the reduction in other OTUs that coincided with invasion 
of these taxa responsible for improved growth in UnCH cagemates? Therefore, we initiated an ef-
fort to culture F. prausnitzii and R. gnavus from the fecal microbiota of healthy Malawian infants 
from the iLiNS-DYAD-M cohort. This culturing effort, which encompassed two iLiNS-DYAD-M 
donor microbiota samples (8243C and 3092C), was successful and yielded three additional strains: 
Clostridium nexile (positively correlated to lean mass gain), Clostridium symbiosum (lean mass 
gain discriminatory), and Dorea formicigenerans (weight and lean mass gain discriminatory).
Analogous to the co-housing experiment, male germ-free C57Bl/6J mice were placed on 
the M8 diet at 4.5-weeks-of-age: three days later they were colonized with the intact microbiota 
from the Un donor, with or without an equivalent mixture of the 5-member consortium (Fig. 
5A). This consortium was given as single gavage. Mice were group housed (n=5/cage/treatment 
group/gnotobiotic isolator) based on the notion that there would be a greater chance that consor-
tium members would be evenly distributed among the coprophagic animals. The results revealed 
that administration of the 5-member consortium produced a significant increase in body weight 
and lean mass gain compared to the untreated group (p=0.03, p=0.01, respectively, at the time of 
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sacrifice 21 days after gavage, Mann-Whitney test) (Fig. 5B). Remarkably, only two members 
of the consortium, R. gnavus strain TS_8243C and C. symbiosum strain TS_8243C successfully 
colonized recipient mice [27±3% (mean±SD) and 2.6±0.3% relative abundance, respectively, in 
feces obtained at sacrifice] (Fig. 5C). None of the other members were detected in recipients 
sampled on days 4, 7 and 14 after gavage. Moreover, the efficiency of incorporation of members 
of the Un donor’s microbiota into recipient mice was indistinguishable between the two treatment 
arms: i.e., (i) R. gnavus and C. symbiosum did not result in extirpation of any major constituents of 
the community (the only species that fell below 0.1% was B. bifidum, an organism whose relative 
abundance was only 0.6±0.1% (mean±SD) at time of sacrifice in the control group); and (ii) the 
proportional representation of OTUs with respect to one another was similar in the two treatment 
arms (Fig. 5C, Table S15). These results provide direct evidence that R. gnavus and C. symbiosum 
ameliorate the impaired growth phenotype transmitted by an immature undernourished donor’s 
microbiota. A reconstruction of selected metabolic subsystems in R. gnavus TS_8243C and C. 
symbiosum TS_8243C yielded predictions about factors (prototrophies, auxotrophies, capacity to 
salvage/exchange critical nutrients) that may critically affect their representation in a normal de-
veloping gut microbiota or that could be used to manipulate their representation in an immature 
gut microbiota (see Supplementary Results, Table S16, and Fig. S8). 
The presence of these two organisms also affected metabolic phenotypes (Fig. 5D, Table 
S17). The metabolic features that most discriminated mice with R. gnavus and C. symbiosum from 
the untreated group were acylcarnitines (C5-C16), which were significantly increased in cecal 
samples and decreased in the liver and serum in mice harboring the two taxa (p<0.05, Students t-
test). Some of these acylcarnitines also distinguished mice harboring the H compared to Un donor 
microbiota (Fig. 3A,B). Among metabolites that were decreased in the livers of treated mice were 
C5, C5-DC and C6-DC acylcarnitines, all of which can be derived from branched-chain amino 
acid catabolism. As proposed for the comparison of mice harboring the H versus Un donor micro-
biota shown in Fig. 3, the decrease in these liver metabolites suggests an impact of the presence 
of two growth-promoting taxa on host metabolic machinery that drives amino acids away from 
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oxidation in favor of protein synthesis and lean mass formation. The mechanisms by which the gut 
microbiota communicates metabolically with other tissues remain to be defined.
Prospectus
Human postnatal development is typically viewed from the perspective of our ‘human’ organs. 
As we come to appreciate how our microbial communities assemble following birth, there is an 
opportunity to determine how this microbial facet of our developmental biology relates to healthy 
growth, as well as to the risk for and manifestations of disorders that produce abnormal growth. 
The preclinical studies reported here provide evidence that gut microbiota immaturity is not only 
associated with undernutrition but causally related to it.
There are a number of interrelated factors that could result in disruption of normal gut mi-
crobiota development in infants and children. They include (i) poor maternal nutritional status and 
its potential effects on peripartum changes in the maternal microbiota and breast milk composi-
tion, (ii) enteropathogen invasion, where pathogen susceptibility may be linked to maturity of the 
microbiota if age- and growth-discriminatory taxa are able to produce signals that impact coloniza-
tion efficiency/virulence factor expression, (iii) the history of consumption of antibiotics that may 
affect not only enteropathogen burden but also the representation of age/growth-discriminatory 
members of the microbiota, (iv) disturbances in gut mucosal immune system development which 
may perpetuate microbiota immaturity and impede maturation in the face of therapeutic interven-
tions (20), and/or (v) the history of complementary feeding and the relationship between these 
complementary foods and the nutrient requirements of age/growth-discriminatory taxa. Carefully 
phenotyped birth cohorts provide an opportunity to perform correlation analyses designed to test 
the significance of the relationship between microbiota maturity (and the representation of specific 
age-/growth-discriminatory taxa), anthropometry, and factors (i)-(v) as well as the enigmatic dis-
order currently described as environmental enteric dysfunction (21).
An intriguing observation from the current study is that microbiota from 6-month-old chil-
dren produce greater effects on growth in recently weaned mice than microbiota from 18-month-
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old donors, although in each donor microbiota age bin the effects produced by a healthy donor’s 
age-appropriate community were greater than those produced by an immature undernourished 
donor microbiota. We take these findings to suggest that (i) in healthy children microbiota de-
velopment is optimized to satisfy the different growth needs of the host at different ages, (ii) an 
immature microbiota that is not configured in a manner appropriate for the chronological age of 
the host manifests a form of neoteny that is not conducive to healthy growth, at least in the con-
text of a macro- and micronutrient deficient diet, and (iii) repair of microbiota immaturity needs 
to be complete enough so that it attains age-appropriateness in order to restore healthy growth. 
An associated question relates to how the host will adapt to therapeutic interventions that result 
in a rate of progression of the microbiota from an immature to age-appropriate state over a time 
frame that is shorter than the extent of immaturity (e.g., rescue occurring over 2 months when the 
child has a microbiota which, at time of diagnosis, is 8 months younger than what is appropri-
ate for his/her chronological age). Are there adaptive mechanisms (including those involving the 
mucosal immune system) that feed back to regulate the rate of restoration of microbiota maturity? 
The answers have implications for designing therapeutic strategies that produce durable rescue of 
stunting, neurodevelopmental and/or immunologic abnormalities associated with undernutrition. 
Young gnotobiotic mice colonized with undernourished donor microbiota manifesting varying 
degrees of immaturity, and subjected to microbial interventions at various times after colonization, 
offer one way of exploring these hypotheses/questions pre-clinically.
Clinical trials with ready-to-use complementary foods (RUCFs) of varying composition 
administered for varying periods of time with and without antibiotics have generally produced only 
modest effects on linear or ponderal growth and the associated longer-term sequelae of undernutri-
tion (22). These less than satisfactory clinical outcomes may reflect the need for earlier interven-
tion, longer duration treatment, or development of new food-based interventions, including those 
specifically targeting taxa in the microbiota that are key mediators of healthy growth/metabolism/
immune function. One testable hypothesis is that certain locally available complementary foods 
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that are provided after cessation of exclusive breastfeeding have the ability to promote coloniza-
tion of growth-discriminatory gut taxa in proportions that are age-appropriate.
Gnotobiotic mice colonized with microbiota from chronologically age-matched healthy 
and undernourished donors, and fed diets representative of those consumed by microbiota donors, 
should permit highly controlled, direct tests of the effects of factors such as antibiotics, breast milk 
components (e.g., bovine mimics of human breast oligosaccharides), and complementary foods 
on the representation, expressed functions, and mechanisms by which growth-promoting bacte-
rial strains influence growth, metabolic, bone, immune and neurologic phenotypes. Gnotobiotic 
mice offer an opportunity to ‘enroll’ the microbiota of a given child with undernutrition into all 
arms of an existing, or an envisioned, randomized clinical trial of different interventions. They can 
also be used to ‘rewind time’ for a given individual and re-enact a therapeutic trial that they have 
participated in with original as well as new interventions to compare relative effect sizes. Such 
studies could be used to test the ability of microbiota-directed complementary food (MDCF)-
based interventions alone to durably repair the gut microbiota, or whether adjunctive microbial 
therapies, identified using approaches such as those in the present study, may be required for com-
plete restoration of a healthy microbiota. Ultimately, an initial clinical study, involving the very 
population whose microbiota and diets were used to construct the preclinical gnotobiotic models 
will be needed to establish proof-of-concept that microbiota immaturity can be durably repaired. 
If proof-of-concept is established, then appropriately powered follow-on studies will be needed to 
ascertain the effect size of such repair on healthy growth.
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M.R.C., S.V., and O.I. generated metabolomics data; T.S. and L.V.B. cultured bacterial isolates; 
B.H., D.A.R., S.A.L., and A.L.O. performed metabolic reconstructions of the R. gnavus and C. 
symbiosum genomes; L.V.B., M.R.C., M.J.B., S.S., C.B.N., and J.I.G. analyzed the data; L.V.B. 
and J.I.G. wrote the paper.
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Figure Legends
Fig. 1. Sparse Random Forests-derived model of gut microbiota maturation obtained from 
concordant healthy Malawian twins/triplets. (A) Random-Forests regression of fecal bacterial 
97%ID OTUs from a training set of healthy Malawian infants/children (n=31) to chronological age 
yielded a rank order of age-discriminatory strains. The top 25 most discriminatory OTUs with their 
taxonomic assignments are shown ranked by feature importance (mean±SD of the Mean Squared 
Error, MSE). The insert shows the results of 10-fold cross-validation; as OTUs are added to the 
model in order of their feature importance rank, the model’s error decreases. Taxa highlighted in 
red indicate OTUs with >97% nucleotide sequence identity with an OTU present in a sparse Ran-
dom Forests-based model of microbiota maturation in healthy Bangladeshi infants/children (13). 
(B) A heatmap of the changes over time in relative abundances of the 25 OTUs in the fecal micro-
biota of test set of healthy Malawian infants/children (n=29). OTUs are hierarchically clustered 
according to pairwise distances by Pearson correlation. (C) Predictions of chronological age using 
the sparse 25 OTU model of microbiota age in healthy children comprising the test set cohort. r2 
calculated from Pearson correlation.
Fig. 2. Transplantation of microbiota from 6- and 18-month-old donors to young germ-free 
mice provides evidence of a causal relationship between gut microbiota maturity and growth 
phenotypes. (A) Experimental design of microbiota screen. Mice (4.5-weeks old) were switched 
to the M8 diet three days prior to gavage with the selected microbiota donor’s fecal sample (n=5 
mice per donor). Fecal samples, body weight and body composition were defined at the indicated 
time. Tissues for metabolic phenotyping were collected at sacrifice five weeks after gavage. (B,C) 
Gnotobiotic mice colonized with fecal samples from healthy children gain more total body weight 
(panel b) and lean mass (panel c) than mice colonized with microbiota from undernourished do-
nors (mean±SEM shown; p-values shown for donor status effect based on 2-way ANOVA). All 
recipient mice harbor microbiota that represent >50% of OTU diversity present in the intact un-
cultured donor’s sample. (D) The 30 most weight-gain discriminatory OTUs and their taxonomic 
assignments, ranked by feature importance (mean MSE±SD values are plotted). Taxa in red indi-
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cate OTUs that appear within the 30 most discriminatory OTUs for both the weight and lean mass 
gain Random Forests-based models. Taxa in purple indicate species that appear in the 25-member 
sparse Random Forests-derived model of Malawi gut microbiota maturation. Bars to the right of 
the OTU ID numbers represent Spearman’s rank correlation of the same OTU ID to chronological 
age within the healthy Malawian infant/child cohort (see Table S9).
Fig. 3. Metabolic features that distinguish gnotobiotic mice colonized with a microbiota 
from a 6-month-old healthy infant or an immature microbiota from a 6-month-old severely 
stunted/underweight infant. Metabolic profiles generated by targeted mass spectrometry of (A) 
acylcarnitines in serum, (B) acylcarnitines in liver, and (C) amino acids in gastrocnemius muscle. 
Each metabolite’s concentration differs significantly between the two recipient groups of mice (p 
< 0.05; Student’s t-test).
Fig. 4. Co-housing results in invasion of species from the microbiota of cagemates colonized 
with the healthy donor’s community into the microbiota of cagemates containing the se-
verely stunted/underweight donor’s community and prevention of growth faltering. (A) Ex-
perimental design for co-housing experiments. Dually housed 4.5-week old mice were switched 
to the M8 diet and colonized 3 days later with either the intact uncultured healthy or stunted/un-
derweight donor microbiota. Four days after gavage, subsets of the mice were co-housed (HCH and 
UnCH, respectively), while healthy and stunted/underweight control mice remained in their original 
isolators and were paired with a new cagemate from that isolator (H-H and Un-Un controls). Fecal 
samples were collected throughout the experiment; growth was assayed by changes in total body 
weight and body composition (the latter by qMR). Mice were sacrificed three weeks after colo-
nization. (B) HCH and UnCH mice have increased lean mass gain relative to the Un-Un controls 15 
days post colonization (Un-Un vs. HCH p = 0.0447, Un-Un vs. UnCH p = 0.0121, Mann-Whitney 
test; n=6 cages of co-housed mice, 3 cages of each dually housed control group/experiment; two 
independent experiments). (C) Heatmap showing results of the invasion assay. Each row repre-
sents a species-level taxon, while each column represents a mouse at a given day post colonization 
(dpc); rows of the heatmap were hierarchically clustered according to pair-wise distances using 
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Pearson correlation. Bars at the right side of each experimental arm represent the fold-change 
(fc) in that species’ relative abundance before and after cohousing (fold-change defined by the 
log2[(average relative abundance of species post cohousing (days 7 through 22))/(average relative 
abundance of species before cohousing (day 4))]. Species in red represent those identified as one 
of the top 30 growth-discriminatory taxa by the weight or lean mass gain Random Forests-based 
models shown in Fig. 2.
Fig. 5. A consortium of five cultured age- and/or growth-discriminatory OTUs augments 
the growth of mice colonized with the 6-month severely stunted/underweight donor’s mi-
crobiota. (A) Experimental design including the composition of the 5-member consortium of 
cultured bacterial strains. (B) Weight gain and lean body mass gain 21 days after gavage of the 
donor microbiota with or without the 5-member cultured consortium. (C) Comparison of the fecal 
microbiota of mice belonging to untreated control and treated experimental groups showing the 
establishment of OTUs from the consortium at 21 days post colonization. (D) The effects of treat-
ment with the consortium on host metabolism (p<0.05 for all metabolites shown, Student’s t-test). 
Each row represents a metabolite from a given tissue, while each column represents an individual 
mouse. Tissues were collected 21 days after colonization.
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Supplementary Materials
Materials and Methods
Human Studies
Human studies were conducted with approval of institutional review boards from the University of 
Malawi, Pirkanmaa Hospital, and Washington University School of Medicine. Details of the 317 
infant twin pairs and three sets of triplets enrolled in the Malawi Twin Cohort study from birth to 
32-months-of-age are described in an earlier publication (14).
Enrollment for the iLiNS-DYAD-M study [clinicaltrials.gov #NCT01239693] was open to 
consenting women over the age of 15 years with ultrasound confirmation of a pregnancy that was 
<20 weeks, who had come for prenatal care at one of three study clinics located in Mangochi Dis-
trict of southern Malawi (one public district hospital in Mangochi, one rural semi-private hospital 
in Malindi, and one rural public health center in Lungwena). This randomized, controlled clinical 
trial tested the effects of providing Small Quantity Lipid-based Nutrient Supplements (SQ-LNS) to 
pregnant and lactating women through 6 months postpartum and to their infants from 6-18-months 
of-age (15).
Bacterial 16S rRNA sequencing
Genomic DNA was extracted by suspending pulverized human fecal samples (~50mg), or in 
the case of mouse studies, resuspending fecal pellets in a solution containing 500μL of extrac-
tion buffer [200 mM Tris (pH 8.0), 200 mM NaCl, 20 mM EDTA], 210μL of 20% SDS, 500μL 
phenol:chloroform:isoamyl alcohol (pH 7.9, 25:24:1, Ambion), and 500μL of 0.1-mm diameter 
zirconia/silica beads. Cells were mechanically disrupted using a bead beater (BioSpec Products, 
Bartlesville, OK; maximum setting for 4 min at room temperature), followed by extraction with 
phenol:chloroform:isoamyl alcohol and precipitation with isopropanol.
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PCR was used to generate amplicons (~365bp) of variable region 4 (V4) of the bacterial 
16S rRNA gene using primers and cycling conditions described in a previous report (13). PCR 
primers incorporated sample-specific barcodes allowing samples to be subjected to multiplex se-
quencing using the Illumina MiSeq instrument (paired-end 250nt reads). Paired V4-16S rRNA 
sequences were trimmed to 200bp and merged into a single sequence with Flash software (23). 
Merged sequences were filtered for low quality reads and binned according to their sample-spe-
cific barcodes. Reads were clustered into 97%ID OTUs using UCLUST (24) and the Greengenes 
OTU reference database (version May 2013). Reads that failed to hit the reference dataset were 
clustered de novo using UCLUST. A representative OTU set was created using the most abundant 
OTU from each bin. Reads were aligned using PyNAST. A custom dataset of manually modified 
NCBI bacterial taxonomy (19) was used to train the Ribosomal Database Project (RDP) version 
2.4 classifier (25) and to assign taxonomy to picked OTUs. Validation of this assignment strategy 
is described in a previous publication (19). For analysis of bacterial abundance and colonization 
efficiency, rare OTUs (<0.1% relative abundance within each sample) were removed.
Random Forests-derived Models and Statistical Analysis
Models were generated using the randomForests package in R. 1000 trees were generated per it-
eration, and 100 iterations were performed to generate average MSE values. The rfcv function was 
utilized for cross-validation.
Univariate analyses (t-tests and ANOVA) were performed using Microsoft Excel or Prism 
6.0 (GraphPad Software, Inc.). Heat maps were generated using Gene-E software (http://www.
broadinstitute.org/cancer/software/GENE-E/index.html). Spearman’s rank correlation analyses 
were performed in the R environment using the ltm package and rcor.test function.
Gnotobiotic Mouse Studies
All gnotobiotic mouse experiments were performed using protocols approved by the Washington 
University Animal Studies Committee. Male germ-free C57Bl/6J mice were maintained in sterile, 
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flexible, plastic gnotobiotic isolators (Class Biologically Clean Ltd., Madison, WI) under a strict 
12-hour cycle (lights on at 0600, off at 1800h). Mice were fed an autoclaved low-fat, polysaccha-
ride-rich chow (LF/HPP) diet (B&K University, East Yorkshire, U.K.; diet 7378000) from wean-
ing until 3 days prior to the beginning of an experiment. At that time, 4.5-week old male mice were 
switched to the M8 diet for the remainder of the experiment. All animals were euthanized without 
prior fasting.
Preparation of the Malawi-8 (M8) Diet
This prototypic Malawian diet was formulated based on the results of a dietary survey of the 
complementary feeding practices of 9-month-old Malawian children enrolled in the iLiNS-DOSE 
study (#NCT00945698) that took place in the Mangochi district. The macro- and micronutrient 
content of components of the children’s diets was computed using the USDA Nutrient Database, 
and linear programming was employed to calculate combinations of ingredients that resembled the 
mean energy and nutrient values for foods identified from the dietary survey.
The M8 diet was prepared as follows. Maseca® corn flour was obtained from Restau-
rant Depot (College Point, NY). The remaining ingredients were purchased from Whole Foods 
Supermarkets. A relish containing 2kg mustard greens, 1.5kg onions, and 1.5kg tomatoes was 
first prepared by pureeing them in a food processor (Robot Coupe Model R23, Jackson, MS) and 
cooking the puree in 1L water for 60 minutes on a Corning stirrer/hot plot (high setting, until 
browned). After cooking, the relish was combined with a pureed mixture of 1kg ground peanuts, 
700g soaked red kidney beans, 1kg canned pumpkin, and 2.5kg peeled bananas in an industrial 
mixer (Globe SP30P 30-quart pizza mixer; gear speed 1; Globe Food Equipment Company, Day-
ton, OH). Corn flour (5kg) and hot, freshly autoclaved water (5L) were then added slowly and 
mixed using the industrial mixer for 5 minutes to ensure uniformity of the food. Dry pellets of 
the M8 diet were generated (extruded diameter, 0.5-inch) (Dyets, Inc. Bethlehem, PA), placed in 
FDA/USDA-compliant poly-nylon vacuum pouches (#S-7556; Uline, Pleasant Prairie, WI; 500 g 
aliquots), double-bagged and sterilized by irradiation (20-50 kGy) within 24 hours of production 
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(Steris Co; Chicago, IL). The nutritional content of all cooked and irradiated custom diets was 
defined by N.P. Analytical Laboratories (St Louis, MO) (Table S4). Irradiated food was stored at 
4°C for up to six months. Sterility was determined by resuspending a small aliquot of each batch 
of food in pre-reduced Gut Microbiota Medium (GMM; (26)) under anaerobic conditions and 
incubating the suspension for 3 days at 37°C. Sterility was further verified by subculture on pre-
reduced anaerobic GMM agar plates.
Generation of clarified stool for gavage into gnotobiotic mice
An aliquot of the frozen sample was pulverized in a Biosafety Class II hood with a ceramic mor-
tar and pestle filled with liquid nitrogen. An aliquot (1g) of the pulverized material, sealed in a 
sterile screw-capped tube (Axygen SCT-200-C-S), was brought into an anaerobic Coy chamber 
(atmosphere: 20% CO2, 5% H2, and 75% N2), immediately suspended in 15mL GMM and vortexed 
on maximum speed (four cycles of blending for 20 seconds followed by a 30 second pause). The 
sample was allowed to stand for 5 minutes so that particulate matter could settle by gravity; the 
resulting supernatant was passed through a 100μm pore diameter filter (BD systems, Inc. Franklin 
Lakes, NJ) to remove remaining particulate material, mixed with an equal volume of pre-reduced 
GMM containing 30% glycerol (final concentration 15% glycerol) and placed in Wheaton crimp 
top tubes for storage at -80°C. Mice received a single oral gavage (200µL) of a clarified uncultured 
human fecal sample 3 days after switching to the M8 diet.
Quantitative magnetic resonance (qMR) analysis of body composition
Body composition was defined using an EchoMRI-3in1 instrument (EchoMRI, Houston, TX). 
Each mouse was transported from a gnotobiotic isolator to the MR instrument in a 9.5” long, 2” 
diameter, HEPA filter-capped glass vessel. At each time point surveyed, each mouse was scanned 
2-3 times in the instrument over a 5 minute period and the values from each scan were averaged.
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Sample collection
Fecal samples were collected at defined times after gavage. At sacrifice, cecal contents, liver, brain, 
and skeletal muscle (gastrocnemius) were collected and immediately frozen in liquid nitrogen. 
Gastrocnemius muscle was freeze-clamped immediately after sacrifice using pre-cooled forceps.
Micro-computed tomography (micro-CT)
Femurs were harvested from mice at time of sacrifice, cleaned of soft tissue and stored at 4°C in 
70% ethanol solution until scanned. Micro-CT was performed using a μCT 40 desktop, cone-beam 
instrument (ScanCO Medical, Brüttisellen, Switzerland). For cortical analyses, 200-300 slices 
were taken of each femur in the transverse plane with a 6μm voxel size (high resolution). For all 
cortical scans, slices began at the midpoint of the femur and extended toward the distal femur. 
Boundaries of and thresholds for bone were drawn manually using the μCT 40 software, and volu-
metric parameters (bone volume/tissue volume, bone mineral density, and cortical thickness) were 
calculated using custom scripts.
Co-housing experiments
Four days after gavage of donor microbiota, all mice were placed into HEPA filter-capped glass 
transport tubes for qMR measurements. Following qMR, control mice were returned to their origi-
nal gnotobiotic isolator and housed with a cagemate of similar body weight colonized with the 
same donor microbiota (H-H controls; Un-Un controls). For pairing of UnCH and HCH mice, ani-
mals were transported to a new gnotobiotic isolator. All mice received fresh autoclaved bedding 
(Aspen wood shavings, NEPCO) upon initiation co-housing. Bedding was changed weekly in all 
cages in each gnotobiotic isolator.
Targeted mass spectrometry
Liver, brain, and muscle tissue samples were homogenized in 50% aqueous acetonitrile containing 
0.3% formic acid (50mg wet weight tissue/mL solution) using a high-speed homogenizer (IKA 
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Model #EW-04739-21) set at maximum speed for 30-45 seconds. Samples were maintained on ice 
or dry ice throughout homogenization.
Amino acids, acylcarnitines, organic acids, acyl CoAs and ceramides were analyzed using stable 
isotope dilution techniques. Amino acids and acylcarnitine measurements were made by flow in-
jection tandem mass spectrometry using sample preparation methods described previously (27, 
28). Data were acquired using a Waters AcquityTM UPLC system equipped with a TQ (triple quad-
rupole) detector and a data system controlled by MassLynx 4.1 operating system (Waters, Milford, 
MA). Organic acids were quantified according to a previously published protocol (29) using Trace 
Ultra GC coupled to ISQ MS operating under Xcalibur 2.2 (Thermo Fisher Scientific, Austin, TX). 
Acyl CoAs were extracted and purified as described previously (30-32), and analyzed by flow 
injection analysis using positive electrospray ionization on a Xevo TQ-S triple quadrupole mass 
spectrometer (Waters, Milford, MA). Heptadecanoyl CoA was employed as an internal standard. 
Ceramides were extracted (33) and analyzed by flow injection tandem mass spectrometry using a 
Xevo TQS spectrometer (Waters Milford, MA,) for precursors of m/z 264.
Culturing and characterization of age- and/or growth- discriminatory bacterial strains from 
the microbiota of healthy Malawian children
Culturing – Fecal samples were resuspended in 10ml of GMM under anaerobic conditions, di-
luted 1:1000, and then plated onto GMM and incubated at 37°C under anaerobic conditions over-
night. Isolated colonies were picked into single wells of a deep 96-well plate, with 600m l liquid 
GMM per well, and grown anaerobically at 37°C overnight. Cultures were then mixed with an 
equal volume of pre-reduced GMM containing 30% glycerol (final concentration 15% glycerol) 
for storage at -80°C. To assign taxonomy, DNA was extracted from each well and V4-16S rRNA 
sequenced. Taxonomies were confirmed by sequencing full-length 16S rRNA amplicons generated 
using primers 8F and 1391R.
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Genome sequencing of two strains obtained from the healthy infant Malawian donor 8243C
DNA libraries for sequencing R. gnavus TS_8243C and C. symbiosum TS-8243C on Illumina 
MiSeq were prepared using a multistep protocol of end-repair, A-tailing, and ligation to custom-
ized sample-specific barcoded Illumina adapters. The resulting adapter-ligated DNA was size-
selected (250-350bp) using agarose gel electrophoresis and then used as a template for enrichment 
PCR (cycling conditions: 98°C for 30 sec, followed by 18 cycles of 98°C for 10 sec, 65°C for 30 
sec, 72°C for 45 sec, and then 72°C for 5 minutes). Multiplex sequencing was performed (paired-
end 250nt reads). Genomes were assembled with the mira software package (34). For R. gnavus 
TS_8243C N50 contig length was 2263429bp with an aggregate genome size of 3.7Mbp. For C. 
symbiosum TS_8243C, N50 contig length was 328298bp with a 5.3Mbp genome size. Annotation 
was initially performed using PROKKA (see Supplementary Results for metabolic reconstruc-
tions) (35).
Supplementary Results
Genomics-based reconstruction of selected metabolic subsystems in R. gnavus and C. 
symbiosum strains
Our approach to the reconstruction of selected metabolic pathways (also termed as subsystems) 
was based on functional gene annotation and prediction using two comparative genomics tech-
niques: (i) homology-based methods and (ii) genome context analysis. First, we scanned their 
predicted proteomes against the KEGG Orthology, Pfam, CAZY, TCDB, Uniprot and SEED data-
bases to identify proteins potentially involved in the carbohydrate utilization, amino acid metabo-
lism and vitamin and cofactor biosynthesis and salvage pathways. We then analyzed the genomic 
and functional contexts of loci encoding the proteins and reconstructed the respective metabolic 
pathways and transcriptional regulons. For the comparative genomics-enabled pathway and regu-
lon inference, we used additional closely related bacterial genomes available in the Integrated Mi-
crobial Genomes (36) and SEED databases (37). Transcriptional regulons (sets of genes co-regu-
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lated via shared transcription factors (TFs) and transcription factor binding sites (TFBS) or shared 
RNA elements, riboswitches, responding to respective pathway metabolites) were predicted and 
reconstructed using the comparative genomics approach (38) implemented in the RegPrecise data-
base (39). This integrative subsystems-based approach was previously used for reconstruction of 
carbohydrate utilization pathways and regulons in the Shewanella, Thermotoga, and Bacteroides 
lineages (40-42).
Carbon and energy: central carbon metabolism, carbohydrate utilization, and short chain 
fatty acid production (Fig. S8A and Table S16).
Overview
We applied the integrated subsystems-based approach described above to systematically map cen-
tral carbon metabolism, peripheral carbohydrate utilization, and fermentation pathways in the se-
quenced genomes of the two TS_8243C strains.
Central carbon metabolism
Both the R. gnavus and C. symbiosum strains possess the complete glycolysis/gluconeogenesis and 
pentose phosphate (PP) pathways, as well as the key enzymes involved in conversion of pyruvate 
to acetyl-CoA or oxaloacetate, and reverse conversion of oxaloacetate to phosphoenolpyruvate 
(PEP). Genes encoding key glycolytic enzymes, as well as key fermentation pathways (see below), 
are co-regulated by the redox-responsive transcriptional regulator Rex (43). The PP pathway in C. 
symbiosum involves multiple paralogs of genes encoding transketolase (TktAB) and transaldolase 
(Tal). In addition, C. symbiosum (but not R. gnavus) encodes the oxidative pathway for utilization 
of glucose-6 phosphate via the PP pathway (Zwf, Pgl, Gnd).
The tricarboxylic acid (TCA) cycle is incomplete in both strains. In R. gnavus, it involves 
two parts: (i) interconversion of pyruvate to malate and fumarate and (ii) fusion of oxaloacetate 
and acetyl-CoA to produce 2-oxoglutarate, a key precursor for glutamate biosynthesis. In contrast, 
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C. symbiosum possesses only the former pathway for conversion of pyruvate to malate and fuma-
rate. The C. symbiosum strain also has the fumarate reductase FrdABC allowing synthesis of suc-
cinate, which is further fermented to produce butyrate and butanol via the committed pathway (see 
below). Interestingly, FrdABC is also present in the reference ATCC 29149 strain of R. gnavus but 
it is missing from the TS_8243C strain, suggesting the former but not the latter strain is capable 
of producing succinate, which is likely excreted as an additional fermentation product since the 
succinate fermentation pathway is absent in R. gnavus.
Carbohydrate utilization (CU) pathways
The reconstructed carbohydrate utilization (CU) potentials of the two Malawian TS_8243C strains 
differ substantially from each other and include numerous novel carbohydrate-specific regulators, 
transporters, and enzymes that are not orthologous to previously characterized proteins (marked 
by an asterisk in Table S16 and Fig. S8A). In R. gnavus, we predicted 28 novel regulators, most 
of which belong to the AraC family and 35 transporter genes encoding 16 transporter complexes, 
whereas the reconstructed CU pathways in C. symbiosum contain 5 novel regulators and 17 trans-
porter genes (5 transporter complexes). Among the most notable novel forms of monosaccharide 
catabolizing enzymes identified in the reconstructed pathways are xylose isomerase (XylA), tag-
atose-6P isomerase (LacC), galactitol kinase (GatK), and bifunctional fuculose-P/rhamnulose-P 
aldolase (FucA) in R. gnavus, as well as arabinose isomerase (AraI) and mannitol dehydrogenase 
(MtlD) in C. symbiosum.
The conserved CU components between R. gnavus and C. symbiosum include 17 genes 
encoding the glucose phosphotransferase system (PTS) transporter and glucokinase (PtsG, Glk), 
galactose catabolic enzymes (GalK, GalM, GalT, GalE), the fructose PTS transporter and catabol-
ic enzymes (FruA, FruK, ScrK), N-acetylglucosamine and sialic acid catabolic enzymes (NagA, 
NagB, NanK, NanA, NanE), galacto-N-biose phosphorylase (GahP), and two neopullulanase iso-
zymes (NplT, NepU). These shared CU genes, combined with other strain-specific upstream path-
way components such as sugar transporters and hydrolytic enzymes, provided the respective CU 
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phenotype predictions for each strain. R. gnavus is predicted to utilize glucose, fructose and its oli-
gosaccharides, lactose, alpha-and beta-galactosides, N-acetylglucosamine, N-acetylneuraminate 
and sialic acids, as well as maltodextrins. (However, we were unable to find a galactose transporter 
in R. gnavus suggesting it can only utilize galactose oligosaccharides.) In contrast, C. symbiosum 
uses the above 17 shared genes and additional upstream components for utilization of glucose, 
fructose and its oligosaccharides, beta-galactosides, N-acetylneuraminate and chitobiose (although 
the respective transporter is missing). In both strains, we were unable to identify a galacto-N-biose 
transporter, despite the presence of galacto-N-biose phosphorylase and all downstream enzymes 
for catabolism of galactose and N-acetylglucosamine-P.
In addition to the CU pathways described above that involve shared genes and other non-
conserved upstream pathway genes, R. gnavus TS_8243C and C. symbiosum TS_8243C possess 
126 and 26 strain-specific CU genes, respectively. R. gnavus has predicted pathways for utilization 
of sucrose, beta-xylosides and rhamnogalacturonides (but not xylose and rhamnose since the re-
spective monosaccharide transporters are missing), fucose and fucosides (with at least eight copies 
of alpha-L-fucosidases), glucuronides and polygalacturonate (but not glucuronate/galacturonate 
for which we found no transporters), beta-glucosides and cellobiose, meliobiose, fucosyllactose, 
hyaluronate as well as galactitol (although a galactitol transporter is missing from the reconstruc-
tion). Orthologs of genes comprising these R. gnavus-specific pathways are absent from C. sym-
biosum TS_8243C, but many of them can be identified in other gut symbionts. C. symbiosum 
TS_8243C has only three additional unique pathways for utilization of monosaccharides, namely 
arabinose, mannitol, and gluconate. Thus, we predict that R. gnavus has a greater potential to 
utilize di- and oligosaccharides, including sugars originating from milk (such as lactose, fucosyl-
lactose, fucosylated oligosaccharides) as compared to C. symbiosum.
R. gnavus TS_8243C and C. symbiosum TS_8243C have shared and unique pathways for 
utilization of other carbon sources, in addition to the carbohydrates described above. Both strains 
share the glycerol and D-lactate utilization pathway components (GlpK, GlpD, GlpD, UgpABCE, 
and LdhD). C. symbiosum TS_8243C has unique pathways for utilization of ethanolamine and 
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citrate that involve the B12-dependent ethanolamine ammonia-lyase EutABC and the CoA-de-
pendent citrate lyase complex CitFEDC. The latter enzyme is represented by multiple paralogs 
in the C. symbiosum genome and is accompanied by two copies of the citrate transporter CitN. R. 
gnavus has a unique pathway for utilization of D-glycerate, which involves a predicted transporter 
(GrtP*), kinase (GarK), and repressor (SdaR). Pathways for utilization of certain amino acids as 
potential carbon sources are described in the following section below.
In the case of C. symbiosum, comparison of CU genes in the TS_8243C and the refer-
ence WAL-14163 type strains did not reveal any differences. This was not the case for R. gnavus. 
The TS_8243C strain of R. gnavus has 36 CU genes that are missing in the ATCC 29149 type 
strain. Most of the R. gnavus TS_8243C-specific genes are organized into five individual gene 
loci encoding the complete pathways for utilization of beta-glucosides, beta-xylosides, meliobi-
ose, lactose and beta-galactosides that involve dedicated transporters, regulators and sugar hydro-
lytic enzymes. Additional R. gnavus TS_8243C-specific genes, including four copies of alpha-L-
fucosidases, three beta-glucosidases, two beta-galactosidases, alpha-rhamnosidase (all predicted 
cytoplasmic glycoside hydrolases), as well as an extracellular beta-glucanase, LicB, are scattered 
thoughout the chromosome (whether they are co-regulated with downstream CU pathway genes 
remains to be determined). A second copy of rhamnogalacturonyl hydrolase (RhiN2) is encoded 
within the polygalacturonate utilization gene cluster in R. gnavus TS_8243C but not in the ATCC 
29149 strain. In contrast, the ATCC 29149 strain of R. gnavus has only eight strain-specific CU 
genes that are missing from the TS_8243C strain. These genes are potentially dispensable since 
they encode second copies of maltose/maltodextrin and sucrose utilization operons.
Short-chain fatty acid production
Short-chain fatty acids (SCFAs), the end products of fermentation of dietary carbohydrates and 
polysaccharides, exert multiple beneficial effects on mammalian energy metabolism and provide 
a primary energy source for colonic epithelial cells (44). Our metabolic reconstruction of central 
carbon metabolism in the R. gnavus TS_8243C and C. symbiosum TS_8243C strains revealed both 
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shared and strain-specific pathways for fermentation of various carbon sources and production of 
SCFAs. Moreover, gene sets comprising the SCFA production pathways of the two TS_8243C 
strains (23 genes in R. gnavus and 38 genes in C. symbiosum) are essentially identical to those of 
the corresponding reference strains.
Both the R. gnavus TS_8243C and C. symbiosum TS_8243C strains possess complete 
pathways for production of formate, lactate, acetate and ethanol from pyruvate. R. gnavus has a 
unique pathway for production of propionate/propanol by fermentation of fucose and rhamnose via 
the committed CU pathways (see above). This pathway involves lactaldehyde reductase (FucO) 
and B12-dependent propanediol dehydratase (PduABCD), plus several other downstream enzymes 
for conversion of propionaldehyde to propionate and propanol. We postulate that the predicted 
transcriptional regulator PduR* from the DeoR family controls genes from this unique pathway. 
C. symbiosum TS_8243C has the complete pathway for conversion of acetyl-CoA to butyrate 
and butanol via crotonoyl-CoA and butyryl-CoA intermediates (as previously described in (45)). 
Most of the butyrate synthesis pathway genes are organized into a single gene locus controlled 
by the redox-responsive transcriptional regulator Rex (43). Two other pathways in C. symbio-
sum TS_8243C that are potentially used for the synthesis of the crotonoyl-CoA (which is further 
converted to butyrate and butanol) start from succinate and 2-oxoglutarate, respectively. The first 
pathway includes the predicted succinate-semialdehyde dehydrogenase AldD* and proceeds via 
4-hydroxybutyrate and 4-hydroxybutyl-CoA intermediates. Succinate for this pathway is provided 
by the fumarate reductase FrdABC, which is also present only in C. symbiosum. Another pathway 
for butyrate synthesis has a missing enzymatic activity, 2-hydroxyglutarate dehydrogenase, while 
the conversion of 2-hydroxyglutarate to crotonoyl-CoA is catalyzed by three enzymatic complexes 
(GctAB, HgdABC and GcdABC). The potential source of 2-oxoglutarate for the latter pathway of 
butyrate production is degradation of exogenous L-glutamate via glutamate dehydrogenase Gdh, 
since isocitrate dehydrogenase Icd is absent from C. symbiosum TS_8243C (see the section on 
amino acid degradation below).
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C. symbiosum TS_8243C also has the complete pathway for further conversion of lactate 
to propionate, which involves propionate CoA-transferase (Pct), lactoyl-CoA dehydratase (Lcd), 
acryloyl-CoA reductase (Acr) and is equipped with predicted propionate permease (PrpP*) for 
end product excretion. Thus, C. symbiosum TS_8243C and R. gnavus TS_8243C possess distinct 
pathways for production of propionate.
Amino acids (Fig. S8B and Table S16)
By using the metabolic subsystem approach implemented in the SEED genomic platform (46) and 
RAST server (37), we reconstructed metabolic pathways for 20 amino acids by identifying the 
committed enzymes, potential amino acid transporters and transcriptional regulators in R. gnavus 
TS_8243C and C. symbiosum TS_8243C.
We found that both R. gnavus TS_8243C and C. symbiosum TS_8243C are capable of syn-
thesizing most amino acids de novo. The histidine biosynthesis pathway in R. gnavus TS_8243C 
is composed of 11 committed enzymes, most of which are organized into a single operon, which 
is controlled by a HisR repressor. The HisR regulon in R. gnavus also includes the predicted 
ABC-type His transporter HisXYZ* suggesting it can also salvage exogenous His. In contrast, 
the reconstructed HisR regulon in C. symbiosum includes the hutH-yuiF operon involved in His 
uptake and degradation; other His degradation genes were also identified in this genome. Thus, C. 
symbiosum is a predicted His auxotroph able to salvage exogenous His and use it both for protein 
synthesis and as a source of carbon, energy and nitrogen. Glutamate is synthesized from 2-oxo-
glutarate using the committed enzyme glutamate synthase GltBD, which is present in R. gnavus 
but not in C. symbiosum, suggesting the latter is a Glu auxotroph. In support of this prediction, we 
found two copies of the glutamate uptake transporter gene gltS in C. symbiosum TS_8243C but 
not in R. gnavus TS_8243C. Furthermore, C. symbiosum TS_8243C but not R. gnavus TS_8243C 
has a unique pathway for degradation of exogenous glutamate to produce butyrate, an important 
short-chain fatty acid that provides energy to colonocytes and has been reported to be capable of 
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inducing production of colonic Foxp3+ CD4+ regulatory T cells (Tregs; (47-49)) (see Fig. S8A, 
plus the section on carbon and energy above).
In addition to the His and Glu uptake transporters described above, specific amino acid 
transporters were predicted for arginine, tyrosine, tryptophan, glutamine, branched chain amino 
acids (isoleucine/leucine/valine), alanine and methionine. These amino acid uptake transporters 
were found both in R. gnavus and C. symbiosum suggesting that these organisms can salvage these 
amino acids from the environment, thus providing an alternative way to supply their biosynthetic 
needs. Uptake transporters for other amino acids are as yet unknown in analyzed Clostridiales 
species.
As noted in the main text, we identified a link between perturbations in microbiota matu-
ration and perturbations in brain metabolism, raising the question of how normal development 
of the gut microbiota is linked to healthy brain development. Tryptophan is a precursor of the 
b-arylamine neurotransmitter tryptamine, which was recently found to be produced by tryptophan 
decarboxylase in several gut Clostridiales, including R. gnavus (50). Tryptamine has a range of 
biological activities; notably, it is found in low quantities in the brain and is a ligand for the trace-
amine-associated receptors (TAARs) that potentiate neuronal inhibition to serotonin (51). The R. 
gnavus gene RUMGNA_01526 (named Trd, see Fig. S8B) encoding tryptophan decarboxylase 
has an ortholog in the R. gnavus TS_8243C strain, suggesting that is able to produce tryptamine. 
In contrast, both strains of C. symbiosum do not have a Trd ortholog.
B-vitamins (Fig. S8C and Table S16)
Vitamins B1 (thiamin), B2 (riboflavin), B3 (niacin), B5 (pantothenate) and B6 (pyridoxine) 
are precursors of thiamin pyrophosphate (TPP), flavin mono- and dinucleotide (FMN and FAD), 
nicotinamide adenine dinucleotide (NAD), coenzyme A (CoA) and pyridoxal phosphate (PLP), 
respectively. Taken together, these cofactors drive hundreds of indispensable biochemical trans-
formations including redox reactions (FMN/FAD and NAD), central carbon metabolism (CoA and 
TPP) and transamidation (PLP). Importantly, none of these phosphorylated cofactors can be deliv-
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ered into cells in their final form. Other B-vitamins, B7 (biotin), B9 (folate) and B12 (cobalamin) 
and their derivatives serve as cofactors of important enzymes involved in fatty acid biosynthesis, 
single carbon metabolism, methionine biosynthesis, and a few other pathways.
We have previously applied the subsystems-based approach described above to character-
ize the biosynthesis, uptake/salvage, recycling of B vitamin related co-factors across numerous 
diverse bacterial species (52, 53). This analysis is captured in a curated collection of subsystems 
in the SEED genomic platform (http://pubseed.theseed.org/) (46), which we recently expanded 
to include > 1,000 genomes from Human Microbiome Project (HMP, http://hmpdacc.org/). In 
general, only limited variations of the main biosynthetic steps and corresponding enzyme families 
are observed, even between very distant species. Components of B-vitamin transport and regula-
tory systems are far more diverse and remain to be identified in many bacterial lineages. The most 
common type of variation is between: (i) organisms capable of synthesizing a particular cofactor 
de novo (prototrophs) and (ii) those that are strictly dependent on an exogenous (dietary) supply 
of a respective B-vitamin or other precursor(s) (auxotrophs). Genomic signatures distinguishing 
prototrophs and auxotrophs for eight common B-vitamins (B1, B2, B3, B5, B6, B7, B9, B12) were 
revealed from a recent analysis of 256 representative HMP genomes (54). Widespread auxotro-
phy among species colonizing the distal gut points to syntrophic B-vitamin metabolism (“vitamin 
exchange”) as a likely prominent feature of the community. Thus, elucidating specific B-vitamin 
requirements for strains that define the different stages of gut microbial community assembly, 
and whose representation in the microbiota is linked to growth, metabolic, immunologic and/or 
neurologic phenotypes is not only important for understanding the ‘rules’ that govern normal mi-
crobiota development but could also yield interventions designed to treat microbiota immaturity 
in undernourished children.
Addition of the R. gnavus TS_8243C and C. symbiosum TS_8243C genomes to eight B-
vitamin subsystems (using RAST server (37)) for automated projection followed by manual cura-
tion, analysis of genomic context, and gap-filling confirmed their multiple auxotrophies, a charac-
teristic feature of most host-associated Clostridiales. This distinguishes them from their free-living 
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phylogenetic neighbors (such as C. acetobutylicum) or other prominent members of the distal 
human gut microbiota, such as the Bacteroides that are typically prototrophic for all B-vitamins 
(except B12, as previously described (54)). The gene sets comprising the B-vitamin/cofactor re-
construction (a total of 54 genes in R. gnavus TS_8243C and 65 in C. symbiosum TS_8243C) are 
essentially identical to those in the corresponding HMP reference type strains. These reconstruc-
tions are displayed as pathway diagrams in Fig. S8C and are briefly described below.
Thiamin (vitamin B1)
A common precursor of thiamin pyrophosphate (TPP), an essential cofactor of several ubiquitous 
enzymes in central carbon metabolism, most notably the pyruvate dehydrogenase complex. Nei-
ther R. gnavus, nor C. symbiosum have a complete set of enzymes for de novo synthesis of TPP, 
and thus should be considered B1 auxotrophs. Both strains contain the key thiamin salvage enzyme 
ThiN (thiamin pyrophosphokinase, EC 2.7.6.2). Different types of B1-specific transporters, ThiT 
(of ECF family (55)) and ThiXYZ (of ABC family) could be identified in R. gnavus, but and C. 
symbiosum, respectively. Alternatively, or in addition to thiamin salvage, both strains are capable 
of synthesizing TPP using exogenous thiazole via the dedicated salvage enzyme ThiM (hydroxy-
ethylthiazole kinase, EC 2.7.1.50). However, in this case, the respective thiazole transporter, ThiW 
(55) was confidently identified only in C. symbiosum. Both strains have the complete machinery 
for synthesis of the second biosynthetic intermediate (HMP-PP), joining it with thiazole-P, and 
downstream phosphorylation to yield the mature TPP cofactor.
The challenge of accurate homology-based functional assignment of transporters can of-
ten be effectively addressed by analyzing genomic context (57), most importantly, operons and 
predicted regulons (sets of co-regulated genes). In this example, all of the aforementioned trans-
porters in both R. gnavus TS_8243C and C. symbiosum TS_8243C were implicated as members 
of predicted regulons controlled by the TPP-specific riboswitch. RNA-based regulatory elements 
(riboswitches) are among the most common types of regulators of vitamin/cofactor metabolism 
that can be confidently mapped in genomes by computational methods due to their highly con-
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served secondary structures (58). In addition to transporters, TPP-responding riboswitches regu-
late expression of nearly all biosynthetic enzymes (except ThiN, which is predicted to contribute 
to both de novo B1 synthesis and salvage routes); the repertoire of these co-regulated enzymes is 
conserved between R. gnavus and C. symbiosum.
Riboflavin (vitamin B2)
A precursor and biosynthetic intermediate of the essential redox cofactors flavin mononucleotide 
(FMN) and flavin adenine dinucleotide (FAD) (involved in the electron transfer chain and several 
other essential processes). The complete canonical de novo riboflavin biosynthetic pathway, from 
GTP and D-ribulose-5-phosphate, is present in C. symbiosum TS_8243C but all respective genes 
are absent in R. gnavus TS_8243C. This is one of the two primary distinctions between these two 
strains, which are otherwise quite similar in terms of their B-vitamin proto- and auxotrophies. 
While this difference cannot be easily rationalized, R. gnavus TS_8243C, unlike C. symbiosum 
TS_8243C, lacks fumarate reductase, one of the primary flavin-dependent enzymes in central car-
bon metabolism (see above). Both strains have a committed riboflavin transporter RibU (55), 
which is essential for R. gnavus but likely dispensable for C. symbiosum, as well as an essential 
bi-functional enzyme RibF for converting riboflavin to FMN and then, FAD. A FMN-sensitive 
riboswitch is present to regulate RibU expression in both strains and de novo synthesis in C. sym-
biosum TS_8243C.
Niacin (vitamin B3)
Niacin, or nicotinic acid, as well as nicotinamide are converted to the most abundant redox co-
factors, NAD and NADP; these cofactors are collectively involved in ~10% of all cellular bio-
chemical transformations. Reconstruction of this subsystem in both R. gnavus TS_8243C and C. 
symbiosum TS_8243C includes both de novo synthesis of NAD from aspartate (prototrophy), and 
potential (optional) salvage of B3 and its amidated precursor. However, the B3 transporter NiaY 
(55) is present only in C. symbiosum TS_8243C. In the absence of additional data, it is impossible 
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to distinguish between two possible interpretations: (i) R. gnavus has a B3 transporter of another, 
yet unknown, type or (ii) the enzymes PncA and PncB are predominantly involved in recycling of 
intracellular nicotinamide, a well-known product of NAD degradation. The first possibility seems 
more likely since in both strains, all three genes of the upstream de novo pathway (from aspartate 
to NaMN) are predicted to be under the control of the NiaR repressor (based on the RegPrecise 
database), which would suppress this pathway when B3 is present (59).
Pantothenate (vitamin B5)
An intermediate in the biosynthesis of CoA, the universal and indispensable cofactor in a variety 
of acyl transfer reactions, most importantly in fatty acid biosynthesis (after transfer of pantetheine 
to acyl-carrier protein), degradation and the TCA cycle. Both strains lack components for de novo 
synthesis of pantothenate and, thus, would be considered B5 auxotrophs. However, auxotrophy is 
fully applicable only to R. gnavus TS_8243C, which has a complete set of downstream enzymes 
for the 5-step conversion of pantothenate to CoA. An interesting distinction of C. symbiosum 
TS_8243C is the absence of two enzymes CoaB and CoaC (typically a fusion protein in bacteria). 
This “gapped” pattern, which occurs in many diverse bacteria, was predicted (52) and later veri-
fied as a signature of the alternative salvage of pantetheine. This metabolite, a product of CoA 
degradation, can be phosphorylated (apparently via the second activity of pantothenate kinase), 
by-passing CoaBC-mediated steps and yielding a substrate for the next step catalyzed by CoaD. 
Therefore, C. symbiosum TS_8243C should be considered a pantetheine rather than a pantothenate 
auxotroph. This genomic signature is rather common among the HMP reference genomes, leading 
to a testable hypothesis that pantetheine should be present in human guts and function as prebiotic 
for some of members of the microbiota, such as C. symbiosum TS_8243C and raising the question 
about its source. We hypothesize that a homolog of the pantothenate symporter PanF, which is 
present in C. symbiosum instead of the PanT transporter as in R. gnavus TS_8243C, is a likely can-
didate for pantetheine transporter, since its canonical function would be obsolete in this organism.
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Transcriptional regulation of CoA biosynthesis has not been described in any microbial 
system. Not surprisingly, our reconstruction of this pathway does not include any regulatory pre-
dictions.
Pyridoxine (B6)
A precursor but not a biosynthetic intermediate of the pyridoxal phosphate (PLP) cofactor that 
drives numerous transamination, decarboxylation and epimerization reactions of various amino 
acids. This pathway reveals a second major phenotypic distinction between R. gnavus TS_8243C 
and C. symbiosum TS_8243C. In contrast to the pattern with riboflavin (B2), C. symbiosum is a B6 
auxotroph, whereas R. gnavus is a B6 prototroph. Both C. symbiosum and R. gnavus contain a B6 
transporter (PdxU) (55), which is regulated by the PdxR repressor. We were unable to find a strong 
candidate gene encoding the enzyme PdxH, which oxidizes pyridoxine or pyridoxine phosphate 
to the functionally active aldehyde. Based on the pathway logics, it represents a classical “missing 
gene” problem (60), and thus a subject for further bioinformatic and experimental analyses. As in 
case of B5, essentially nothing is known and could be predicted about transcriptional regulation of 
B6/PLP metabolism in these two species.
Biotin (B7)
Biotin is the critical cofactor in transcarboxylation reactions (including the initiation of fatty acid 
synthesis); it performs its function after covalent attachment to carrier protein(s) by the univer-
sally conserved and essential enzyme BirA (biotin ligase). At first glance, both strains could be 
deemed B7 auxotrophs, and this is how they were described in the survey of 256 reference HMP 
genomes (54). Indeed, neither R. gnavus TS_8243C nor C. symbiosum has recognizable enzymes 
involved in the upstream steps of B7 biosynthesis, including the critical enzyme BioF (8-amino-
7-oxononanoate synthase). Both strains contain the biotin transporter BioY (55) predicted to be 
under control of the same transcriptional repressor (the second function of the bifunctional protein 
BirA (61)). At the same time, both species also contain BioB pointing to dethiobiotin as a potential 
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alternative “surrogate ” vitamin. As in case of B5, this genomic signature is rather widespread in 
HMP genomes suggesting that dethiobiotin may be yet another candidate prebiotic as well as an-
other target for metabolomic and mechanistic analyses. Moreover, the presence of two additional 
enzymes, BioA and BioD, upstream of BioB, in C. symbiosum TS_8243C (and at least 50 other di-
vergent species in the HMP collection of reference strains but not in R. gnavus TS_8243C) points 
to two other testable possibilities; (i) salvage of 8-amino-7-oxononanoate as yet another undocu-
mented “surrogate” vitamin, and (ii) an alternative upstream pathway merging with the canonical 
route at the stage of 8-amino-7-oxononanoate. The first possibility appears more likely, and it is 
indirectly supported by the presence of the second BioY paralog in C. symbiosum (but not in R. 
gnavus) in the chromosomal neighborhood of the bioA-bioB operon, which may be considered a 
candidate for the 8-amino-7-oxononanoate transporter. If confirmed experimentally, it would point 
to yet another candidate for community vitamin exchange (and, potentially, a selective prebiotic). 
The second possibility would make C. symbiosum TS_8243C a B7 prototroph.
Folate (B9)
Folate is a precursor of folate-derived cofactors DHF, THF and its polyglutamate derivatives that 
play a critical role in single carbon metabolism, including numerous methylation reactions. While 
folate auxotrophy is relatively rare, and in many bacteria such as E. coli folate de novo synthesis 
cannot be compensated by exogenous folate, both TS_8243C strains are obvious B9 auxotrophs 
containing only downstream enzymes and the folate transporter FolT (55). This transporter in both 
strains and the FolC enzyme in C. symbiosum are under regulation of the THF-responding ribo-
switch (62).
Cobalamin (B12)
Cobalamin is involved in a limited number of very important reactions (e.g., methionine biosyn-
thesis). However, in some B12-independent organisms these reactions are either not needed or 
are catalyzed by an alternative B12-independent enzyme (as in case of two distinct methionine 
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synthases, MetH and MetE). It is also the pathway with the largest number of committed biosyn-
thetic steps. Therefore, it could be perceived as the first candidate for exclusion from the B-vitamin 
biosynthetic repertoire. Indeed, it is the only B-vitamin pathway missing in ~50% of analyzed 
Bacteroides spp. even though the exogenous supply and uptake of B12 was shown to be important 
for successful colonization of the respective auxotroph (63). In this light, it appears remarkable 
that both analyzed strains (each with multiple auxotrophies) have a complete B12 biosynthesis 
pathway. In addition, C. symbiosum TS_8243C (and not R. gnavus TS_8243C) contains the B12-
specific transporter BtuFCD under regulation of a B12 riboswitch.
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Supplementary Figure legends
Fig. S1. Distribution of ages at the time of sample collection of healthy microbiota donors 
that were used to generate the Random Forests-derived model of age-discriminatory bacte-
rial 97%ID OTUs. Histogram of donor ages in the training set cohort (n=121 samples; minimum 
age 0.6 months, maximum age 33.51 months, median age 13.7 months) and testing set cohort (n 
=117 samples; minimum age 0.98 months, maximum age 31.8 months, median age 12.35 months). 
ns, no significant difference based on Kolmogorov-Smirnov test.
Fig. S2. Random Forests-derived model of lean body mass gain discriminatory OTUs. The 
30 most lean mass gain discriminatory OTUs with their taxonomic assignments, ranked by feature 
importance as determined by mean squared error. Models were iterated 100 times, and average 
mean squared error values were used to generate the final rankings. Red indicates OTUs that ap-
pear within the 30 most discriminatory OTUs for both the weight and lean mass gain models. 
Purple indicates species that also appear in the 25-taxa sparse model of Malawian microbiota 
maturation. Bars to the right of the OTU ID numbers represent Spearman’s rank correlation of the 
same OTU ID to chronological age in the healthy Malawian infant/child cohort (Table S9).
Fig. S3. Effects of microbiota donor health status and age on femoral bone morphology. 
Micro-CT was performed on femurs harvested from gnotobiotic mice colonized with microbiota 
from 6- and 18-month-old healthy or undernourished donors (in all cases, the efficiency of trans-
plantation was >50%). Each circle represents a single mouse. (A) Bone morphologic phenotypes 
expressed as a function of donor nutritional status irrespective of donor age. Differences in the 
ratio of bone volume to tissue volume (BV/TV) and volumetric bone mineral density (vBMD) in 
the cortical region of femurs are shown. (B) Bone morphologic phenotypes expressed as a function 
of age, irrespective of donor nutritional status. p-values are based on a Mann-Whitney test.
Fig. S4. Random Forests-derived models of OTUs that discriminate femoral bone metrics 
defined by micro-CT. Top 20 most discriminatory OTUs, ranked by mean squared error values, 
for (A) cancellous bone mineral density, (B) cancellous bone volume per tissue volume, (C) corti-
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cal volumetric bone mineral density, (D) cortical bone volume per tissue volume, and (E) cortical 
thickness. Inserts show cross-validation of each model; error decreases as OTUs are added to the 
model. Red indicates that the OTU is also among the top 30 ranked OTUs the Random Forests-
derived models of both weight- and lean mass gain-discriminatory taxa. Boldface indicates that the 
OTU appears in all five bone metric models.
Fig. S5. Discordant growth phenotypes transmitted by two exemplary iLiNS-DYAD-M do-
nor gut communities: one from a healthy 6-month-old donor with normal gut microbiota 
maturity and the other from a severely stunted/underweight 6-month-old donor with sig-
nificant microbiota immaturity. (A) Gain of lean body mass (n=5 recipients/donor microbiota). 
Mean±SEM values are shown. p<0.0001 (2-way ANOVA). (B) Bacterial composition of the fecal 
microbiota of gnotobiotic mice in the co-housing experiments (relative abundances, averaged over 
all time points, of taxa from all animals in each treatment group). Abbreviations: ‘screen’, initial 
survey of mice harboring donor microbiota; ‘H’, cagemates colonized with the healthy donor’s 
microbiota in each co-housing experiment; ‘Un’, cagemates colonized with the severely stunted/
underweight donor’s microbiota.
Fig. S6. Differences in brain metabolism in gnotobiotic recipients of 6-month-old healthy 
compared to severely stunted/underweight donor microbiota. (A) Metabolic profile of the ce-
rebral cortex recovered at sacrifice. Columns represent individual animals. Rows represent metab-
olites whose concentrations are significantly different between the two treatment groups (p<0.05 
for all metabolites shown, Student’s t-test). Rows are hierarchically clustered based on pairwise 
distances calculated from Pearson correlation values. (B) Concentrations of amino acids in the ce-
rebral cortex of mice colonized with the healthy (H) or stunted/underweight (Un) donor microbiota 
(mean±SEM values plotted; p<0.05 for all metabolites shown; Student’s t-test).
Fig. S7. Spearman’s rank correlation rho values for bacterial species relative abundances in 
the fecal microbiota versus concentrations of metabolites in gnotobiotic mouse recipients of 
healthy and severely stunted/underweight infant donor gut communities. Spearman correla-
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tions involving (A) acylcarnitines in serum, (B) amino acids in liver and gastrocnemius muscle, 
and (C) organic acids in liver and gastrocnemius muscle. Rows are hierarchically clustered based 
on pairwise distances calculated from Pearson correlation values. Bars to the right of each heatmap 
indicate significant species enrichment (p<0.05; Student’s t-test) in the fecal microbiota of mice 
colonized with the healthy (purple) or stunted/underweight (yellow) donor’s gut community.
Fig. S8. Reconstructed Ruminococcus gnavus TS_8243C and Clostridium symbiosum 
TS_8243C metabolic pathways involved in carbohydrate and central carbon metabolism, 
amino acid biosynthesis and degradation, and vitamin and cofactor biosynthesis. Enzymatic 
reactions and transporters are depicted by solid and dashed lines, respectively. Red and purple 
lines indicate the presence of the enzyme or transporter in the cultured strains of R. gnavus and C. 
symbiosum, respectively, while gray lines indicate absence of the enzyme or transporter in either 
strain. Common names of enzymes and transporters are shown in black and blue font, respectively. 
Enzymes are also identified by their enzyme commission (EC) numbers. Major families of carbo-
hydrate transporters indicated in parentheses are ATP-Binding Cassette (ABC) transporters, Ma-
jor Facilitator Superfamily (MFS) permeases, TRipartite ATP-independent Periplasmic (TRAP) 
transporters, and phosphoenolpyruvate-dependent PhosphoTransferase System (PTS) transport-
ers. Cognate transcriptional regulators of sugar utilization pathways are highlighted in yellow 
ovals. Central carbon metabolism genes controlled by the global redox-responsive regulator Rex 
in both genomes are marked by yellow vertical stripes. Genes involved in amino acid and vitamin 
metabolism that are controlled by local regulators and metabolite-responsive riboswitches are de-
noted by colored circles. Gene locus tags and functional annotations are listed in Table S16. Genes 
with novel predicted functions (see Supplementary Results) are marked with an asterisk. Putative 
pathways and transporters for which no gene annotation could be identified are indicated with a 
question mark.
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Supplementary Data Tables
Table S1. Summary of the ages, anthropometry, and time of fecal collection from Malawian 
cohorts. (A) Concordant healthy Malawian twins pairs/triplet sets. (B) Members of the iLiNS-
DYAD-M birth cohort.
Table S2. Summary of bacterial V4-16S rRNA datasets from human donors. (A) Malawi Twin 
cohort. (B) iLiNS-DYAD-M cohort.
Table S3. Random Forests-derived sparse model of microbiota maturation in healthy Ma-
lawian infants/children. (A) Rank order of OTU feature importance. (B) Comparison of OTUs 
comprising the sparse Malawian and sparse Bangladeshi models.
Table S4. V4-16S rRNA-based characterization of fecal microbiota sampled from transplant 
recipients. (A) Maturity indices for microbiota selected for transplantation into gnotobiotic mice. 
(B) Summary of 16S rRNA datasets generated from the fecal microbiota of recipient mice in the 
initial screen of 19 donor microbiota. (C) Summary of 16S rRNA datasets generated from the 
follow-up transplant studies using microbiota from a 6-month-old healthy and a 6-month-old se-
verely stunted/underweight donor.
Table S5. Composition of the Malawi-8 (M8) diet. (A) Summary of ingredients. (B) Nutritional 
analysis.
Table S6. Summary of growth phenotypes in recipients of the 19 microbiota from 6- and 
18-month-old healthy and undernourished Malawian donors. (A) Weight gain. (B) Lean body 
mass gain and fat body mass gain.
Table S7. Consumption of M8 chow in each donor group of gnotobiotic recipient mice from 
the screen of 19 donor microbiota.
Table S8. Rank order list of feature importance scores of OTUs in Random Forest models 
based on the growth phenotypes of gnotobiotic mice with 19 different transplanted micro-
biota from 6- and 18-month-old Malawian donors. (A) Weight gain. (B) Lean body mass gain.
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Table S9. Spearman’s rank correlations to mouse growth phenotypes and to chronological 
age in 238 members of concordant healthy Malawian twin pairs/triplet sets and 259 singleton 
members of iLiNS-DYAD-M. (A) Weight gain. (B) Lean body mass gain.
Table S10. Rank order list of OTU feature importance scores in Random Forest models 
based on the femoral bone metrics of groups of recipient mice with 19 different transplanted 
microbiota from 6- and 18-month-old Malawian donors.
Table S11. List of OTUs and their relative abundances used to construct the bargraphs shown 
in Fig. S4B.
Table S12. Metabolic phenotypes of gnotobiotic mice colonized with a normally mature mi-
crobiota from a 6-month-old healthy (H) infant and a significantly immature microbiota 
from a 6-month-old severely stunted/underweight (Un) donor.
Table S13. Spearman’s rank correlations between levels of metabolites and the abundances 
of bacterial species in the fecal microbiota of mice colonized with the healthy versus the se-
verely stunted/underweight infant microbiota. (A) Serum acylcarnitines. (B) Amino acids in 
liver and gastrocnemius muscle. (C) Organic acids assayed in liver and gastrocnemius muscle.
Table S14. Direction and success of invasion in co-housing experiments involving HCH and 
UnCH mice.
Table S15. List of OTUs and their relative abundances (%) used to construct the bargraphs 
shown in Fig. 5C.
Table S16. Genes included into the reconstructed metabolic pathways for Ruminococcus gna-
vus TS_8243C and Clostridium symbiosum TS_8243C based on subsystem-based compara-
tive genomic reconstructions. (A) Overall number of genes in the reconstructed metabolic path-
ways of the two strains. The three major functional categories of studied genes are those involved 
in (i) carbohydrate and central carbon metabolism, (ii) amino acid metabolism and (iii) vitamin 
and cofactor biosynthesis. (B,C). Detailed lists of genes in R. gnavus TS_8243C and C. symbio-
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sum TS_8243C, and their orthologs in the type strains, R. gnavus ATCC 29149 and C. symbiosum 
WAL-14163. Enzymes are identified by their enzyme commission (EC) numbers. Functional de-
scriptions for carbohydrate active enzymes (CAZymes) include their assigned glycoside hydrolase 
(GH) families and their predicted localization (intracellular versus secreted as defined by SignalP). 
Transcriptional regulators and riboswitches that are predicted to control expression of individual 
genes from the reconstructed pathways (according to conservative propagation in the RegPrecise 
database) are listed in the last column. Central carbon metabolism genes controlled by the global 
redox-responsive regulator Rex are also indicated. Genes with novel predicted functions (see Sup-
plementary Results) are marked with an asterisk.
Table S17. Metabolic phenotypes, as defined by targeted mass spectrometry, of gnotobiotic 
mice colonized with the microbiota from the severely stunted/underweight infant donor or 
mice colonized with the donor’s microbiota together with R. gnavus TS_8243C and C. sym-
biosum TS_8243C.
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Summary
Identifying interventions that more effectively promote healthy growth of children with undernu-
trition is a pressing global health goal. Analysis of human milk oligosaccharides (HMOs) from 
6-month postpartum mothers in two Malawian birth-cohorts revealed that sialylated HMOs are 
significantly less abundant in mothers with severely stunted infants. To explore this association, 
we colonized young germ-free mice with a consortium of bacterial strains cultured from the fe-
cal microbiota of a 6-month-old stunted Malawian infant and fed recipient animals a prototypic 
Malawian diet with or without purified sialylated bovine milk oligosaccharides (S-BMO). S-BMO 
produced a microbiota-dependent augmentation of lean body mass gain, changed bone morphol-
ogy and altered liver, muscle and brain metabolism in ways indicative of a greater ability to utilize 
nutrients for anabolism. These effects were also documented in gnotobiotic piglets using the same 
consortium and Malawian diet. These preclinical models establish a causal microbiota-dependent 
relationship between S-BMO and growth promotion.
Introduction
The global burden of childhood undernutrition is great, causing 3.1 million deaths annually and 
accounting for 45% of all deaths under five years of age in 2011 (Black et al, 2013). Linear growth 
faltering, or stunting, defined by a height-for-age Z-score (HAZ) below two standard deviations 
from the mean for a reference international cohort of children with healthy growth phenotypes, is 
the most prevalent form of undernutrition, affecting ~165 million children under five years. Stunt-
ing has lifelong consequences beyond reduced height, including impaired intellectual develop-
ment (Prendergast and Humphrey, 2012; Victora et al, 2008). The causes of stunting are not fully 
understood but are believed to include environmental factors together with genetic and epigenetic 
components (Martorell and Zongrone, 2012). Current interventions in the first 2 years of life have 
largely focused on education, improved hygiene and provision of micronutrient-fortified comple-
mentary foods during the weaning period. The effects of these approaches on growth, immune 
function and neurodevelopmental outcomes have been modest (Dewey and Adu-Afarwuah, 2008).
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Recent culture-independent studies of the bacterial composition of fecal samples collected serially 
from infants and children living in Malawi and Bangladesh have demonstrated that the normal pat-
tern of microbiota assembly is disrupted in children with undernutrition. The resulting microbiota 
immaturity is not repaired with current therapeutic food interventions leading to the proposal that 
disrupted microbiota development impairs healthy postnatal growth (Subramanian et al, 2014).
The World Health Organization (WHO) recommends exclusive breastfeeding for 6 months 
(Kramer and Kakuma, 2002). Human milk is composed of lactose, lipids, micronutrients, proteins 
and many other bioactive substances including a diverse repertoire of free and conjugated human 
milk oligosaccharides (HMOs) that may be decorated with fucose and/or sialic acid moieties (Cop-
pa et al, 2011; Smilowitz et al, 2014). HMOs are not absorbed in the proximal gut (Engfer et al, 
2000) and function as prebiotics that promote colonization of the infant gut with bacterial strains, 
including members of the genus Bifidobacterium, which are associated with numerous benefits 
[e.g., improved vaccine responses (Huda et al, 2014), enhanced gut barrier function (Ewaschuk et 
al, 2008; Weng et al, 2014) and protection from enteropathogen infection (Fukuda et al, 2011)].
To date, the relationship between the overall abundance of breast milk HMOs (and con-
stituent HMO classes) and the growth phenotypes in infants, particularly in low-income countries 
with populations where undernutrition is pervasive, has not been well characterized. The current 
study addresses this issue by first characterizing breast milk HMO content in mothers, enrolled 
in two birth cohort studies conducted in rural southern Malawian villages, whose 6-month-old 
infants either exhibited healthy growth or were severely stunted. Differences identified in their 
breast milk HMO profiles were then translated to preclinical tests of whether one difference, in-
volving sialylated HMOs, was causally related to the infants’ growth phenotypes. These tests were 
conducted in two gnotobiotic animal models; young recently weaned mice and newborn piglets, 
a mammalian species with greater physiologic similarity to humans. In both cases, animals were 
colonized with a collection of sequenced bacterial strains from a 6-month-old Malawian infant and 
fed a representative Malawian diet with or without a purified preparation of sialylated bovine milk 
oligosaccharides (S-BMO; structurally similar to sialylated HMO). The results not only establish 
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that this S-BMO preparation produces a microbiota-dependent promotion of growth and metabolic 
changes indicative of improved nutrient utilization in both species harboring the stunted human 
donor’s gut community members, but illustrate a generalizable preclinical pathway for character-
izing the effects of new lead or existing compounds for diet-based interventions designed to treat 
and ultimately prevent undernutrition and its co-morbidities in infants.
Results
Human milk oligosaccharide content correlates with growth in Malawian infants
Breast milk samples were collected from Malawian mothers at 6 months postpartum as part of the 
Lungwena Child Nutrition Intervention Study #5 (LCNI-5; Mangani et al, 2013). Samples were 
selected for HMO analysis from mothers (n=88) whose children exhibited either healthy growth 
at the time of breast milk collection [Height-for-Age Z-score (HAZ) > 0; n=29 mothers] or severe 
stunting (HAZ < -3; n=59). Liquid chromatography time-of-flight mass spectrometry (LC-TOF 
MS) detected over 50 unique oligosaccharide structures among the samples (Table S1A). HMOs 
containing sialic acid and/or fucose residues represented 71.8±1.5% (mean ± SEM) of total HMOs 
(Table S1A). Mothers of healthy infants had significantly higher concentrations of total, sialylated 
and fucosylated HMOs than mothers of severely stunted infants (Figure 1A). The most growth 
discriminatory sialylated HMO for the entire sampled LCNI-5 cohort was sialyllacto-N-tetraose 
b (LSTb), while the most discriminatory fucosylated HMOs were 2’-fucosyllactose (2’FL) and 
lacto-N-fucopentaose I (LNFP I) (Table S1A).
Mothers with a functional FUT2 gene produce α1-2 linked fucosylated HMOs (‘secretor 
phenotype’; Newburg et al, 2005). The representation of mothers who were non-secretors (owing 
to a non-functional FUT2) was 21.6%. As expected, the total and fucosylated HMO content of 
breast milk samples collected from secretor mothers in this cohort (n=69) was significantly higher 
than that of non-secretor mothers [n=19; p<0.05, two-way ANOVA (Table S1A)]. Among non-
secretor mothers, those whose children were severely stunted at 6 months of age had HMO profiles 
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that were significantly deficient in fucosylated and sialylated HMOs compared to milk from moth-
ers of healthy growing infants (Figure 1A). The most discriminatory HMOs were the sialylated 
glycan, LSTb, as well as the recently reported sialylated 4021b species [Neu5Ac(a2-6)Gal(b1-4)
GlcNAc(b1-3)Gal(b1-4)GlcNAc(b1-3)Gal(b1-4)Glc (Table S1A); Wu et al, 2010]. Among secre-
tor mothers, no significant differences in HMO abundances were observed between those with 
healthy infants and those with stunted infants (Table S1A). One interpretation of these data is that 
some non-secretor Malawian mothers are unable to compensate for deficiencies in fucosylated 
HMOs through increased output of other (e.g., sialylated) HMOs, resulting in breast milk that is 
less supportive of healthy infant growth.
We extended our analysis of breast milk HMOs to mothers enrolled in a second birth cohort 
study (iLiNS-DYAD-M) conducted in rural Malawi (Ashorn et al., 2013). The target population 
for enrollment included healthy pregnant women at less than 20 weeks of gestation living in the 
Mangochi District of Malawi. Breast milk samples (n=215) were selected for HMO analysis based 
on infant HAZ scores at 6 months postpartum (HAZ < -2 or HAZ > 0). Similar to LCNI-5 mothers, 
we found that total and sialylated HMO content was significantly elevated for mothers of healthy 
infants (HAZ > 0; n=70) compared to mothers of stunted infants [HAZ < -2; n=145 (Figure 1B, 
Table S1B)]. Fucosylated HMO content was not significantly enriched for mothers of healthy in-
fants in the iLiNS-DYAD-M cohort.
For this second cohort, we also observed that breast milk from non-secretor mothers of 
healthy infants (n=20) exhibited significantly higher levels of total, fucosylated and sialylated 
HMOs than milk of non-secretor mothers of stunted infants (n=40; Figure 1B). While milk sam-
ples from secretor mothers displayed no statistically significant differences in total or fucosylated 
HMOs between infant anthropometry bins (Table S1B), as observed with LCNI-5, levels of si-
alylated HMOs were significantly elevated in milk from those with healthy infants (n=50) com-
pared to those with stunted infants (n=105; p<0.01, Welch’s t-test). Taken together, these data from 
two independent clinical studies in Malawi raise the possibility that HMOs may play an important 
role in infant growth.
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Considerations for testing the physiological effects of HMOs in gnotobiotic models
We reasoned that the hypothesis that HMOs are causally related to healthy growth in Malawian 
infants could be tested in gnotobiotic animals colonized with members of the gut microbiota of a 
stunted Malawian infant and fed a Malawian diet representative of foods consumed after wean-
ing by this population. The diets could then be supplemented with purified bovine milk-derived 
oligosaccharides (BMOs) that are analogous to HMOs. Fucosylated oligosaccharides are poorly 
represented in bovine milk. However, whole bovine milk contains sialylated BMOs that could be 
purified as a source for gnotobiotic animal experiments (Aldredge et al, 2013; Sundekilde et al, 
2012).
We also postulated that colonizing germ-free animals with a genome-sequenced bacterial 
culture collection, generated from the fecal microbiota of an individual infant donor representing 
a human population and physiologic state of interest would be valuable for a number of reasons. 
First, members of the collection have co-evolved in the same environment and represent a snap-
shot of the microbial exposures experienced by the host, including inheritance of microbes from 
the mother. Second, the strains represented in that individual’s microbiota reflect selection placed 
on the microbiota of humans from a given geographic region by their dietary practices. Third, the 
culture collection in its entirety, or subsets of the collection, can be introduced into groups of re-
cipient gnotobiotic animals in order to define the contributions of bacterial strains to host biology; 
this is not possible when transplanting intact, uncultured communities.
A clonally arrayed, genome-sequenced collection of bacterial strains from the fecal microbiota 
of a stunted Malawian infant
With the above considerations in mind, we generated a clonally arrayed collection of anaerobically 
cultured bacterial strains from the fecal microbiota of a severely stunted 6-month-old Malawian 
infant (HAZ: -3.48, weight-for-height Z-score: 0.05). Using a threshold of ≥96% genome-wide 
nucleotide sequence similarity to distinguish isolates in the arrayed culture collection as represent-
ing a given strain, we determined that the collection was composed of 25 distinct strains [44.65 ± 
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29.32-fold (mean ± SD) genome sequencing coverage; see Table S2A for statistics related to these 
de novo assembled draft genomes]. The bacterial composition of the uncultured fecal microbiota 
from which the culture collection was derived was characterized by sequencing 16S rRNA gene 
amplicons (V4 region) from that sample. Examination of the OTUs present at >0.1% relative 
abundance in the uncultured fecal sample revealed that 77.8% of the bacterial diversity detected 
in the intact community (97% ID OTUs, weighted by relative abundance) was represented in the 
culture collection (Figure 2A).
The culture collection included four species of Bifidobacterium that are common members 
of fecal microbiota sampled from breast fed infants, including B. bifidum, B. breve, B. catenulatum 
and two strains of B. longum subspecies infantis. The presence of virulence factors in members of 
the collection was determined by mapping draft genomes to the Virulence Factor Database (Chen 
et al, 2012). This analysis indicated that 16 strains possessed at least one putative virulence factor, 
and eight had more than three (Table S2B). We noted that the Salmonella enterica strain possessed 
homologs to 170 of the 176 virulence factors (96.6%) found in S. enterica subsp. enterica serovar 
Typhimurium, a pathogen in both humans and mice. The sole E. coli strain contained two key 
virulence factors, aggR and aap, associated with enteroaggregative E. coli.
Bacterial strains isolated directly from an individual can vary substantially from laboratory 
strains both in terms of their genome content and biological properties. Therefore, we compared 
each strain in the culture collection to the NCBI type strain harboring the most similar full-length 
16S rRNA sequence. The full-length 16S rRNA amplicon sequences generated from 22 of the 25 
strains shared greater than 97%ID with their closest assignable reference type strain’s 16S rRNA 
gene sequence (Figure 2B). In contrast, whole genome alignment revealed that only six isolates 
shared greater than 90% overall genome nucleotide sequence similarity, none had greater than 
93% and three shared less than 40% with their reference type strain (Figure 2B). These observa-
tions highlight the importance of using primary bacterial isolates from populations of interest in 
preclinical studies using gnotobiotic models.
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S-BMO supplementation of a prototypic Malawian diet improves growth in young mice 
colonized with the stunted Malawian donor’s cultured bacterial community
Since large-scale purification of HMOs from human milk is not feasible, we purified a monosac-
charide and lactose-free mixture of sialylated bovine milk oligosaccharides (S-BMO) from a com-
mercial cheese whey stream. 3’- and 6’-sialyllactose accounted for 88% of the oligosaccharide 
content of S-BMO; the remaining oligosaccharides were predominantly neutral trihexoses of glu-
cose, galactose and N-acetyl-glucosamine/-galactosamine (~10.5%) and longer neutral oligosac-
charides (1.5%; see Table S3A for a complete analysis of the oligosaccharide composition of this 
S-BMO preparation).
Dietary information for Malawian infants during the transition from exclusive breastfeed-
ing to weaning was compiled from food diaries (see Experimental Procedures) and allowed us to 
develop a representative Malawian diet consisting of eight principal ingredients (M8). This diet 
does not satisfy the recommended daily nutritional needs of humans or mice (see Tables S3B,C 
for ingredients and measured nutritional composition).
Groups of co-housed 5-week-old male germ-free C57BL/6J mice (n=4-5/cage) were colo-
nized with a single oral gavage of the defined 25-strain community. Mice were fed either M8 alone 
or M8 supplemented with S-BMO starting three days prior to colonization (see Figure 2C for 
experimental design). A separate group of mice received M8 supplemented with the structurally 
distinct, indigestible fructan, inulin. S-BMO and inulin were separately added to M8 at a con-
centration of 5.4% (g/g dry mouse diet), corresponding to HMO abundance in mature mother’s 
milk when expressed as a percentage of its dry components (Coppa et al, 2011). Importantly, the 
supplemented diets were isocaloric to M8, as judged by bomb calorimetry (153-155 kcal/100g, 
Table S3C).
We applied short read length shotgun sequencing of fecal DNA (COmmunity PROfiling 
by sequencing; COPRO-Seq), to determine colonization efficiency at strain-level resolution (Mc-
Nulty et al, 2011). Colonization was operationally defined as achieving >0.1% mean relative abun-
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dance in the fecal microbiota of at least one diet treatment group 44 days following gavage of the 
culture collection. The results revealed that 19 of the 25 strains (76%) colonized recipient gno-
tobiotic mice (Table S4A): those that failed to colonize included both strains of Bifidobacterium 
longum subsp. infantis, Klebsiella varicola, Peptoniphlius harei and one strain each of Enterococ-
cus faecalis and Olsenella uli. The strains that successfully colonized gnotobiotic mice represent 
10/11 (91%) of the bacterial genera and all four bacterial phyla that constitute the 25-member 
defined community. Thus, the great majority of the community’s overall phylogenetic diversity is 
represented in the gut microbiota of these animals. Colonization was highly reproducible among 
replicate animals within and across treatment groups (Figure S1A,B, Table S4A).
Body weight and composition (defined by quantitative magnetic resonance) was moni-
tored over a 5-week period following gavage. Weight gain was significantly increased by S-BMO 
supplementation but not by supplementing with inulin (Figure 3A). Lean body mass gain was sig-
nificantly increased by S-BMO (Figure 3B). No significant differences in fat mass gain were ob-
served [1.72±0.33 g, 1.40±0.30 g, and 0.97±0.08 g for unsupplemented, inulin-supplemented and 
S-BMO-supplemented mice, respectively (mean±SEM); p>0.05, Student’s t-tests]. The significant 
effect of S-BMO on body weight and composition was replicated in two independent gnotobiotic 
mouse experiments.
The observed differences in weight and lean body mass gain were not attributable to dif-
ferences in food consumption, which was not significantly different between treatment groups 
[2.17±0.44 g/mouse/day (mean±SD) vs 2.92±0.33 g/mouse/day for control and S-BMO-treated 
animals, respectively (consumption monitored daily for a 4-day period); p=0.08, Students t-test]. 
S-BMO-associated growth promotion was also microbiota-dependent, as it was not observed in 
germ-free animals (n=5 mice/treatment group; Figure 3C).
A previous comparison of germ-free and conventionally-raised mice indicated that the mi-
crobiota affects bone mass (Sjogren et al, 2012). Microcomputed tomography (μCT) of femurs 
harvested at the time of euthanasia revealed that S-BMO supplementation was associated with 
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significant increases in cortical thickness, cortical volumetric bone mineral density (vBMD) and 
cortical bone volume normalized to tissue volume (BV/TV; TV = cortical area plus medullary 
area) compared to controls consuming the M8 diet alone (Figure 3D, Table S5). Histological 
analysis of femurs also disclosed significantly increased BV/TV in the trabecular region in mice 
consuming the S-BMO-supplemented diet (Figure 3D,E). No significant difference was observed 
in osteoclast number normalized to bone surface area [2.24±0.24 (mean ± SD) cells/mm versus or 
2.33±0.91 cells/mm, S-BMO versus control group; p=0.86, Student’s t-test]. These data indicate 
that increased BV/TV and vBMD with S-BMO supplementation are not due to fewer osteoclasts 
resorbing bone. It is formally possible that the S-BMO associated bone phenotype is due to in-
creased mechanical loading that accompanies increased body weight. Mechanical loading is asso-
ciated with reduced endosteal bone resorption and a reduced medullary area in the cortical region 
of femur (Kodama et al, 1999). However, we observed no significant difference in cortical medul-
lary area in the femurs of S-BMO-supplemented mice [1.05±0.01 mm2 (mean±SD)] compared to 
controls (1.07±0.11 mm2) fed the unsupplemented M8 diet (p=0.85, Student’s t-test), suggesting 
that increased loading is not responsible for increased BV/TV and vBMD associated with S-BMO 
treatment.
Members of the distal gut microbiota respond transcriptionally to S-BMO in vivo
16S rRNA analysis of fecal samples disclosed that S-BMO treatment did not produce a robust 
change in the relative abundance of any community member over the course of the experiment 
other than E. coli (Table S4C). The effect on E. coli was seen during the first 16 days following 
introduction of the culture collection, during which time this strain exhibited a significantly greater 
relative abundance in the fecal microbiota of SBMO-treated animals (Figure 4A).
We subsequently identified bacterial species that responded transcriptionally to S-BMO 
supplementation by sequencing RNA isolated from the cecal contents of treated and control ani-
mals and then mapping reads to the strains’ genomes (10.8±1.5 million reads/sample). Remark-
ably, S-BMO treatment did not produce statistically significant changes in gene expression, as 
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judged by DESeq (see Experimental Procedures), in any of the three Bifidobacterium strains (B. 
catenulatum, B. breve and B. bifidum) that established themselves in the gut microbiota of recipi-
ent gnotobiotic mice. In addition, no genes in the S. enterica strain were differentially expressed 
with S-BMO supplementation after correction for multiple hypotheses (α=0.1; data not shown). 
To further rule out the possibility that the growth effects observed in S-BMO-treated mice were 
attributable to this enteropathogen, groups of five-week old male germ-free animals (n=5 mice/
cage) were colonized with the culture collection, with or without this strain; its removal had no 
significant effect on body weight or lean body mass gain (p>0.05, repeated measures two-way 
ANOVA; data not shown).
The two organisms that exhibited the greatest transcriptional response to S-BMO were E. 
coli and B. fragilis (Figure 4B). A total of 111 E. coli genes were differentially expressed (p<0.1, 
negative binomial test after Benjamini-Hochberg correction), with 110 exhibiting greater repre-
sentation in the cecal meta-transcriptome of S-BMO-treated compared to untreated animals (Table 
S6). These transcriptional responses represented increased gene expression, rather than increased 
abundance of E. coli; there was no statistically significant difference in this strain’s relative abun-
dance between the two groups of animals at the time their cecal contents were collected 44 days 
following gavage as determined by 16S rRNA sequencing (Figure 4A). The similar abundance 
of E. coli between treatment groups at this time point was independently confirmed by COPRO-
Seq (1.65 ± 0.8% versus 1.19 ± 0.2% in M8 and M8 + S-BMO treated mice, respectively; p=0.54, 
Student’s t-test; Table S4A). Although this strain contains homologs of two key virulence factors 
associated with enteroaggregative E. coli (Table S2B), neither gene (aggR and aap) had detectable 
levels of expression in either diet context. KEGG annotation of the set of differentially expressed 
E. coli genes revealed several pathways involved in central energy metabolism that were upregu-
lated by S-BMO, including the TCA cycle, plus pathways for glycolysis/gluconeogenesis, pyru-
vate metabolism, galactose metabolism, purine and pyrimidine metabolism and aminoacyl-tRNA 
biosynthesis (Figure 4C).
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E. coli is not known to be a direct consumer of HMOs. Therefore, we hypothesized that 
its response to S-BMO reflects its membership in a bacterial food web, where primary consum-
ers catabolize S-BMO and E. coli benefits secondarily. Members of the genus Bacteroides harbor 
arsenals of polysaccharide utilization loci (PULs), each of which specifies proteins that function 
to detect, import and catabolize dietary and host glycans (Comstock 2009, Martens et al, 2009). 
PULs are minimally defined by an adjacent pair of genes homologous to two B. thetaiotaomicron 
starch utilization system (Sus) genes: susC and susD. Two species of Bacteroides, B. fragilis and 
B. ovatus, were represented in the Malawian infant community that colonized recipient gnoto-
biotic mice. The former strain’s genome does not encode B. fragilis enterotoxin, a zinc-depen-
dent metalloprotease associated with diarrheal disease in humans (Sears, 2001; 2009). While no 
differences in PUL expression were documented in B. ovatus, several B. fragilis PULs exhib-
ited differential expression with S-BMO supplementation. One upregulated PUL contains susC 
(BACFRAMC1_2659) and susD (BACFRAMC1_2660) homologs adjacent to genes encoding an 
N-acetylneuraminic acid lyase (EC4.1.3.3) and an N-acetylglucosamine epimerase (EC5.1.3.8) 
(Figure 4D), consistent with this PUL being involved in S-BMO metabolism (N-acetylneuraminic 
and N-acetylglucosamine are major components of S-BMO; Table S3A).
Cross-feeding between the B. fragilis and E. coli strains
These findings suggested that B. fragilis is a primary consumer of S-BMO and that it could be in-
volved in a food web where E. coli acts as a secondary consumer. To test this notion, we incubated 
B. fragilis or E. coli in PBS containing 5% S-BMO and assayed the supernatants for sialyllactose 
and sialic acid using ultra high performance liquid chromatography-mass spectrometry (UPLC-
MS; see Experimental Procedures). This analysis confirmed that B. fragilis degraded sialyllactose, 
producing a concomitant increase in free sialic acid. In contrast, E. coli did not significantly alter 
the concentration of either compound under these conditions (Figure 4E).
To determine w hether the products of S-BMO degradation by B. fragilis could support the 
growth of E. coli, S-BMO was incubated with B. fragilis and then used as the sole carbon source 
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for E. coli in minimal medium. Growth was robust in medium containing B. fragilis-conditioned 
S-BMO but minimal with unconditioned S-BMO (Figure 4F). Growth in medium containing con-
ditioned S-BMO was also significantly increased compared to controls with sialic acid added as 
the sole carbon source (Figure 4F), even though E. coli degraded sialic acid [28.0±4.2% decrease 
(mean±SD) in sialic acid levels in culture supernatants compared to uninoculated controls, p<0.01, 
Student’s t-test; data not shown]. These results suggested that lactose, or its constituent monomers, 
glucose and galactose, are likely the primary substrates used by E. coli under these conditions.
These observations raised the possibility that the microbiota-dependent growth promotion 
observed in vivo with S-BMO supplementation could be attributed either directly to primary con-
sumers of S-BMO (e.g., B. fragilis) or indirectly to secondary consumers (e.g., E. coli). Therefore, 
we assessed the ability of S-BMO to promote growth of 5 week-old male gnotobiotic mice colo-
nized with just the B. fragilis and E. coli strains. S-BMO did not produce a significant difference in 
growth of co-colonized mice over a 5-week period compared to M8 controls (Figure 4G). We con-
cluded that (i) colonization of the gut per se is not sufficient to produce the S-BMO-enhancement 
of growth, and (ii) other members of the community and/or higher-order interactions between B. 
fragilis, E. coli and these other members are required to mediate this growth promotion.
S-BMO supplementation modulates metabolism in host tissues
To examine host metabolic changes that accompany S-BMO-sponsored growth promotion, we 
used targeted MS/MS and GC/MS to measure a panel of 176 metabolites (Ferrara et al, 2008; 
Newgard et al, 2009), including amino acids, acylcarnitines, organic acids, fatty acyl CoAs and 
ceramides in liver, serum and brain obtained from S-BMO-supplemented versus M8 control mice 
at the time of euthanasia 5 weeks after initial gavage of the 25-member bacterial culture collec-
tion (n=4-5 mice/treatment group). The major impact of S-BMO supplementation was greatly 
enhanced changes in fatty acid-derived metabolite concentrations in the fasted compared to non-
fasted (fed) states. As such, we observed a significantly lower level of medium- and long-chain 
acylcarnitine species in the sera of non-fasted, S-BMO-treated versus control animals (Figure 
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5A); this observation was mirrored by decreases in 11 medium- and long-chain acylcarnitines and 
five fatty acyl CoAs in their livers (Figure S2A, Table S7A). The decreased levels of fatty acid 
metabolites in the liver and serum of these non-fasted mice could reflect decreased oxidation of 
fat and enhanced lipid storage, consistent with a more normalized anabolic state. Accordingly, we 
documented that these animals had significantly elevated concentrations of serum triglycerides, 
insulin and leptin (Figure S2B-D). We also noted a trend of higher serum non-esterified fatty acids 
(NEFA) [0.75±0.14 mM (mean±SD) versus 0.59±0.06 mM for S-BMO-supplemented and control 
animals, respectively (p=0.1, Student’s t-test)]. Low serum leptin levels were reported to be a ma-
jor predictor of childhood mortality in a cohort of undernourished Ugandan children (Bartz et al, 
2014). Moreover, leptin levels correlate with bone mineral density in women (Thomas et al, 2001).
These observations suggest that S-BMO-supplemented mice can more effectively utilize 
dietary components for anabolism. To test the corollary that S-BMO-treated animals are better 
equipped to mobilize nutrients during periods of fasting, we measured the same 176 metabolites in 
the livers and sera of mice that had been fed M8 with or without S-BMO (or inulin) and euthanized 
following an 8-hour fast. The concentrations of medium- and long-chain acylcarnitines (notably 
C18, C18:1 and C18:2) were elevated in sera of fasted, S-BMO-treated animals compared to M8 
controls (Figure 5A, Table S7B). In addition, concentrations of 15 acylcarnitine and 29 long-chain 
fatty acyl CoA species were significantly higher in the livers of S-BMO-treated animals (Figure 
5B, Table S7B). Importantly, these observations were largely specific to S-BMO: similar changes 
were not seen in mice consuming the isocaloric inulin-supplemented M8 diet. In aggregate, our 
findings demonstrate a greater increment of lipid-derived metabolite concentrations in S-BMO-
treated mice between the fed and fasted states than in mice fed an unsupplemented diet. This 
metabolite pattern is consistent with more efficient switching from anabolic storage of fat in the 
fed state to its oxidation in the fasted state, which can also be described as metabolic flexibility 
(Muoio 2014).
We used targeted MS/MS to measure metabolites in the cecal contents of fasted mice and 
observed no statistically significant differences in the concentrations of organic acids or amino 
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acids (including branched-chain amino acids) between S-BMO-treated and control animals (Table 
S7B). We also broadened our search for metabolic biomarkers associated with S-BMO-sponsored 
growth by performing non-targeted gas chromatography-mass spectrometry (GC/MS; Scholtens et 
al, 2014) on serum samples obtained from fasted S-BMO-supplemented mice at time of euthana-
sia. Orthogonal projection to latent structures discriminatory analysis (O-PLS-DA) revealed that 
the serum metabolic profile of S-BMO-treated mice clustered distinctly from that of controls fed 
the M8 diet (Figure 5C inset). We used this method to identify particular serum metabolites that 
discriminate S-BMO-supplemented animals from controls and found that a branched-chain amino 
acid (BCAA) metabolite, 2-ketovaline, and a product of fatty acid oxidation, b-hydroxybutyrate, 
were associated with and increased by S-BMO in fasted mice (Figure 5C, Table S7D). The in-
crease in b-hydroxybutyrate in fasted S-BMO-supplemented mice supports our interpretation that 
increased fatty acid oxidation underlies the increased levels of fatty acid-derived acyl CoA and 
acylcarnitine species in liver and serum of these animals. The increase in a BCAA-derived me-
tabolite also suggests that amino acids are being utilized as energy substrates in the fasted state, an 
expected and normal physiologic response. BCAA are also known to promote muscle protein syn-
thesis by activating mammalian target of rapamycin (Norton and Layman, 2006). This is notable 
given the significant augmentation in gain of lean body mass observed with S-BMO treatment 
(Figure 3B).
In addition to stunted growth, childhood undernutrition results in persistent deficits in cog-
nitive development (Victora et al, 2008). Sialic acids, a group of compounds derived from neur-
aminic acid, including the nine-carbon monosaccharide N-acetylneuraminic acid (NeuAc), are 
integral to postnatal brain development; NeuAc is a component of gangliosides and is covalently 
linked to neural cell adhesion molecules (NCAMs) that mediate cell-cell interactions involved in 
synaptogenesis and memory (Wang, 2009; Wang and Brand-Miller, 2003). Dietary supplementa-
tion with sialylated glycoproteins has been shown to increase polysialylation of NCAM and im-
prove memory (Wang et al, 2007a). Since NeuAc is a core component of S-BMO (Table S3A), 
we used nontargeted UPLC-MS to characterize the representation of metabolites in the cerebrums 
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of gnotobiotic mice. O-PLS-DA analysis revealed that the cerebral metabolic profiles of S-BMO-
treated mice were distinct from control animals fed the M8 diet (Figure S3A inset, Table S7E). 
Interestingly, we compared the m/z feature that was most discriminatory for the brain of S-BMO-
treated animals (mass 346.0546 Da; Figure S3A) to the human metabolome database (Wishart 
et al, 2013) and found that the compound closest in mass was an adduct of NeuAc (M+K-2H; 
346.054587 Da).
Applying targeted GC-MS to the same cerebral sample extracts also revealed distinct meta-
bolic profiles. Free NeuAc, inosine and adenosine were among eight metabolites identified as sig-
nificantly elevated in the brains of S-BMO-treated mice (Figure S3B,C and Table S7F). Inosine 
treatment promotes axonal rewiring and improves behavior in animal models of traumatic brain 
injury (Chen et al, 2002; Dachir et al, 2014; Smith et al, 2007), while adenosine has both neuro-
modulatory and neuroprotective functions in the brain (Fredholm et al, 2005).
S-BMO supplementation promotes growth in gnotobiotic piglets
We next examined whether the observed effects of S-BMO supplementation on growth and me-
tabolism in mice also occurred in a second mammalian species whose physiology was closer to 
humans. We selected gnotobiotic piglets because (i) the digestive physiology of swine is similar 
to that of humans (Kararli, 1995; Miller and Ullrey, 1987), (ii) following birth, piglets grow very 
rapidly (Miller and Ullrey, 1987), providing a convenient window to test the effects of interactions 
between a stunted human donor microbiota and diet and (iii) procedures have been described for 
re-deriving piglets as germ-free (Willing and Van Kessel, 2007, 2009).
Since newborn piglets exhibit impaired gut barrier function (Pluske et al, 1997; Wijtten et 
al, 2011), we excluded the eight members of the defined community generated from the stunted 
Malawian donor that possessed more than three known virulence factors in their genomes, includ-
ing E. coli (Table S2). A group of six germ-free domestic piglets was colonized at 3 days of age 
with the remaining 17-strain consortium (see Figure 6A and Table S2A for a list) and weaned 
from a sterile sow’s milk replacement formula to the M8 diet over the course of the next seven 
132
days. At day 13 of postnatal life, piglets were split into control and experimental groups (n=3 pig-
lets/group). For a period of six days, piglets in the experimental group were exclusively fed M8 
supplemented with 5.4% S-BMO (wt/wt), while control animals were fed the M8 diet alone (see 
Figure 6A for a schematic representation of the experimental design).
COPRO-Seq analysis of fecal samples collected at time of euthanasia revealed that coloni-
zation was efficient, with 14/17 (82%) of input strains detected in the piglets’ fecal microbiota at 
>0.1% relative abundance (Table S4B). The failure of three human-derived strains (Peptoniphilus 
harei and both strains of Bifidobacterium longum subsp. infantis) to colonize germ-free piglets in 
addition to germ-free mice could reflect a number of factors including their inability to thrive in 
the M8 diet context, the absence of syntropic partners in the culture collection used for coloniza-
tion or restricted host specificity. As observed in mice, microbiota structure was similar between 
S-BMO-supplemented and control animals (Figure S1C,D, Table S4D). Despite the short period 
of treatment, piglets receiving the S-BMO-supplemented M8 diet displayed significantly greater 
body weight gain compared to controls (Figure 6B).
The processing of S-BMO within the gut was characterized by triple quadrupole mass 
spectrometry of mucosal scrapings obtained at time of euthanasia from the proximal and distal 
segments of the small intestine and spiral colon (corresponds to the ascending colon in humans), 
plus cecal contents and feces. As expected, the concentrations of NeuAc were significantly higher 
in both the cecal contents and feces of S-BMO-supplemented animals (Figure 6C). Importantly, 
we documented a significant increase in the concentration of mucosal NeuAc in the proximal small 
intestine (Figure 6D), suggesting that dietary NeuAc (a primary component of S-BMO) is incor-
porated in host glycans. This observation was site-specific, as no significant differences in mucosal 
NeuAc concentrations were observed in the distal small intestine or spiral colon.
To investigate the effects of S-BMO on the community meta-transcriptome, we performed 
microbial RNA-Seq on cecal samples harvested at the time of euthanasia [n=42.5±15.2 million 
reads per sample (mean±SD)]. We were unable to detect differences in gene expression for any 
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community members using p<0.1 as a threshold for statistical significance (negative binomial test 
corrected using the Benjamini-Hochberg procedure). Relaxing this cutoff to p<0.2 revealed 1,482 
bacterial genes that exhibited differential expression with 1,481 (99.9%) showing significantly 
higher expression with S-BMO treatment (Table S8). These differences are not attributable to bac-
terial abundance; COPRO-Seq analysis established that S-BMO did not significantly impact the 
relative abundance of any bacterial strain colonizing piglets (p>0.05, Student’s t-test; Table S4B). 
Expression levels of 587 B. fragilis genes were significantly elevated with S-BMO-supplementa-
tion, more than any other community member. Among these 587 genes, six encode enzymes that 
catalyze several key steps in the KEGG pathway for biosynthesis of three BCAA (valine, leucine 
and isoleucine; Figure S4). Differentially expressed genes were not evenly distributed across the 
bacterial community; five of the community’s 14 strains (Bacteroides fragilis MC1, Bacteroides 
ovatus MC1, Collinsella aerofaciens MC1, Collinsella aerofaciens MC2 and Bifidobacterium ca-
tenulatum MC1) together accounted for 1,300/1,482 (88%) of the differentially expressed genes 
(Table S8). One interpretation of these data is that, in the absence of E. coli, primary consumption 
of S-BMO (by B. fragilis, for example) opens a niche for other strains to fill.
Consistent with our observations in non-fasted gnotobiotic mice, the liver metabolic pro-
files of non-fasted, S-BMO-treated piglets exhibited significantly reduced levels of five acylcarni-
tine and nine fatty acyl CoA metabolites compared to controls (Figure 6E, Table S7C). In addi-
tion, we documented a striking pattern of increased amino acid concentrations, including BCAAs, 
in serum as well as skeletal muscle (biceps femoris) of S-BMO-supplemented piglets (Figure 
6F,G, Table S7C). Non-fasted, S-BMO-treated piglets also displayed trends for decreased me-
dium- and long-chain serum acylcarnitines [0.14±0.02 μM (mean±SD) versus 0.17±0.02 μM in 
controls; p=0.12, Student’s t-test], increased serum triglycerides [30.33±13.05 mg/dL (mean±SD) 
versus 10.33±8.08 mg/dL; p=0.08, Student’s t-test] and increased serum NEFA [0.07±0.03 mM 
(mean±SD) versus 0.04±0.01 mM; p=0.2, Student’s t-test]. Despite the increased expression of 
BCAA biosynthesis genes by B. fragilis, S-BMO administration produced no significant differ-
ences in the concentration of BCAA in cecal contents compared to controls (p>0.05, Student’s 
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t-test; Table S7C). The mechanism underlying the strong increment in amino acids documented in 
S-BMO-treated piglets and its relationship to their augmented growth rate remains to be defined.
Together, these results led us to conclude that the effects of S-BMO supplementation on 
weight gain and metabolic phenotypes are a shared feature of gnotobiotic piglets and mice and that 
these changes reflect, at least in part, improved utilization of dietary components. Furthermore, 
the fact that S-BMO promoted growth in the absence of E. coli provided additional evidence that 
other members of the microbiota and/or their higher order interactions are necessary to mediate 
these effects.
Discussion
We describe two gnotobiotic animal models, each colonized with a collection of bacterial strains 
cultured from a single stunted Malawian infant and fed a prototypic Malawian diet, to show that 
a purified preparation of sialylated bovine milk oligosaccharides, resembling sialylated HMOs 
depleted in the breast milk of mothers with stunted infants, produces beneficial microbiota-depen-
dent effects on growth and metabolism.
The data presented here from two separate studies of undernutrition in Malawi indicate that 
breast milk of mothers whose children exhibit growth faltering contains lower levels of HMOs, 
including sialylated glycans, compared to milk from mothers of healthy infants. Sialic acid-con-
taining oligosaccharides are present at up to 20-fold higher levels in mature human milk compared 
to mature bovine milk (Bruggencate et al, 2014; Tao et al, 2009; Wang et al, 2001). As a result, 
existing bovine milk-based infant formulas and complementary/therapeutic foods used to treat 
undernutrition are deficient in these important human milk components.
The brains of breastfed infants possess higher levels of ganglioside- and glycoprotein-
bound sialic acid than the brains of formula-fed infants (Wang and Brand-Miller, 2003), consistent 
with the higher sialic acid content of breast milk compared to bovine milk-based infant formulas 
(Wang et al, 2001). Although the liver can synthesize sialic acid de novo from glucose, the activity 
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of the limiting enzyme, UDP-N-acetylglucosamine-2-epimerase, is low during the neonatal pe-
riod (Gal et al, 1997), suggesting that in the absence of human milk, sialic acid may be a limiting 
resource at the time of rapid postnatal brain development. Our finding that dietary S-BMO sup-
plementation of gnotobiotic mice harboring microbiota from an undernourished Malawian infant 
leads to elevated levels of NeuAc in the brain suggests that S-BMO can function as a supplemen-
tary source of bioavailable sialic acid and may represent a novel treatment for children at risk for 
stunting and associated neurodevelopmental deficits whose dietary sialic acid intake is inadequate.
In addition to neural development, sialic acid may play a fundamental role in other fac-
ets of healthy growth, including those involving the musculoskeletal system. Studies of a mouse 
model of myopathy in which GNE, which encodes a bifunctional rate-limiting enzyme in sialic 
acid biosynthesis, is mutated, showed that addition of 6’-sialyllactose to animals’ drinking water 
led to increased muscle mass and improved contractility (Yonekawa et al, 2014). BCAA promote 
muscle protein synthesis by activating mTOR, and an increase in a key BCAA-derived metabolite 
also suggests restoration of normal amino acid metabolism in fasted S-BMO-supplemented mice. 
S-BMO also increased bone cortical thickness and trabecular bone volume in young gnotobiotic 
mice. The underlying mechanisms need to be investigated, but this observation has a clinical cor-
relate: studies in Uganda reported reductions in fibular bone width in 3.5- to 7.5-year old children 
that exhibited low body weight during their first 2 years of postnatal life (McFie and Welbourn, 
1962).
Our data also indicate that orally administered S-BMO restores normal substrate utiliza-
tion patterns, most notably: (i) a strong activation of fatty acid oxidation in fasting, as reflected 
by increased levels of acylcarnitines, acyl CoAs and the fatty acid oxidation end product b-hy-
droxybutyrate, and (ii) a pattern consistent with enhanced anabolic metabolism of lipids in the fed 
state, including increases in triglycerides and insulin, and decreased levels of fatty acid oxidation 
intermediates.
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Our findings demonstrate that specific bacterial members of the gut microbiota obtained 
from an undernourished Malawian infant are able to metabolize S-BMO-derived sialyllactose to 
its constituent monosaccharides, which are then available to the host and other members of the mi-
crobiota, both mutualistic and pathogenic. The latter includes pathogenic E. coli that are unable to 
harvest sialic acids themselves from host glycans or dietary sources (Almagro-Moreno and Boyd, 
2009). Therefore, it is important to consider that the presence of primary consumers of sialylated 
oligosaccharides may create opportunities for enteropathogens to achieve a fitness benefit that 
could have deleterious effects on the host (Ng et al, 2013). These findings encourage mindfulness 
with respect to balancing potential benefits and risks when designing gut microbiota-directed clini-
cal trials involving milk oligosaccharides.
In conclusion, our analysis of breast milk specimens from clinical trials of undernutrition 
in Malawi has disclosed an association between HMO abundance and composition and infant 
growth. To test for a causal relationship, we have used preclinical gnotobiotic models to uncover 
microbiota-dependent growth promoting activities of purified S-BMO in young gnotobiotic mice 
and piglets. Preclinical models of the type we describe can play critical roles in characterizing 
BMO species that are structurally similar to human HMOs and that can be purified at a scale com-
patible with clinical testing and potentially into a commercially viable product. These preclinical 
models provide a means to (i) elucidate mechanism of action, including underlying effects on host 
metabolism that would otherwise be difficult or impossible to glean from non-invasive clinical 
studies, especially those involving infants, (ii) define the generalizability of the effects of S-BMO 
in the context of microbiota from different donors representing different geographic locations 
and dietary practices, (iii) identify clinically translatable microbial and host biomarkers related 
to mechanism and safety and (iv) guide patient stratification and inform the design of proof of 
concept clinical studies that incorporate appropriate de-risking strategies and careful surveillance 
to establish the efficacy and safety of approaches such as S-BMO supplementation to the diets of 
undernourished children.
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Experimental Procedures
Human studies
Human studies were conducted with the approval of institutional review boards from the Univer-
sity of Malawi, Pirkanmaa Hospital (Finland), and Washington University School of Medicine in 
St. Louis. The mothers and infants included in this study were enrolled in two randomized, con-
trolled, single-blind, parallel group clinical trials, LCNI-5 and iLiNS-DYAD-M [ClinicalTrials.
gov identifiers: NCT00524446 and NCT01239693]. See Extended Experimental Procedures for 
additional information.
Generating a clonally arrayed culture collection from a 6-month-old Malawian infant
The 25-member clonally arrayed culture collection was produced from a frozen fecal sample col-
lected from a severely stunted 6-month-old Malawian infant [patient ID h264A in Yatsunenko et 
al. (2012)] using methods described in Goodman et al. (2011). For detailed information relating to 
bacterial isolation, plus genome sequencing, assembly and annotation see Extended Experimental 
Procedures.
Purification and compositional analysis of S-BMO
S-BMO was purified from commercially available whey permeate using a series of ultrafiltration 
and chromatographic steps described in Extended Experimental Procedures.
Design and preparation of the Malawi 8 (M8) diet
This diet was formulated based on a dietary survey of the complementary feeding practices of 
43 nine-month-old Malawian infants and children enrolled in the iLiNS-DOSE clinical study 
(#NCT00945698) that took place in the Mangochi district of Malawi. See Extended Experimental 
Procedures for details.
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Studies involving gnotobiotic mice
All gnotobiotic mouse experiments were performed using protocols approved by the Washington 
University Animal Studies Committee. Male germ-free C57Bl/6J mice were maintained in sterile, 
flexible plastic gnotobiotic isolators. Mice received a single oral gavage of the complete 25-mem-
ber culture collection or subsets of the collection 3 days after initiation of one of the M8-based 
diets. For additional information, see Extended Experimental Procedures.
16S rRNA gene sequencing of fecal microbiota
Multiplex sequencing of barcoded bacterial 16S rRNA amplicons generated from fecal microbiota 
samples was performed using an Illumina MiSeq instrument. 97% ID OTUs were clustered using 
UCLUST (Edgar, 2010). Taxonomic assignments were made with the Ribosomal Database Project 
(RDP) version 2.4 classifier (Wang et al, 2007b). See Extended Experimental Procedures for de-
tailed information about sample preparation, PCR conditions, multiplex sequencing and analysis 
of the resulting datasets.
Microbial RNA-Seq
Multiplex microbial cDNA sequencing was performed using Illumina Hi-Seq2000 and MiSeq 
instruments. Sequencing reads were split according to 8-bp barcodes used to pool samples. Reads 
were mapped to genes in a custom database of 25 draft genomes included in the defined Mala-
wian infant bacterial community. Read counts were normalized and analyzed with the R statistical 
package, DESeq (Anders and Huber, 2010). See Extended Experimental Procedures for additional 
information.
Mass spectroscopy of metabolites contained in biospecimens obtained from gnotobiotic 
animals
Tissue samples were collected from gnotobiotic animals at time of euthanasia, frozen immediately 
in liquid nitrogen and stored at -80°C. In preparation for GC/MS and MS/MS analyses, samples 
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were homogenized in 50% aqueous acetonitrile containing 0.3% formic acid (50 mg wet weight 
tissue/mL solution). See Extended Experimental Procedures for details about analytic methods.
Experiments involving gnotobiotic piglets
All experiments involving pigs were performed under the close supervision of a veterinarian using 
protocols approved by the Washington University Animal Studies Committee. Pregnant domestic 
sows (mixture of Landrace and Yorkshire genetic backgrounds, mated to Duroc breed domestic 
boars) were obtained from Oak Hill Genetics (Ewing, IL). For detailed procedures relating to the 
derivation of germ-free piglets and experimental design, see Extended Experimental Procedures.
Supplemental Information
Supplemental information includes Extended Experimental Procedures, four figures, and eight 
tables.
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Figure Legends
Figure 1: HMOs are more abundant in breast milk of Malawian mothers with healthy in-
fants. (A,B) Abundance of total, fucosylated and sialylated HMOs present in breast milk of Ma-
lawian mothers collected from the LCNI-5 cohort (n=88 mothers, panel A) and iLiNS-DYAD-M 
cohort (n=215 mothers, panel B) 6 months postpartum, binned by anthropometry of their infants 
(LCNI-5: healthy, HAZ>0; stunted, HAZ<- 3; iLiNS-DYAD-M: healthy, HAZ>0; stunted: HAZ< 
-2). HMO abundance values correspond to spectral abundance as determined by LC-TOF MS, 
normalized to the mean abundance of samples assigned to the healthy bin for each respective com-
parison. *p<0.05, **p<0.01, ***p<0.001 (two-tailed, Welch’s t-test). See also Table S1.
Figure 2: Cultured bacterial strain collection generated from the fecal microbiota of a 
6-month-old stunted Malawian infant. (A) Taxonomic representation of 97% ID OTUs in the 
intact, uncultured infant fecal sample from which the culture collection was generated. (B) Com-
parison of culture collection strains and representative type strains. Black dots indicate percent 
sequence identity between full-length 16S rRNA gene sequences from each strain and its most 
similar reference type strain. Bars indicate percent nucleotide sequence similarity between the 
strain’s de novo assembled genome and its most similar type strain’s genome. Strains are clustered 
by Euclidean distance between full-length 16S rRNA gene sequences. (C) Experimental design. 
Mice were colonized at 5 weeks of age. See also Table S2.
Figure 3: S-BMO promotes growth in gnotobiotic mice harboring the Malawian infant cul-
ture collection and fed a prototypic Malawian diet. (A) Weight gain over time normalized to 
body weight at the time of colonization. (B) Lean body mass gain, as measured by quantitative 
magnetic resonance (qMR), 44 days after colonization of animals fed either the M8 diet alone or 
M8 diet supplemented with inulin or S-BMO. (C) Weight gain over time of germ-free mice fed M8 
or M8 supplemented with S-BMO for 4 weeks (normalized to weight at 5 weeks of age). (D) Corti-
cal and trabecular bone volume/tissue volume (BV/TV; TV = cortical area + medullary area) and 
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(E) representative histomorphometry images of femurs from mice colonized with the culture col-
lection and fed either M8 or M8 supplemented with S-BMO. Bone phenotypes were characterized 
37 days post colonization. Black boxes highlight the trabecular region of interest, and arrowheads 
point to examples of trabeculae. For (A), ***p<0.001, two-way, repeated measures ANOVA. For 
(B) and (D), *p<0.05, **p<0.01 two-tailed, unpaired Student’s t-test. All comparisons are made to 
M8 controls. See also Figure S1 and Table S5.
Figure 4: Members of the gut microbiota respond transcriptionally to S-BMO in vivo and 
degrade S-BMO in vitro. (A) Relative abundance of E. coli (mean±SEM) over time in feces of 
gnotobiotic mice colonized with the stunted Malawian infant’s culture collection and fed M8 or 
M8 supplemented with S-BMO. *p<0.05 two-tailed, unpaired Student’s t-test. (B) Volcano plot of 
bacterial gene expression in the cecal microbiota of gnotobiotic mice. Expression is plotted on the 
x-axis as the log2 fold difference between S-BMO-supplemented mice and unsupplemented mice. 
Significantly up- or downregulated genes are labeled in black or by bacterial species of origin. 
-Log10(p-values) are plotted on the y-axis (negative binomial test, corrected using the Benjamini-
Hochberg procedure). (C) Heatmap of select differentially regulated E.coli genes, grouped by 
KEGG functional pathway. Red asterisks denote that differences in expression are statistically 
significant after Benjamini-Hochberg correction for multiple hypotheses (α=0.1). See Table S6 for 
a full list of differentially expressed E. coli genes. (D) Effects of S-BMO on expression of genes 
in a B. fragilis PUL. Expression is plotted on the y-axis as the log2 fold difference between S-
BMO-supplemented and control mice. *p<0.05, **p<0.01 (two-tailed, unpaired Student’s t-test). 
(E) Abundance (mean±SEM) of siallyllactose and sialic acid in E. coli or B. fragilis monoculture 
supernatants after a 24-hour incubation with 5% S-BMO (wt/vol). Control incubations contained 
uninoculated PBS buffer. ***p<0.001 two-tailed, unpaired Student’s t-test. (F) OD600 (mean±SEM) 
of E. coli grown in minimal medium containing various single carbon sources. ‘Conditioned S-
BMO’ refers to filter-sterilized supernatant harvested from a 24 hour monoculture of B. fragilis 
with 5% S-BMO (wt/vol). (G) Weights (mean±SEM; normalized to weight at time of coloniza-
tion) of gnotobiotic mice colonized at five-weeks-of-age with the entire 25-member Malawian 
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infant culture collection or with only B. fragilis and E. coli (Bf + Ec). Mice were fed the M8 diet 
with or without S-BMO (n=5 mice/group).
Figure 5: S-BMO supplementation alters levels of serum and liver metabolites in gnotobi-
otic mice. (A) Sum of the concentrations of medium- and long-chain serum acylcarnitines (chain 
length ≥10) in fasted or non-fasted gnotobiotic mice fed M8 or M8 supplemented with S-BMO 
or inulin. * p<0.05, Student’s t-test. (B) Heatmap of liver metabolites whose concentrations are 
affected by S-BMO-treatment in mice fasted 8 hours prior to euthanasia. Rows represent replicate 
gnotobiotic mice, grouped by dietary treatment. Columns represent individual metabolites identi-
fied by targeted MS/MS. *p<0.05 (two-tailed, unpaired Student’s t-test). All comparisons were 
made to controls. Red asterisks represent significant differences between the two groups of ani-
mals after Benjamini-Hochberg correction for multiple hypotheses (α=0.1). See Table S7A,B for 
concentrations of all measured metabolites. (C) O-PLS-DA score plot (inset) and O-PLS-DA S-
plot of fasted serum metabolites in gnotobiotic mice fed M8 with or without S-BMO. Metabolites 
highlighted in purple represent branched-chain amino acid metabolites while those highlighted in 
green are ketone body metabolites. See also Figure S2 and Figure S3.
Figure 6: S-BMO modulates growth and metabolism in gnotobiotic piglets. (A) Experimental 
design. Full-term piglets were delivered into gnotobiotic isolators immediately after caesarian sec-
tion and colonized with a 17-member consortium of the stunted Malawian infant’s culture collec-
tion at postnatal day 3. Piglets were weaned from a sterile sow’s milk replacement formula onto the 
M8 diet by day 11 and then split into two groups. For 6 days, starting at postnatal day 13, the treat-
ment group received M8 supplemented with S-BMO while controls were fed the unsupplemented, 
isocaloric M8 diet. (B) Weight gain normalized to body weight at postnatal day 13 (mean±SEM). 
**p<0.01, two-way, repeated measures ANOVA. (C,D) N-acetylneuraminic acid (NeuAc) con-
centrations in cecal contents and feces (panel C), as well as in proximal and distal small intestine 
(SI) and spiral colon mucosa (panel D), harvested from gnotobiotic piglets fed M8 ± S-BMO. All 
samples were obtained at the time of euthanasia. *p<0.05, **p<0.01 two-tailed, unpaired Stu-
dent’s t-test. (E) Heatmap displaying acylcarnitine and fatty acyl CoA concentrations in the livers 
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of non-fasted gnotobiotic piglets, measured at the time of euthanasia on postnatal day 19. (F,G) 
Amino acid concentrations in (F) serum and (G) skeletal muscle of non-fasted gnotobiotic piglets, 
measured at the time of euthanasia. In panels E,F, columns represent individual metabolites, and 
rows represent replicate gnotobiotic piglets, grouped by treatment. *p<0.05 (two-tailed, unpaired 
Student’s t-test). All comparisons made to controls. Red asterisks denote statistical significance 
after Benjamini-Hochberg correction for multiple hypotheses (α=0.1). See also Figure S1, Figure 
S6, Table S7C and Table S8.
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Extended Experimental Procedures
Human studies
Human studies were conducted with approval of institutional review boards from the University 
of Malawi, Pirkanmaa Hospital (Finland) and Washington University School of Medicine in St. 
Louis. The mothers and infants included in this analysis were enrolled in two randomized, con-
trolled, single-blind, parallel group clinical trials, LCNI-5 and iLiNS-DYAD-M [ClinicalTrials.
gov identifiers: NCT00524446 and NCT01239693] of micronutrient fortified lipid-based nutrient 
supplements conducted in southern Malawi (Ashorn et al, 2015; Mangani et al, 2013). Anthropo-
metric measurements of 6 month-old infants were performed in triplicate to determine height-for-
age Z-scores (HAZ).
De-identified breast milk samples were collected from women enrolled in the two trials 
when their infants were six months old. The entire contents of one breast were manually expressed 
into a sterile container approximately 2 h after the last reported feeding on that breast. Aliquots 
were stored at -40°C to -80°C in Malawi and later shipped on dry ice to Washington University in 
St. Louis, where the samples were maintained at −80 °C until being shipped to UC Davis for HMO 
analysis. A fresh morning fecal sample was collected from the infants of these mothers on the day 
of their six-month clinic visit. The sample was divided into aliquots in a laboratory and stored at 
−20°C on the same day. Within three days, samples were transferred to -40°C or -80°C freezers in 
Malawi prior to shipment to Washington University.
Mass spectrometry of breast milk samples
Mass spectrometry analysis of breast milk HMO content was performed on all available samples 
from mothers of children enrolled in the LCNI-5 and iLiNS-DYAD-M study cohorts that met the 
anthropometric criteria stated in the main text (n=88 and 215 for LCNI-5 and iLiNS, respectively). 
Free HMOs from whole milk were extracted using previously reported methods (Ninonuevo et al, 
2006; Wu et al, 2010; Wu et al, 2011; Totten et al. 2014). Briefly, 50 µL aliquots of breast milk 
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samples obtained from mothers in the LCNI-5 cohort and 25 µL aliquots of samples obtained from 
members of the iLiNS-DYAD-M cohort were distributed into 96-well plates, diluted and defatted 
by centrifugation. To precipitate proteins, two volumes of ethanol were added to the aqueous layer 
and the mixtures incubated for 1.5 hours at -80°C. After centrifugation, the supernatant was col-
lected, and the resulting glycans were reduced with 1.0 M NaBH4 for 1.5 hours at 65°C. Samples 
were then purified by solid phase extraction, loaded onto graphitized carbon cartridges, desalted 
with nanopure water and then eluted with 20% acetonitrile in water and 40% acetonitrile in 0.05% 
trifluoroacetic acid (v/v). The eluent fractions were combined and the solvent evaporated. After 
reconstitution, the samples were diluted to appropriate concentrations and subjected to nano-high 
performance liquid chromatography (HPLC)-chip/time-of-flight (TOF) mass spectrometry.
The Agilent 1200 series liquid chromatography unit utilizes a dual pump system with sam-
ple loading and analyte separation performed on a microfluidic chip. The chip has a 40 nL enrich-
ment column and a 75 µL x 43 mm analytical column packed with porous graphitized carbon. This 
system is coupled to an Agilent 6220 series TOF mass spectrometer via chip-cube interface. The 
HPLC capillary pump loads the sample onto the chip’s enrichment column at a flow rate of 4.0 µL/
min with a 1 µL injection volume, and the nano pump achieves separation with a binary gradient 
of aqueous solvent (3% acetonitrile/water (v/v) in 0.1% formic acid (FA) and organic solvent (90% 
acetonitrile/water (v/v) in 0.1% FA). The separation method was developed and optimized for 
HMO mixtures (Wu et al, 2010; Wu et al, 2011). To monitor instrument performance and minimize 
batch effects, an external HMO pool was run intermittently throughout sample analysis.
Data were collected using Agilent MassHunter Workstation Data Acquisition software, 
version B.02.01 and then analyzed using Agilent MassHunter Qualitative Analysis software ver-
sion B.03.01. HMO compounds were identified using the ‘Find Compounds by Molecular Feature’ 
function and peak alignment was performed using custom scripts. Specific structures were as-
signed by matching exact mass (within 20 ppm mass error of theoretical values) and retention time 
to established HMO libraries (Wu et al, 2010; Wu et al, 2011). Absolute abundances in ion counts 
were normalized to total HMO abundance found in the external HMO pool run respective to that 
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sample’s batch. Glycan types were divided into four classes: fucosylated, sialylated, fucosylated 
and sialylated, and non-fucosylated neutrals. Relative class abundances were calculated by divid-
ing absolute class abundance by each mother’s total HMO abundance. The same normalization 
and relative abundance calculations were performed for individual structures.
Phenotypic secretor status for all mothers was determined by analyzing abundances of 
individual HMO structures and examining their chromatographic profiles. LCNI-5 secretor status 
assignment was based on a previously developed method (Totten et al, 2012). Secretor status as-
signment for mothers in the iLiNS-DYAD-M cohort also used this method but with the following 
modifications: absolute abundances of compounds with known α1-2 fucose linkage [fucose(α1-2)
galactose] were summed and normalized to each mother’s total oligosaccharide abundance in order 
to calculate relative α1-2 fucosylation for each mother. The structures used for this determination 
were 2’fucosyllactose (2’FL), lactodifucotetraose (LDFT), trifucosyllacto-N-hexaose (TFLNH), 
difucosyllacto-N-hexaose a (DFLNHa) and fucosyl-iso-lacto-N-hexaose I (IFLNH I) (Newburg 
and Neubauer, 1995). Secretor status was confirmed by comparing the extracted ion chromato-
grams of those structures between assigned secretors and non-secretors.
Generating a clonally arrayed sequenced collection of bacterial strains from a 6-month-old 
severely stunted Malawian infant
A de-identified fecal sample, collected and immediately frozen in a dry cryogenic storage dewar 
(pre-charged with liquid nitrogen), from a 6-month-old infant that had been enrolled in a previ-
ously reported study of twins living in five rural southern Malawian villages (patient ID h264A in 
Yatsunenko et al, 2012), was used to produce a clonally arrayed collection of anaerobic bacterial 
strains with a protocol modified slightly from what we had described previously (Faith et al, 2013; 
Goodman et al, 2011; Ridaura et al, 2013). An aliquot of the frozen sample was pulverized in a 
Biosafety Class II hood with a ceramic mortar and pestle filled with liquid nitrogen. An aliquot 
(1g) of the pulverized material, sealed in a sterile screw-capped tube (Axygen SCT-200-C-S), was 
brought into an anaerobic Coy chamber (atmosphere: 20% CO2, 5% H2, and 75% N2), immediately 
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suspended in 15 mL Gut Microbiota Medium (GMM; Goodman et al, 2011) and blended with a 
Waring MC1 blender set on maximum speed (four cycles of blending for 20 seconds followed by 
a 30 second pause). The sample was allowed to stand for 5 minutes so that particulate matter could 
settle by gravity; the resulting supernatant was passed through a 100 μm pore diameter filter (BD 
systems, Inc. Franklin Lakes, NJ) to remove remaining particulate material, mixed with an equal 
volume of pre-reduced GMM containing 30% glycerol (final concentration 15% glycerol) and 
placed in Wheaton crimp top tubes for storage at -80°C.
A vial of the -80°C anaerobic glycerol stock containing an aliquot of the clarified sample 
was diluted into pre-reduced GMM lacking resazurin in an anaerobic chamber and dispensed into 
a pre-reduced 384-well flat-bottomed polypropylene multi-well plate (170 μL per well; Costar 
#3964, Corning, NY). All liquid handling steps were performed using a set of custom interfaces 
for a Precision XS robot (BioTek) so that picking, arraying and archiving of the bacterial culture 
collection could be done with economy and speed under anaerobic conditions.
To determine the dilution at which approximately 30% of wells would receive one or more 
bacterial cells in the initial inoculation, two- and fourfold serial dilutions of the clarified fecal 
suspension were performed (from 10-6 to 10-10) in a trial inoculation (48 wells per dilution; 170 
μL per well). Plates (Nunc 260251) were sealed with sterile foil lids (VWR 60941-076) and in-
cubated in a Coy chamber for 3 days at 37°C under anaerobic conditions (atmosphere: 20% CO2, 
5% H2, and 75% N2). The dilution at which ~30% of wells were turbid (OD630 > 0.1) was chosen 
for a subsequent large-scale culturing effort. To do this, a second vial of the frozen clarified fe-
cal sample was added to 500 mL of pre-reduced GMM at the calculated dilution and dispensed 
into 384-well plates as above (170 μL per well, 3,840 wells total) and incubated at 37°C under 
anaerobic conditions for 3 days. Frozen anaerobic glycerol stocks of each plate were prepared by 
resuspending cells (by pipetting) and transferring 25 μL aliquots to a pre-reduced 384-well plate 
containing an equal volume of pre-reduced GMM with 30% glycerol. Glycerol stock plates were 
frozen on dry ice inside the anaerobic chamber and stored in a -80°C freezer. The anaerobic status 
of frozen stocks was verified by including resazurin in the storage medium. An additional 60 μL 
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of the resuspended cell culture was taken from each well for measuring OD630 and sequencing of 
bacterial genomic DNA.
Based on the results of sequencing amplicons generated from the V4 region of each iso-
late’s 16S rRNA gene, the library was subsequently condensed to include up to seven representa-
tives of each unique V4 16S rRNA sequence. (Condensing at this step consisted of recovering the 
frozen 384-well stock plates in GMM, purifying each isolate on GMM agar plates and inoculating 
fresh 96-well plates with the isolates).
Genomic DNA from each isolate was subjected to shotgun sequencing in multiplex using a 
HiSeq2000 instrument [101 nt paired-end reads, 44.65±29.32 fold coverage (mean±SD), see Table 
S2A]. Genomes were assembled using Velvet and Velvet Optimizer, version 2.1.7. Genes encoding 
proteins, tRNAs and rRNAs were annotated with Glimmer3.0, tRNAScan 1.23 and RNAmmer 
1.2, respectively.
Shared genome content at the nucleotide level was computed using Nucmer as described in 
an earlier report (Faith et al, 2013). Shared genome content was calculated between two genomes 
(A and B) by the following formula,
where X is the length of A that aligns to B, Y is the length of B that aligns to A, len(A) is the length 
of A, and len(B) is the length of B. Isolates were clustered at the level of >96% shared genome 
content using Nucmer (Delcher, 2002). A single representative of each cluster was selected based 
on draft genome sequence quality and used to generate the 25-member strain collection.
Each of the selected isolates listed in Table S2A was re-purified on LYHBHI agar plates 
(Sokol et al, 2008) and a full-length 16S rRNA amplicon was generated [50 μL PCR reactions con-
tained 44 μL ReddyMix PCR master mix (Thermo Scientific#AB-0575/LD), 2 μL Forward primer 
(8F; 10 μM) and 2 μL Reverse primer (1392R; 10 μM); cycling conditions were 95°C for 10 min-
utes, followed by 35 cycles of 95°C for 45 seconds, 56°C for 45 seconds, and 72°C for 2 minutes, 
164
followed by 72°C for 10 minutes]. Amplicons were sequenced using the dideoxy chain termination 
method (Retrogen, Inc; San Diego, CA). Our designation of a strain as B. longum subsp. infantis 
was based on (i) the presence of genes encoding urease subunits (LoCascio et al, 2010) and (ii) 
the presence of HMO utilization gene clusters containing all four glycoside hydrolases active on 
HMO linkages [β-galactosidase, sialidase, fucosidase and hexosaminidase) (Sela et al, 2008); see 
Table S2C].
The 25-strain library was stored in a “sparse” 96-well format where members were delib-
erately spaced across the plate in between un-inoculated wells employed as a ‘buffer’ to monitor 
potential contamination events. To prepare the strain collection for gavage into germ-free animals, 
a frozen archived ‘stock plate’ was thawed at room temperature inside the anaerobic chamber and 
a 30 µL aliquot of the contents of each well was transferred using a Precision XS robot (BioTek) 
into 600 μL of either fresh pre-reduced GMM or pre-reduced LYHBHI medium (Sokol et al, 
2008) located in the wells of a new 96-well microtiter plate (Nunc, #260251). Following an over-
night incubation at 37°C in an anaerobic chamber, cultures were independently assayed for growth 
(OD630), an equal volume (200 µL) was taken from each well and the aliquots were pooled. An 
equal volume of pre-reduced PBS containing 30% glycerol was mixed with the pooled cultures, 
and the mixture was dispensed, in 1 mL aliquots, into Wheaton crimp cap tubes and stored at -80°C 
until use. Stocks of the pooled material were kept at -80°C and then thawed immediately prior to 
gavage of gnotobiotic animals.
Purification and compositional analysis of S-BMO
S-BMO was purified from commercial whey permeate after lactose was partially removed by 
concentration and crystallization. BMO in delactose permeate was first concentrated with a single 
stage ultrafiltration membranes (molecular mass cut off of 1000 Da; GE Waters, Inc.; Boulder, CO, 
USA) at 30oC. S-BMO was then extracted from this ultrafiltrate by anion-exchange chromatogra-
phy on a column containing 100 L of dimethylamine functionalized chloromethylated copolymer 
of styrene and divinyl benzene (Bucher-Alimentech Ltd.; Auckland, NZ). Chromatography was 
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run at 150 liter/hour at 30oC. The S-BMO peak collected from anion-exchange chromatography 
was further concentrated by ultrafiltration at 30oC using the same type of membrane to remove 
minerals in the solution. The final concentrate was freeze-dried and stored in a vacuum desiccator 
at room temperature.
The total carbohydrate composition of S-BMO was determined on an Agilent 6520 accu-
rate-mass Q-TOF LC/MS with a microfluidic nano-electrospray chip and high-performance anion-
exchange chromatography with pulsed amperometric detection (Thermo Scientific HPAE-PAD 
ICS-5000, Sunnyvale, CA, USA).
Design and preparation of the Malawi 8 (M8) diet
This diet was formulated based on a dietary survey of the complementary feeding practices of 
43 nine-month-old Malawian infants and children enrolled in the iLiNS-DOSE clinical study 
(#NCT00945698) that took place in the Mangochi district of Malawi. The United States Depart-
ment of Agriculture Nutrient Database (http://ndb.nal.usda.gov/ndb/search/list) was used estimate 
the macro- and micronutrient content of components of their diets. We then used linear program-
ming to calculate combinations of ingredients that resembled the mean energy and nutrient values 
for diets identified from the dietary survey. Table S3B lists the composition of food ingredients in 
M8.
The M8 diet was prepared for administration to gnotobiotic animals as follows: Meseca® 
corn flour was obtained from Restaurant Depot (College Point, NY). The remaining ingredients 
were purchased from Whole Foods Supermarkets. The diet was prepared in batches of 20 kg. 
A relish containing 2kg mustard greens, 1.5kg onions and 1.5kg tomatoes was pureed in a food 
processor (Robot Coupe Model R23, Jackson, MS) and the puree was cooked in 1L of water for 
60 minutes on a Corning stirrer/hot plot (high setting, until browned). After cooking, the relish 
was combined with a pureed mixture of 1kg ground peanuts, 700g soaked red kidney beans, 1kg 
canned pumpkin and 2.5kg peeled bananas in an industrial mixer (Globe SP30P 30-quart pizza 
mixer; gear speed 1; Globe Food Equipment Company, Dayton, OH). Corn flour (5kg) and hot, 
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freshly autoclaved water (5L) were then added slowly and mixed using the industrial mixer for 5 
min.
Purified powdered S-BMO or inulin (from dahlia tubers, Santa Cruz Biotechnology, Inc., 
Product Number 9005-80-5) were then added to the M8 diet at the concentrations noted in the 
main text. Batches of unsupplemented M8, S-BMO-supplemented M8 or inulin-supplemented M8 
diets were allowed to cool in clean plastic containers in a 4°C cold room prior to vacuum packing 
in 500 g aliquots in FDA/USDA-compliant poly-nylon vacuum pouches (#S-7556; Uline, Pleas-
ant Prairie, WI). Sealed diet aliquots were double-bagged and sterilized by irradiation (20-50 kGy) 
within 24 hours of production (Steris Co; Chicago, IL).
For experimental convenience and consistency, dry pelleted versions of M8 and S-BMO-
supplemented M8 were also obtained from Dyets, Inc. (Bethlehem, PA). Pellets were extruded 
with a 1/2-inch diameter for gnotobiotic mouse studies and a 3/16-inch diameter for gnotobiotic 
piglet studies.
The nutritional content of all cooked and irradiated custom diets was defined by N.P. Ana-
lytical Laboratories [St Louis, MO (Table S3C)]. Measurement of chow consumption by gnoto-
biotic animals confirmed comparable caloric and nutritional consumption between paste and pel-
leted versions of the diets (data not shown). Irradiated food was stored at 4°C for up to six months. 
Sterility was determined by resuspending a small aliquot of each batch of food in pre-reduced 
GMM under anaerobic conditions and incubating the suspension for 3 days at 37°C. Sterility was 
further verified by subculture on pre-reduced anaerobic GMM agar plates.
Studies involving gnotobiotic mice
All gnotobiotic mouse experiments were performed using protocols approved by the Washington 
University Animal Studies Committee. Male germ-free C57Bl/6J mice were maintained in sterile, 
flexible, plastic gnotobiotic isolators (Class Biologically Clean Ltd., Madison, WI) under a strict 
12-hour cycle (lights on at 0600, off at 1800 h). Mice were fed an autoclaved low-fat, polysaccha-
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ride-rich chow (LF/HPP) diet (B&K University, East Yorkshire, U.K.; diet 7378000) from wean-
ing until 3 days prior to the beginning of an experiment. At that time, 4.5-week old male animals 
were switched to the M8 diet or the M8 diet supplemented with S-BMO or inulin for the remainder 
of the experiment. Mice received a single oral gavage (200 µL) of the complete 25-member culture 
collection or subsets of the collection 3 days after switch to one of the M8-based diets.
Quantitative magnetic resonance (qMR) analysis of body composition
Body composition was defined using an EchoMRI-3in1 instrument (EchoMRI, Houston, TX). 
Each mouse was transported from its gnotobiotic isolator to the MR instrument in a HEPA filter-
capped glass vessel.
Sample collection
Fecal samples were collected at defined times after gavage. At the time of euthanasia, blood, cecal 
contents, liver, brain and skeletal muscle (soleus or gastrocnemius) were collected and immedi-
ately frozen in liquid nitrogen. Soleus and gastrocnemius muscle samples were freeze-clamped 
after euthanasia in situ using pre-cooled forceps prior to harvest and storage.
Micro-computed tomography
Femurs were harvested from mice at time of euthanasia, cleaned of soft tissue, fixed for 24 hours 
in 10% formalin and stored at 4°C in 70% ethanol until scanning. Micro-computed tomography 
was performed using a µCT 40 desktop cone-beam instrument (ScanCO Medical, Brüttisellen, 
Switzerland). For cortical analyses, 200-300 slices were taken for each sample in the transverse 
plane with a 6 µm voxel size (high resolution). For all cortical scans, slices began at the midpoint 
of the femur and extended toward the distal femur. Boundaries of and thresholds for bone were 
drawn manually using µCT 40 software. Calculation of volumetric parameters (bone volume/tis-
sue volume, bone mineral density and cortical thickness) was automated with custom scripts.
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Histological analysis of distal femur morphology
Previously fixed femurs were decalcified by incubation at room temperature in 15 mL of 14% 
EDTA, pH 7.2 (#EDS; Sigma Aldrich) for 14 days with gentle agitation. The EDTA solution was 
replaced daily. Decalcified femurs were subsequently washed four times with deionized water, 
rehydrated with stepwise immersions in 30% ethanol, 50% ethanol and 70% ethanol (30 minutes 
each), embedded in paraffin, cut into 5 μm thick longitudinal sections and stained for tartrate-
resistant acid phosphatase (TRAP) for osteoclasts (Oddie et al, 2000) and hematoxylin for nuclei. 
Sections were imaged at 100x magnification with an Olympus U-CMAD3 microscope. The result-
ing images were analyzed using BioQuant OSTEO 2012 software (BIOQUANT Image Analysis 
Co.; Nashville, TN). Personnel were blinded to sample identifications. The region of interest for 
analysis of trabecular bone was defined for each section as the 2-dimensional area beginning 750 
μm proximal to the distal growth plate and extending to the very proximal edge of the growth plate 
and spanning the full width of the bone. Osteoclasts were identified as TRAP+ cells. Regions lo-
cated adjacent to the growth plate where osteoclast density was too high to accurately count cells 
were excluded from the analysis.
Multiplex sequencing of amplicons generated from bacterial 16S rRNA genes
Genomic DNA was extracted by resuspending fecal pellets (~50 mg) or cecal contents (~50 mg) 
in a solution containing 500 µL of extraction buffer [200 mM Tris (pH 8.0), 200 mM NaCl, 20 
mM EDTA], 210 µL of 20% SDS, 500 µL phenol:chloroform:isoamyl alcohol (pH 7.9, 25:24:1, 
Ambion) and 500 µL of 0.1-mm diameter zirconia/silica beads. Cells were mechanically disrupted 
using a bead beater (BioSpec Products, Bartlesville, OK; maximum setting for 4 min at room tem-
perature), followed by extraction with phenol:chloroform:isoamyl alcohol and precipitation with 
isopropanol.
Amplicons (~365bp) spanning variable region 4 (V4) of the bacterial 16S rRNA gene were 
generated by polymerase chain reaction (PCR) using primers and cycling conditions described in 
an earlier report (Subramanian et al, 2014). PCR primers incorporated sample-specific barcodes 
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allowing samples to be subjected to multiplex sequencing using an Illumina MiSeq instrument 
(paired-end 250 nt reads). Paired V4-16S rRNA sequences were trimmed to 200 bp and merged 
into a single sequence with Flash software (Magoc and Salzberg, 2011). Merged sequences were 
filtered for low quality reads and binned according to their sample-specific barcodes. Reads were 
clustered into 97%ID OTUs using UCLUST (Edgar, 2010) and the Greengenes references OTU 
database. Reads that failed to hit the reference dataset were clustered de novo using UCLUST. 
A representative OTU set was created using the most abundant OTU from each bin. Reads were 
aligned using PyNAST (Caporaso et al, 2010). A custom dataset of manually curated NCBI bacte-
rial taxonomy (Ridaura et al, 2013) was used to train the Ribosomal Database Project (RDP) ver-
sion 2.4 classifier (Wang et al, 2007b) and to assign taxonomy to picked OTUs. Validation of this 
assignment strategy is described in a previous publication (Ridaura et al, 2013). For analysis of 
bacterial abundance and colonization efficiency, rare OTUs (<0.1% relative abundance on average 
across all samples collected from a given treatment group and timepoint) were removed.
Microbial RNA-Seq
Protocols for microbial RNA-Seq are described in our previous publications (Faith et al, 2011; 
McNulty et al, 2013; Turnbaugh et al, 2009). A slightly modified procedure was followed for 
this study. Cecal contents (100-300mg), collected 44 days after gavage, were suspended in 1 mL 
RNAprotect bacteria reagent (Qiagen), vortexed for 5 min at room temperature and centrifuged 
for 10 min at 5000 x g (4°C). After decanting the supernatant, pelleted cells were suspended 
in 500 μL extraction buffer (200 mM NaCL, 20 mM EDTA), 210 μL of 20% SDS, 500 μL of 
phenol:chloroform:isoamyl alcohol (pH7.9, 125:24:1, Ambion) and 250 μL of acid-washed glass 
beads (Sigma-Aldrich, 212-300 μm diameter). Microbial cells were lysed by mechanical disrup-
tion using a bead beater (Biospec; maximum setting; 5 min at room temperature), followed by 
phenol:chloroform:isoamyl alcohol extraction and precipitation with isopropanol. RNA was treat-
ed with RNAse-free TURBO-DNAse (Ambion) and 5S rRNA and tRNAs were removed (MEGA-
Clear columns, Ambion). A second DNAse treatment was performed (Baseline-ZERO DNAse; 
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Epicenter). RNA integrity was checked by gel electrophoresis (100 ng, 1% agarose gel). 16S and 
23S rRNA was depleted using the Ribo-zero meta-bacterial rRNA removal kit (Epicenter), fol-
lowed by ethanol precipitation. cDNA was synthesized using SuperScript II (Invitrogen), followed 
by second strand synthesis with RNAseH, E. coli DNA polymerase (NEB) and E. coli DNA ligase 
(NEB). Samples were sheared using a BioRuptor XL sonicator (Diagenode); 200-300 bp frag-
ments were gel selected and prepared for sequencing.
Multiplex microbial RNA-Seq for gnotobiotic mouse experiments was performed using an 
Illumina Hi-Seq2000 instrument to generate 10.78±1.45 million (mean±SD) unidirectional 101 nt 
reads per sample. Sequencing reads were split according to the 8-bp barcodes used to label each 
of the twelve samples pooled together per HiSeq lane (sequencing was performed over three lanes 
with reads pooled for analysis).
Reads were mapped to genes in a custom database of 25 unique draft genomes included 
in the defined Malawian infant bacterial community. If a read mapped to more than one location 
in a genome or to multiple genomes, the counts for each gene were added according to the gene’s 
fraction of unique-match counts. Read counts (rounded to the nearest integer) for each gene were 
split by genome and then normalized and analyzed with the R statistical package, DESeq (Anders 
and Huber, 2010).
Community profiling by sequencing (COPRO-Seq)
Protocols for determining bacterial community composition by COPRO-Seq are described in our 
previous publication (McNulty et al, 2011). Briefly, DNA samples were sheared using a BioRuptor 
Pico sonicator (Diagenode); 200-300 bp fragments were gel selected and prepared for sequencing. 
Samples were sequenced in multiplex using an Illumina NextSeq instrument to generate unidirec-
tional 75 nt reads. Sequencing reads were split according to 8 bp barcodes assigned to each sample, 
processed and mapped to the draft genomes of members of the Malawian infant’s culture collec-
tion using COPRO-Seq software (https://github.com/nmcnulty/COPRO-Seq).
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Mass spectroscopy of metabolites contained in biospecimens obtained from gnotobiotic 
animals
Targeted ultra high performance liquid chromatography-mass spectrometry (UPLC-
MS) of liver, muscle, brain, serum and cecal contents
Liver, brain, muscle and cecal samples were homogenized in 50% aqueous acetonitrile containing 
0.3% formic acid (50 mg wet weight tissue/mL solution) using a high-speed homogenizer (IKA 
#EW-04739-21) set at maximum speed for 30-45 seconds. Samples were maintained on ice or dry 
ice throughout this procedure.
Amino acids, acylcarnitines, organic acids, acyl CoAs and ceramides were analyzed using 
stable isotope dilution techniques. Amino acids and acylcarnitine measurements were made by 
flow injection tandem mass spectrometry using sample preparation methods described previously 
(An et al, 2004, Ferrara et al, 2008). Data were acquired using a Waters AcquityTM UPLC system 
equipped with a TQ (triple quadrupole) detector and a data system controlled by MassLynx 4.1 
operating system (Waters, Milford, MA). Organic acids were quantified according to a previously 
published protocol (Jensen et al, 2006) using Trace Ultra GC coupled to ISQ MS operating under 
Xcalibur 2.2 (Thermo Fisher Scientific, Austin, TX). Acyl CoAs were extracted and purified as 
described (Deutsch et al, 1994; Magnes et al, 2005; Minkler et al, 2008), and analyzed by flow 
injection analysis using positive electrospray ionization on Xevo TQ-S, triple quadrupole mass 
spectrometer (Waters, Milford, MA). Heptadecanoyl CoA was employed as an internal standard. 
Ceramides were extracted using a previously reported procedure (Merrill et al, 2005) and analyzed 
by flow injection tandem mass spectrometry using a Xevo TQS spectrometer (Waters Milford, 
MA,) for precursors of m/z 264.
Non-targeted gas chromatography/mass spectrometry (GC-MS) of serum
Serum samples were spiked with perdeuterated myristic acid (D27-C14:0) as an internal standard 
for retention time locking (RTL IS). Following treatment with 7.5 volumes of methanol, the mix-
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ture was centrifuged and the supernatant was decanted and dried. Derivatization of all dried su-
pernatants for GC-MS followed a method adapted with modifications from Roessner et al. (2000). 
Reagents were from Sigma-Aldrich (St. Louis, MO), unless otherwise noted. Briefly, certain re-
active carbonyls were first methoximated at 50ºC with a saturated solution of methoxyamine hy-
drochloride in dry pyridine, followed by replacement of exchangeable protons with trimethylsilyl 
(TMS) groups using N-methyl-N-(trimethylsilyl) trifluoroacetamide with a 1% v/v catalytic ad-
mixture of trimethylchlorosilane (Thermo-Fisher Scientific), also at 50ºC. GC-MS methods gener-
ally used a 6890N GC connected to a 5975 inert single-quadrupole MS (Agilent, Santa Clara, CA). 
A large-volume ProSep inlet (Apex Technologies, Inc.; Independence, KY) enabled programmed 
temperature vaporization and diversion of heavy contaminants away from the GC and MS. The 
two wall-coated, open-tubular GC columns connected in series were both from J&W/Agilent (part 
122-5512, DB5-MS; 15 m in length, 0.25 mm in diameter, with a 0.25 µm luminal film). Prior to 
each run, initial inlet pressures were empirically adjusted such that the resulting retention time of 
the TMS-D27-C14:0 standard was set at ~16.727 min. Under these conditions, derivatized me-
tabolites eluted from the column and reached the electron-ionization source in the MS at known 
times. A mid-column, microfluidic splitter (Agilent) provided a means for hot back-flushing of 
the upstream GC column at the end of each run while the oven was held at 325ºC for a terminal 
“bake-out” [another antifouling and anti-carryover measure analogous to that described in (Chen 
et al, 2009)]. During this terminal “bake-out,” the inlet was also held at 325ºC and purged with a 
large flow of the carrier gas, helium. Positive ions generated with conventional EI at 70 eV were 
scanned broadly from 600 to 50 m/z in the detector throughout the run.
Raw data from Agilent’s ChemStation software environment were imported into AMDIS 
(Automatic Mass Spectral Deconvolution and Identification Software; Stein, 1999). Deconvoluted 
spectra were identified, to the extent possible, using several commercial and public spectral librar-
ies. Our primary source was the Fiehn GC-MS Metabolomics RTL Library (a gift from Agilent 
Technologies, Santa Clara, CA; part number G1676-90000). Additional spectra for comparison 
were gleaned from the Golm Metabolome Library (Kopka et al, 2005), the commercial NIST/
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EPA/NIH Mass Spectral Library and our own purpose-built spectral library. Where indicated, peak 
alignment was performed with SpectConnect freeware (Styczynski et al, 2007). Chemometrics 
were performed with Mass Profiler Professional (Agilent), along with our own custom macros, 
written in Visual Basic for use in the Excel software environment.  
Non-targeted analysis of brain metabolites using GC-MS
Left cerebral hemispheres of mouse brains were homogenized using the same procedures de-
scribed above for UPLC-MS of liver, serum and cecal contents. Homogenates were centrifuged 
(20,800 x g for 10 min at 4°C). A 200µL aliquot of the resulting supernatant was transferred to a 
clean tube and combined with 400 µL ice-cold methanol. The mixture was subsequently vortexed 
and centrifuged, and a 500 µL aliquot of the resulting supernatant, together with 10 µL of lysine-
13C6,
15N2 (2 mM), was evaporated to dryness using a speed vacuum. To derivatize the sample, 80 
µL of a solution of methoxylamine (15 mg/mL in pyridine) was added to methoximate reactive 
carbonyls (incubation for 16 h for 37ºC), followed by replacement of exchangeable protons with 
trimethylsilyl groups using N-methyl-N-(trimethylsilyl) trifluoroacetamide (MSTFA) with a 1% 
(vol/vol) catalytic admixture of trimethylchlorosilane (Thermo-Fisher Scientific) (incubation for 
1h at 70ºC). Heptane (160 µL) was added and a 1 µL aliquot of each derivatized sample was in-
jected into an Agilent 7890A gas chromatography system, coupled with a 5975C mass spectrom-
eter detector (Agilent, CA). The quantity of each metabolite was determined from spike-in internal 
standards.
Non-targeted UPLC-MS of brain metabolites
Frozen mouse left cerebral hemisphere samples were homogenized with 20 vol/wt of cold metha-
nol and 1 vol/wt cysteine 13C6,
15N2 (4 mM). Samples were subsequently incubated at -20°C for 
1h and centrifuged 10 min at 20,800 x g. The resulting supernatant (300µL) was collected and 
dried in a SpeedVac at room temperature. Dried samples were resuspended in 100 µL of 95:5 
water:ethanol, clarified for 5 min by centrifugation at 20,800 x g for 10 min at 4oC and the super-
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natant was separated for UPLC-MS. Analyses were performed on a Waters Acquity I Class UPLC 
system (Waters Corp., Milford, MA) coupled to an LTQ-Orbitrap Discovery (Thermo Fisher Cor-
poration). Mobile phases used for negative ionization were (A) 5 mM ammonium acetate in water 
and (B) 5 mM ammonium acetate in acetonitrile/water (95%/5%).
Experiments involving gnotobiotic piglets
All experiments involving pigs were performed under the close supervision of a veterinarian using 
protocols approved by the Washington University Animal Studies Committee.
Derivation of germ free piglets
Pregnant domestic sows (mixture of Landrace and Yorkshire genetic backgrounds, mated to Duroc 
breed domestic boars) were obtained from Oak Hill Genetics (Ewing, IL). Piglets were delivered 
one day prior to the anticipated date of farrow. To prepare for surgery, the sow was sedated with 
ketamine (20 mg/kg administered intramuscularly) and anesthetized with isofluorane (2-3%, de-
livered by mask or endotracheal tube). A local incisional block was achieved using 60-80 mL of 
2% lidocaine injected subcutaneously. The sow’s paralumbar abdominal area was shaved, washed, 
and disinfected with povidone-iodine (1% titratable iodine). Piglets were delivered by making a 
paralumbar abdominal incision on the sow, exteriorizing the uterus and removing piglets individu-
ally into the sterile surgical field. Each piglet’s umbilical cord was tied off to prevent bleeding and 
then severed. Piglets were then immediately passed, prior to their first breath, through a sterile 
tank filled with 10% betadine into a sterile gnotobiotic ‘nursery’ isolator made of flexible plastic. 
Piglets were revived within the ‘nursery’ isolator and kept on a heated pad until the procedure was 
complete. At the completion of surgery, the sow was euthanized by pentobarbital overdose (>150 
mg/kg intravenously).
Immediately after piglets were revived (breathing independently and moving), they were 
transported within the nursery isolators from the operating room to a gnotobiotic facility. Within 
24 hours, all piglets were transferred from the initial nursery isolators to larger, steel gnotobiotic 
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isolator tubs (Class Biologically Clean; Madison, WI) where they were maintained for the duration 
of the experiment. Steel isolators were equipped with a flexible plastic canopy allowing trained 
personnel to examine and interact with the animals. Gnotobiotic piglets were group-housed (three 
piglets per isolator, complying with USDA animal housing regulations) and closely monitored 
throughout the experiment.
The room where gnotobiotic piglets were housed in their isolators was maintained at 85°F-
90°F. Gnotobiotic isolators were maintained at 95°F-100°F using electric heaters positioned near 
their exterior (Cuori #HD904-A7Q 1500-watt electric oil-filled radiant portable heaters). Ther-
mometer probes were positioned near inlets and outlets for airflow to monitor isolator tempera-
tures. Piglet weights were measured using a hanging scale after carefully tying a rope around the 
piglet’s abdomen and forelimbs.
Experimental design
Piglets were initially fed a powdered sow’s milk replacement (Soweena Litter Life, Merrick 
#C30287N). The powdered sow’s milk replacement was prepared in 120g vacuum-sealed, gam-
ma-irradiated packets for reconstitution in gnotobiotic isolators (120g/ 1L autoclaved water). Pig-
lets were fed by bottle for the first 2-3 days of life as they were trained to drink independently from 
troughs. Bottle-feeding was withdrawn when all piglets were observed to be drinking indepen-
dently. Piglets were slowly weaned from sow’s milk replacement formula to custom M8 pelleted 
chow starting at postnatal day 5 of life and completing on day 11. To do so, pelleted chow was 
introduced as creep feed in addition to formula, and the amount of formula provided to piglets was 
reduced stepwise until all piglets were observed eating pelleted chow. A small amount of sterile 
water was added to pelleted chow to encourage eating, and water was made available ad libitum to 
all animals in separate troughs. Behavior and the condition of all piglets were monitored multiple 
times each day to ensure their well-being. Piglets were fed at 3-hour intervals on days 1-2 after 
birth, at 4-hour intervals during days 3-4 and at 8-hour intervals from postnatal day 5 until the end 
of the experiment.
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The germ-free status of piglets prior to colonization on postnatal day 3 was confirmed by 
aerobic and anaerobic culture of rectal swabs in LYHBHI medium (Sokol et al, 2008). Anaerobic 
cultures were taken by placing rectal swabs in anaerobic transport medium tubes (Anaerobe Sys-
tems ATM 6.0ML #AS-911) for transport to an anaerobic chamber (atmosphere: 20% CO2, 5% H2, 
and 75% N2).
Gnotobiotic piglets were colonized at day 3 of life by oral gavage. Briefly, equal volumes 
of overnight pre-reduced LYHBHI cultures of the 17 strains from the Malawian infant’s bacterial 
culture collection that lacked more than three known virulence factor were mixed, diluted 1:10 in 
LYHBHI medium and mixed with an equal volume of pre-reduced PBS containing 30% glycerol 
[final glycerol concentration 15% (vol/vol)]. Aliquots of the bacterial consortium were stored at 
-80°C until use. For each piglet, 1 mL of this inoculum was resuspended in 10 mL of sow’s milk 
replacement formula and introduced by intragastric gavage using a Kendall KangarooTM 2.7 mm 
diameter feeding tube (Cat #8888260406; Covidien, Minneapolis, MN).
Gnotobiotic piglets were euthanized on day 19 of postnatal life. Piglets were removed from 
the gnotobiotic isolator, sedated with ketamine (20 mg/kg IM), anesthetized with isofluorane and 
euthanized by pentobarbital overdose (>150 mg/kg IV). Whole blood was collected under anesthe-
sia in Vacutainer tubes (BD #366404), immediately prior to euthanasia, stored on ice for at least 30 
minutes and then centrifuged at 4000 × g for 5 minutes. Serum was collected, separated into small 
aliquots, and stored at -80°C. Other tissues were collected immediately after euthanasia, frozen in 
liquid nitrogen and stored at -80°C. Muscle samples were collected from the biceps femoris im-
mediately after euthanasia and frozen in liquid nitrogen within 3-4 minutes.
Microbial RNA-Seq
Fecal samples were collected at the time of euthanasia on day 19 of postnatal life, RNA was ex-
tracted and microbial RNA-Seq was performed using an Illumina NextSeq instrument to generate 
42.5±15.2 million unidirectional 75 nt reads per sample. Reads were demultiplexed using the 8 
nt sample-specific barcode adapters and processed/mapped to the draft genomes of strains in the 
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culture collection using a set of custom scripts. Read counts were normalized and analyzed using 
DESeq (Anders and Huber, 2010).
Gut mucosa glycan analysis by triple quadrupole mass spectrometry
Mucosal samples were collected from three segments of the gut: (i) proximal small intestine (de-
fined as a 10 cm segment distal to the stomach); (ii) distal small intestine (a 10 cm segment proxi-
mal to the cecum), and (iii) the spiral colon (10 cm segment distal to the cecum). Each of these 
segments was opened with clean steel scissors and luminal contents were gently removed with a 
clean steel spatula. The mucosa was gently scraped with a separate clean steel spatula and scrap-
ings from each segment immediately frozen in liquid nitrogen. In addition, cecal contents and 
feces were recovered.
Each sample was diluted in water to 0.1 mg/10 µL, vortexed and briefly centrifuged at 
2,000 x g. 100 µL of the resulting supernatant was taken and mixed with 100 µL of 0.2 M trifluo-
roacetic acid (TFA), then heated at 80°C for 1 hour. The solvent was then dried using a centrifugal 
evaporator. Samples were subsequently reconstituted in 200 µL of water and centrifuged at 21,130 
x g for 30 min. 10 µL of the resulting supernatant was then added to 40 µL water and centrifuged 
at 21,130 x g for 20 min.
Analysis was performed on an Agilent ultra high-pressure liquid chromatography-elec-
trospray ionization (UPLC-ESI)-triple quadrupole (QqQ) mass spectrometer in dynamic multiple 
reaction monitoring (MRM) mode. The Agilent 1290 infinity UPLC system incorporates a binary 
solvent system of solvent A [3% acetonitrile/water (v/v) in 0.1% formic acid (FA)] and solvent B 
[95% acetonitrile/water (v/v)] with an injection volume of 1 µL and flow rate of 0.3 mL/min with 
a Waters ACQUITY UPLC BEH amide column. Samples were run under isocratic conditions of 
85% solvent A and 15% solvent B with a total run time of 3 min. The UPLC system is coupled to 
an Agilent 6490 QqQ mass spectrometer that was run in the positive mode. The MRM transitions 
used for monitoring sialic acid were ([M + 1H]1+ 310.2 m/z 197.0 and m/z 121.1). MRM data were 
analyzed using Agilent MassHunter Quantitative Analysis B.05.02 software.
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Measurement of serum leptin, insulin and triglycerides
Mouse serum triglycerides were measured using a DxC600 clinical analyzer (Beckman 445850; 
Brea, CA). Mouse insulin and leptin were measured using a duplex assay and an SI-2400 electro-
chemiluminescent imager (Meso Scale Discovery K15124C-1; Rockville, MD).
Porcine insulin and leptin were measured using a cross-reactive duplex assay developed 
for human sera (Meso Scale Discovery K151BYC-1; Rockville, MD). Porcine leptin was also 
measured with a human leptin kit (R&D Systems DLP00; Minneapolis, MN) as well as a porcine-
specific kit from Biomatik (EKU05595; Wilmington, DE) using an SpectraMax M2e plate reader 
(Molecular Devices; Sunnyvale, CA). Porcine leptin was below the limit of detection by both 
methods.
In vitro S-BMO consumption and growth assays
Frozen stock cultures were recovered by incubation overnight at 37°C in an anaerobic chamber 
in pre-reduced LYHBHI broth (Sokol et al, 2008). For incubation with S-BMO, strains were first 
grown overnight in 5 mL pre-reduced LYHBHI to an OD600 of approximately 0.8, then pelleted 
by centrifugation at 2600 x g for 5 minutes and washed twice with pre-reduced sterile PBS. Cell 
pellets were resuspended in 5 mL pre-reduced PBS containing 5% (wt/vol) and incubated at 37°C 
for 24 hours under anaerobic conditions (atmosphere: 20% CO2, 5% H2, and 75% N2). Cells were 
pelleted by centrifugation at 2600 x g for 5 minutes, and the resulting culture supernatants were 
collected for UPLC-MS or GC-MS analysis of metabolites.
For E. coli growth experiments, starter cultures of E. coli strain MC1 were grown overnight 
in pre-reduced LYHBHI to an OD600 of approximately 0.8, pelleted, washed as above and resus-
pended in 5 mL pre-reduced sterile PBS. E. coli cultures were started using a 100-fold dilution in 
a 200 μL volume of pre-reduced Davis Minimal Broth without dextrose (Sigma-Aldrich #15758, 
Saint Louis, MO) supplemented with 0.5% glucose, 0.5% sialic acid (Santa Cruz Biotechnology, 
Santa Cruz, CA), 2% S-BMO, 2% B. fragilis conditioned S-BMO (prepared by a 24 hour incuba-
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tion of B. fragilis with S-BMO, as described above) or PBS only. All culture assays (n=8 technical 
replicates) were performed with negative controls (no E. coli inoculum) in a 96-well plate format. 
The OD600 of cultures was monitored over a 24-hour period using a Biotek Eon plate reader (Biotek 
Instruments, Winooski, VT) within the anaerobic Coy chamber.
Statistical analysis
Multivariate analyses (O-PLS-DA) of metabolomics data were performed using the R package, 
Muma (Gaude et al, 2013). Univariate analyses (t-tests and ANOVA) were performed using Mi-
crosoft Excel or Prism 6.0 (GraphPad Software, Inc.). Heat maps were generated using Gene-E 
software (http://www.broadinstitute.org/cancer/software/GENE-E/index.html). Two-way ANOVA 
of HMO and secretor status data from the LCNI-5 and iLiNS studies was performed by treating 
both factors (mother’s secretor status and infant HAZ bin) as categorical variables. HMO abun-
dance was treated as a continuous response variable. Spearman’s rank correlation analyses were 
performed in the R environment using the test.cor function.
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Supplemental Figure Legends
Figure S1: Colonization with the Malawian infant bacterial culture collection is reproduc-
ible across recipient mice and piglets (relates to Figure 2, Figure 3 and Figure 6). (A,B) 16S 
rRNA-based weighted UniFrac principal coordinates plots displaying the phylogenetic structure 
of the fecal microbiota in recipient gnotobiotic mice as a function of time after colonization with 
all 25-members of the culture collection and diet (unsupplemented M8 diet or the isocaloric M8 
diet supplemented with inulin or S-BMO) (n=4-5 mice/treatment group). Panel A displays the first 
principal component (mean±SEM; 33.27% variance explained). Panel B displays the second prin-
cipal component (mean±SEM; 21.84% variance explained). (C,D) 16S rRNA weighted UniFrac-
based principal coordinates plots showing the first principal component (mean±SEM; 70.04% 
variance explained) and the second principal component (mean±SEM; 7.65% variance explained) 
of the fecal microbiota from gnotobiotic piglets colonized with 17-members of the defined Mala-
wian infant bacterial community and fed either the M8 diet or M8 supplemented with S-BMO (n=3 
piglets/treatment group). The x-axis displays days after introduction of the bacterial community. 
Vertical dashed lines indicate the start of the period of S-BMO treatment.
Figure S2: S-BMO supplementation modulates levels of liver and serum metabolites in gno-
tobiotic mice (relates to Figure 5). (A) Heatmap showing liver acylcarnitines and fatty acyl CoAs 
whose concentrations in non-fasted mice harboring the 25-member Malawian infant community 
are affected by S-BMO supplementation (measurements made 37 days post-colonization). Rows 
represent replicate gnotobiotic mice grouped by dietary treatment. Columns represent individual 
metabolites identified by targeted MS/MS. *p<0.05 (two-tailed, unpaired Student’s t-test). Red 
asterisks indicate that levels of the metabolite are significantly different between groups after 
Benjamini-Hochberg correction for multiple hypotheses (α=0.1). (B-D) Concentrations of serum 
insulin, leptin and triglycerides in gnotobiotic mice harboring the Malawian infant community, fed 
M8 with or without S-BMO supplementation; samples collected 37 days post colonization from 
non-fasted animals. **p<0.01 (two-tailed, unpaired Student’s t-test).
185
Figure S3: S-BMO supplementation alters levels of brain metabolites (relates to Figure 5). (A) 
O-PLS-DA score plot (inset) and O-PLS-DA S-plot of metabolites measured by untargeted UPLC-
MS in the left cerebral hemispheres of gnotobiotic mice fed M8 or M8 supplemented with S-BMO. 
The mass of the most strongly S-BMO-associated metabolite is indicated (putative assignment, 
N-acetylneuraminic acid). (B) N-acetylneuraminic acid (NeuAc) and (C) inosine abundance in the 
left cerebral hemisphere of gnotobiotic mice colonized with the Malawian defined community and 
fed M8 with or without S-BMO supplementation (measured 37 days after colonization). **p<0.01 
two-tailed, unpaired Student’s t-test. See Table S7E,F for abundances of all measured left cerebral 
hemisphere metabolites.
Figure S4: S-BMO supplementation increases expression of B. fragilis genes involved in 
branched chain amino acid biosynthesis in gnotobiotic piglets colonized with a 17-member 
consortium of bacterial strains from a stunted Malawian infant (relates to Figure 6). Repre-
sentation of the KEGG pathway for ‘valine, leucine, and isoleucine biosynthesis’, with enzymes 
labeled by enzyme commission (EC) number. Genes encoding enzymes with EC numbers high-
lighted with a red box exhibit significantly increased expression in B. fragilis in the context of 
S-BMO supplementation (negative binomial test after correction using the Benjamini-Hochberg 
procedure).
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Supplemental Tables
Table S1. Breast milk HMO content analysis from two cohorts of Malawian mothers.
Table S2. A clonally-arrayed, genome-sequenced bacterial culture collection generated 
from a stunted, 6-month-old Malawian infant.
Table S3. Components of the prototypic Malawian diet and S-BMO supplement.
Table S4. COPRO-Seq and 16S rRNA analysis of relative abundances of Malawian 
infant culture collection strains in the fecal microbiota of gnotobiotic mice and piglets.
Table S5. Femur morphological parameters in gnotobiotic mice fed M8 with or without 
S-BMO supplementation.
Table S6. Escherichia coli MC1 genes differentially expressed with S-BMO supplemen-
tation in gnotobiotic mice.
Table S7. Tissue metabolite concentrations in gnotobiotic mice and pigs colonized with 
the stunted Malawian donor’s culture collection and fed the M8 diet with or without S-
BMO supplementation.
Table S8. Genes in 17-member bacterial community that are differentially expressed 
with S-BMO supplementation in gnotobiotic piglets.
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Chapter 4
Future Directions
The findings presented in this dissertation demonstrate that immature gut microbiota from Mala-
wian children with undernutrition transmit growth and metabolic abnormalities to young, recently 
weaned gnotobiotic mice consuming a prototypic Malawian diet (Chapter 2). The results reported 
in Chapter 3 go on to show that dietary supplementation with a purified preparation of sialylated 
bovine milk oligosaccharides (S-BMO) promotes increased body weight and lean body mass gain 
in the context of gnotobiotic mice and gnotobiotic piglets harboring a defined consortium of bac-
teria isolated from a stunted Malawian infant’s gut microbiota and fed a Malawian diet. Critically, 
this effect was dependent on the presence of the gut microbiota. S-BMO supplementation was also 
associated with increased femoral bone volume, increased sialic acid concentrations in brain, and 
responses to the feeding/fasting transition that are consistent with enhanced metabolic flexibility. 
This future directions chapter focuses on experimental approaches for (i) obtaining a more detailed 
understanding of the effects of S-BMO on growth and metabolism, (ii) identifying individual milk 
oligosaccharide structures that recapitulate the effects of S-BMO, and (iii) characterizing the mi-
crobial determinants of S-BMO-associated growth phenotypes. In addition, this chapter discusses 
the potential for, and challenges facing, milk oligosaccharide supplementation as a treatment for 
childhood undernutrition.
Characterizing the effects of S-BMO on bone morphology and metabolic flexibility
S-BMO supplementation has various effects on growth and metabolism in the context of gnoto-
biotic mice and piglets. A more detailed understanding of these effects is required to appreciate 
their mechanistic underpinnings and therapeutic potential. S-BMO treatment was associated with 
increased trabecular and cortical bone volume (normalized to tissue volume) in mouse femurs 
(Chapter 3), but whether this represents an increase in bone formation or a decrease in bone loss 
in S-BMO supplemented animals was not determined. One could address this question by apply-
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ing dynamic histomorphometry techniques (Slyfield et al, 2012). With this approach, gnotobiotic 
mice, harboring the 25-member Malawian infant defined community and fed a Malawian diet with 
or without added S-BMO, would be injected with a marker of bone formation, such as calcein, in 
two doses (one week prior and one day prior to euthanasia). The marker would be incorporated 
into mineralizing bone, creating ‘fronts’ that would be visible by fluorescence microscopy of sec-
tions prepared from femurs. If S-BMO supplemented mice exhibit an increase in bone formation, 
one would expect to observe a larger distance between fronts (bone formation rate) and a greater 
labeled bone surface area (mineralizing bone) than what is observed in unsupplemented animals. 
If the observed bone volume difference accompanying S-BMO supplementation were a reflection 
of reduced bone loss, however, one would expect to see no detectable difference between bone 
marker fronts in either group of animals (Kulak and Dempster, 2010).
Compared to gnotobiotic animals that were not fed an S-BMO supplemented diet, supple-
mented animals displayed enhanced metabolic flexibility [an increase in serum fatty acid metabo-
lites (acylcarnitines and fatty acyl CoAs) upon fasting]. Moving forward, follow-on experiments 
in gnotobiotic mice and piglets, serially sampled during feeding-to-fasting transitions would al-
low us to determine the period of time required after initiation of S-BMO supplementation for 
enhancement of metabolic flexibility to occur. Additional follow-on experiments should include 
measurement of the respiratory quotient by indirect calorimetry (Even and Nadkarni, 2012) to 
determine which substrates (fats and/or carbohydrates) are used during feeding and fasting, with 
or without S-BMO supplementation Metabolic inflexibility is a feature usually associated with 
overnutrition (metabolic syndrome) and is thought to be a result of high concentrations of both 
lipids and carbohydrates that lead to a regulatory ‘roadblock’ (Muoio 2014). The relationship, 
therefore, between metabolic inflexibility and undernutrition is unclear. One testable hypothesis 
is that the aberrant metabolic response of unsupplemented animals is the result of an inability to 
adequately store dietary nutrients as fats during feeding and subsequently no capacity to release 
stored fats upon fasting. A key regulator of lipid storage is malonyl-CoA, which serves as a precur-
sor for de novo lipogenesis (McGarry 2002). Malonyl-CoA also acts as an allosteric inhibitor of 
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carnitine palmitoyltransferase-1 (CPT-1), a key enzyme for mitochondrial beta-oxidation of fatty 
acids (McGarry 2002). In the follow-on experiments described above, an observed increase in 
malonyl-CoA in liver upon feeding in S-BMO supplemented animals (metabolically flexible) but 
not in unsupplemented controls (metabolically inflexible), would support this hypothesis.
Identifying milk oligosaccharide structures that promote growth in gnotobiotic animal 
models
The effects of dietary supplementation with a mixture of sialylated milk oligosaccharides on growth 
and metabolism represent a promising avenue of research for the development of microbiota-di-
rected therapeutics. However, the molecular mechanisms by which these milk-derived compounds 
act remain unclear. A critical path forward is to identify specific components of S-BMO that are 
necessary and sufficient for mediating effects on growth and metabolism in gnotobiotic mouse and 
piglet models. Identification of these bioactive structures would inform additional studies of the 
microbial and host factors that underlie oligosaccharide-mediated growth as well as the sourcing 
of oligosaccharides for therapeutic application.
The S-BMO preparation used for the studies reported in Chapter 3 is composed primar-
ily of sialyllactose, which represents 88% of its oligosaccharide content. Sialyllactose, a triose 
consisting of glucose, galactose, and sialic acid monomers is present in two distinct configura-
tions, defined by either an α-2,3 or an α-2,6 glycosidic bond between the sialic acid and galactose 
moieties [termed 3’SL and 6’SL, respectively (Bruggencate et al, 2014)]. The abundance of these 
structures in S-BMO, along with their commercial availability in kilogram quantities, makes them 
prime candidates for follow-on studies, conducted in gnotobiotic animal models, designed to iden-
tify bioactive milk oligosaccharide structures.
Testing the biological activity of 3’SL and 6’SL would follow an experimental design 
similar to the studies detailed in Chapter 3, wherein gnotobiotic mice are colonized with the 
25-member defined consortium of bacteria isolated from a stunted Malawian infant and fed a 
representative Malawian diet with or without addition of 3’SL and/or 6’SL. One could then moni-
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tor growth and metabolic phenotypes in recipient animals, including body weight gain, lean body 
mass, bone morphology, and metabolic flexibility, as a function of 3’SL or 6’SL supplementation. 
Furthermore, one could examine the effect of these oligosaccharides on gut microbiota structure 
(COPRO-Seq analysis of serially collected fecal samples to quantify the proportional representa-
tion of members of the defined community as a function of treatment), on bacterial gene expres-
sion (microbial RNA-Seq analysis of fecal samples as well as samples collected along the length 
of the gut at the time of sacrifice), and on levels of various metabolites, including sialic acid, in 
the gut, liver, brain, muscle, and serum (as defined by targeted mass spectrometry). Importantly, 
the proposed studies would reveal whether there was structural specificity for the effects of sialyl-
lactose on growth and metabolic phenotypes. Lastly, oligosaccharide structures that effectively 
recapitulate S-BMO mediated growth in gnotobiotic mice could be evaluated in the context of 
gnotobiotic piglets, which bear greater anatomic and physiologic similarity to humans (Kararli, 
1995; Miller and Ullrey, 1987).
The dose of oligosaccharides to be administered is an important consideration. It is logi-
cal to initially select a dose that recapitulates the concentration of sialyllactose present in S-BMO 
supplemented diets, but additional studies could incorporate 3’SL and/or 6’SL at higher levels to 
determine whether larger effect sizes can be achieved and whether such effects saturate. These 
studies are important components of a pipeline that tests milk oligosaccharide supplements as 
candidate therapeutic agents. Determining optimal dosing is critical to define not only efficacy and 
safety, but also for determining the economic feasibility of this approach.
Dependence of milk oligosaccharide-mediated growth on members of the infant gut 
microbiota
S-BMO promotion of growth did not occur in germ-free mice. In addition, S-BMO had no impact 
on growth in gnotobiotic mice harboring a two-member community composed of Bacteroides 
fragilis and Escherichia coli, though both of these organisms exhibited transcriptional responses 
to S-BMO supplementation. These observations indicate that S-BMO mediated growth is micro-
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biota-dependent and not simply attributable to bacterial colonization. Gnotobiotic mice provide a 
highly manipulable system for determining which human gut bacterial species/strains are essential 
for mediating the effects of S-BMO on growth and metabolism. Once an intact culture collection 
from an undernourished donor is shown to be able to transmit growth faltering phenotypes to 
gnotobiotic mice and to support S-BMO ameloriation of these phenotypes, follow-up experiments 
can be performed in which animals are colonized with different subsets of this collection (Faith 
et al, 2014). S-BMO associated growth was documented in the context of a 25-member Mala-
wian infant bacterial community; thus one could interrogate the requirement of various members 
of this community by selective removal of species/strains. Infant-associated Bifidobacteria spe-
cies, for example, are prodigious consumers of milk oligosaccharides, including sialyllactose, and 
constitute five strains present in the 25-member community (Pacheco et al, 2015). Members of 
this genus have also been documented to modify gene expression in colonic epithelial cells after 
growth on milk oligosaccharides (Chichlowski et al, 2012). The hypothesis that Bifidobacteria 
strains are important effectors of S-BMO mediated growth can be tested by colonizing young 
gnotobiotic mice with the defined community minus Bifidobacteria and documenting the effect of 
dietary S-BMO supplementation on growth and metabolic phenotypes. If no effect is observed in 
these animals, one could conclude (with appropriate positive controls) that these Bifidobacteria 
strains are required for S-BMO mediated growth. Furthermore, applying a similar strategy in ad-
ditional follow-up experiments could identify which Bifidobacteria isolates are necessary to medi-
ate S-BMO associated growth. This would be accomplished by their individual removal from the 
25-member community. These studies could then be performed in gnotobiotic piglets to test the 
generalizability (and translatability) of the findings in mice.
This experimental paradigm could be extended to other members of the 25-member com-
munity, including potentially pathogenic strains (e.g., Enterococcus faecalis) whose representation 
and/or expressed functions could be enhanced or attenuated by sialylated oligosaccharides. Such 
experiments could be conducted in a targeted, hypothesis-driven manner as above or by ‘random’ 
subsetting of the bacterial community [since the combinatorial possibilities are great, the size of 
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the subset is an important parameter to consider, as is the need to have overlapping membership 
between the subsets to reduce the effort in identifying which microbes or groups of microbes are 
required to mediate S-BMO effects (Faith et al, 2014)].
Identification of the microbial determinants of S-BMO mediated growth would further en-
able the determination of required bacterial genes [e.g., using random mutagenesis techniques like 
INSeq (Goodman et al, 2009)] and give a greater mechanistic understanding of the role of milk 
oligosaccharides in promoting infant growth and nutrition.
The results of the studies detailed above are extraordinarily important with respect to the 
therapeutic potential of milk oligosaccharide supplementation. The structure of the gut microbiota 
varies substantially across geographically distinct populations and between individuals within a 
given population (Yatsunenko et al, 2012), and the gut microbiota structure of undernourished 
infants is distinct (more immature) from that of their healthy counterparts (Chapter 2). Thus, the 
representation of taxa that are critical for S-BMO mediated effects may vary between infants, and 
infants lacking those strains may be unresponsive (or more responsive) to treatment. The ability 
to screen children for the presence of required strains in their gut microbiota could guide recruit-
ment for clinical studies and/or development of treatments that incorporate the administration of 
required bacterial species.
Challenges facing milk oligosaccharides as novel therapeutics for the treatments of 
childhood undernutrition
S-BMO and similar preparations of milk oligosaccharides are attractive candidates for next gen-
eration, microbiota-directed therapeutics for the prevention and/or treatment of childhood under-
nutrition. Key challenges must be addressed, however, to make milk oligosaccharide preparations 
a viable form of treatment.
First, scalable sources of milk oligosaccharides must be identified. Milk oligosaccharides 
occur naturally in bovine milk at low levels and can be purified from existing whey waste streams. 
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This approach may carry the benefit of the resulting products being viewed as foods, rather than as 
drugs, both by target populations and regulatory agencies. An important consideration, however, 
is that the sourcing and purification of milk oligosaccharide preparations must be economically 
feasible (profitable for dairy farmers). The economic viability of producing milk oligosaccharide 
preparations will likely depend on many factors, including the required purity of the mixtures 
produced. Enzymatic removal of lactose, for example, could be cost prohibitive, but inclusion of 
lactose in oligosaccharide mixtures may not preclude the biological activity of other milk oligo-
saccharides that are present. Alternatively, the identification of individual bioactive milk oligosac-
charide structures, as described above, may allow a synthetic approach (by chemical engineering 
or through production in engineered microbes), wherein one or more structures can be synthesized 
at scale for the purpose of treating childhood undernutrition/stunting. A key advantage of the latter 
approach is that it would allow tight control of product quality and clear characterization of dosing 
and safety.
Secondly, the effectiveness and safety of oligosaccharide supplements for the treatment of 
childhood undernutrition/stunting must be rigorously established through randomized, controlled 
clinical trials. Preclinical studies, of the type described in this chapter, will help to elucidate the 
microbial dependencies of oligosaccharide-mediated growth, determine the generalizability of the 
effects (by testing S-BMO against microbiota from a number of children exhibiting varying de-
grees of linear growth defects from various regions of a given country or countries), and inform the 
design of clinical studies. For example, study cohorts could be designed to consider only those in-
fants harboring species required for processing of milk oligosaccharides. Another approach might 
involve co-administration of required bacterial species with milk oligosaccharide supplements to 
encourage effectiveness of treatment.
An important role for preclinical studies in gnotobiotic animal models is to help define risk 
associated with various pathogenic members of the gut microbiota. Previous reports have docu-
mented expansion of enteric pathogens in mouse models accompanying the liberation of sialic 
acid from host glycans (Ng et al, 2013). This is consistent with the crossfeeding behavior observed 
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between B. fragilis and E. coli, reported in Chapter 3. Sialylated milk oligosaccharide supplemen-
tation may, therefore, carry substantial risk in the context of high enteropathogen burden. This 
information should guide de-risking strategies for the design of clinical trials using milk oligosac-
charide supplements as well as avoiding treatment of infants with high enteropathogen burdens.
In conclusion, purified preparations of milk oligosaccharides are attractive candidates for 
next generation, microbiota-directed therapeutics for the treatment of childhood stunting/under-
nutrition, and preclinical studies of the type described above will enable better understanding of 
their mechanisms of action and inform design of clinical trials to establish their safety and efficacy.
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The Long-Term Stability of the Human 
Gut Microbiota
Jeremiah J. Faith, Janaki L. Guruge, Mark Charbonneau, Sathish Subramanian, Henning Seedorf, 
Andrew L. Goodman, Jose C. Clemente, Rob Knight, Andrew C. Heath, Rudolph L. Leibel, Michael 
Rosenbaum, Jeffrey I. Gordon*
Introduction: Understanding the dynamics and stability of the human gut microbiota is important 
if its characterization is to play a role in the diagnosis, treatment, and prevention of disease. To char-
acterize stability in related and unrelated individuals and its responsiveness to physiologic change 
(weight loss), we developed a method for bacterial 16S rRNA amplicon sequencing at high depth 
with high precision. We also sequenced the genomes of anaerobic bacteria represented in culture 
collections prepared from fecal samples collected from individuals over time.
Methods: Low-error amplicon sequencing (LEA-Seq) is a quantitative method based on redundant 
sequencing of bacterial 16S rRNA genes. A dilute, barcoded, oligonucleotide primer solution is used 
to create ~150,000 linear PCR extensions of the template DNA. The labeled, bottlenecked linear 
PCR pool is amplifi ed with exponential PCR, using primers that specifi cally amplify only the linear 
PCR molecules. The exponential PCR pool is sequenced at suffi cient depth to obtain ~20× coverage. 
Multiple reads enable the generation of an error-corrected consensus sequence for each barcoded 
template molecule. LEA-Seq can be used for a variety of other applications.
Results and Discussion: LEA-Seq of fecal samples from 37 healthy U.S. adults sampled 2 to 13 
times up to 296 weeks apart revealed that they harbored 195 ± 48 bacterial strains, representing 
101 ± 27 species. On average, their individual microbiota was remarkably stable, with 60% of 
strains remaining over the course of 5 years. Stability followed a power law, which, when extrapo-
lated, suggests that most strains in an individual’s intestine are residents for decades (fi gure, panel 
A). Members of Bacteroidetes and Actinobacteria are signifi cantly more stable components than 
the population average. LEA-Seq of four individuals sampled during an 8- to 32-week period dur-
ing a calorie-restricted dietary study showed that weight stability is a signifi cantly better predictor 
of microbiota stability than the time interval between samples (fi gure, panel B). After generat-
ing clonally arrayed collections of anaerobic bacteria from frozen fecal samples collected from six 
weight-stable individuals sampled 7 to 69 weeks apart, we produced draft genome sequences for 
534 isolates representing 188 strains and 75 species. A targeted approach focused on Methanobre-
vibacter smithii isolates from two sets of twin pairs and their mothers and Bacteroides thetaiotao-
micron strains from nine donors including sister-sister and mother-daughter pairs. Strains, defi ned 
as isolates sharing >96% of their genome content, were maintained over time within an individual 
and between family members but not between unrelated individuals. Thus, early gut colonizers, 
such as those acquired from our parents and siblings, have the potential to exert their physiologic, 
metabolic, and immunologic effects for most, and perhaps all, of our lives.
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Fig. 1. Multiplex bacterial 16S rRNA gene 
sequencing using LEA-Seq; comparison with 
previous methods using mock communities 
composed of sequenced gut bacterial species.
Fig. 2. Measuring the stability of an 
individual’s fecal microbiota over time 
with LEA-Seq.
Fig. 3. Relationship among weight stability, 
time, and fecal microbiota stability.
Fig. 4. Comparison of genome stability 
in fecal bacterial isolates recovered from 
individuals over time.
Table 1. Species composition of the sequenced 
arrayed culture collections from six donors.
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confi dence bounds over 10- and 50-year extrapolations 
(inset). (B) Microbiota stability is inversely related to the 
stability of each individual’s body mass index. 
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The Long-Term Stability
of the Human Gut Microbiota
Jeremiah J. Faith,1* Janaki L. Guruge,1 Mark Charbonneau,1 Sathish Subramanian,1
Henning Seedorf,1 Andrew L. Goodman,1† Jose C. Clemente,3* Rob Knight,3,4,5
Andrew C. Heath,2 Rudolph L. Leibel,6 Michael Rosenbaum,6 Jeffrey I. Gordon1‡
A low-error 16S ribosomal RNA amplicon sequencing method, in combination with whole-genome
sequencing of >500 cultured isolates, was used to characterize bacterial strain composition
in the fecal microbiota of 37 U.S. adults sampled for up to 5 years. Microbiota stability followed
a power-law function, which when extrapolated suggests that most strains in an individual are
residents for decades. Shared strains were recovered from family members but not from unrelated
individuals. Sampling of individuals who consumed a monotonous liquid diet for up to 32 weeks
indicated that changes in strain composition were better predicted by changes in weight than by
differences in sampling interval. This combination of stability and responsiveness to physiologic
change confirms the potential of the gut microbiota as a diagnostic tool and therapeutic target.
Our growing understanding of the humangut microbiota as an indicator of andcontributor to human health suggests
that it will play important roles in the diagnosis,
treatment, and ultimately prevention of human
disease. These applications require an under-
standing of the dynamics and stability of the
microbiota over the life span of an individual.
Amplicon sequencing of the bacterial 16S rRNA
gene from fecal microbial communities (micro-
biota) has revealed that each individual harbors
a unique collection of species (1–3). Estimates
of the number of species present in an individ-
ual’s microbiota have varied greatly. Culture-
based techniques (4) indicate ~100 such species,
whereas culture-independent deep shotgun se-
quencing of fecal community DNA (5) indicates
~160 such species. Several times these numbers
of species are suggested by the results of 16S
rRNA amplicon sequencing, even after in silico
attempts to remove chimeric molecules formed in
the course of a polymerase chain reaction (PCR)
and errors introduced during sequencing (2).
These artifacts complicate tracking of individ-
ual bacterial taxa across time by inflating the set
of strains in each sample with false positives.
Shotgun sequencing of the community’s micro-
biome is another approach for defining diversity
(6), but it is difficult to associate gene sequences
with their genome of origin.
With these limitations in mind, we have de-
veloped a method for amplicon sequencing to
assay the bacterial composition of the gut micro-
biota of individuals at high depth with high
precision over time. When combined with high-
throughput methods for culturing and sequenc-
ing the genomes of anaerobic bacteria, these
results reveal that the majority of the bacterial
strains in an individual’s microbiota persist for
years, and suggest that our gut colonizers have
the potential to shape many aspects of our bi-
ological features for most and in some cases all
of our lives.
A Method for Low-Error Amplicon Sequencing
(LEA-Seq) of Bacterial 16S rRNA genes
A 16S rRNA sequencing method for assaying
the stability of an individual’s microbiota over
time would ideally retain high precision at high
sequencing depth [precision = (true positives)/
(true positives + false positives)]. Low-precision
data complicate comparison of sequences be-
tween samples, as it becomes difficult to differ-
entiate species (typically defined as isolates that
share ≥97% sequence identity in their 16S rRNA
genes) and strains (isolates of a given species with
more minor variations in their 16S rRNA gene
sequences) from sequencing errors. Standard
amplicon sequencing is limited in its precision by
the overall error rate of the sequencing method.
If sequencing depth is low, it becomes impos-
sible to determine whether a strain has dropped
out of a given individual’s microbiota or has fallen
below the limits of detection at the sampling
depth used.
In many applications it would be advanta-
geous to exchange sequencing depth for improved
sequence quality. Despite several optimizations
we developed to increase the precision of stan-
dard amplicon sequencing at shallow depths, we
found that sequencing a sample beyond 10,000
reads did not substantially increase the lower
detection limit possible at high precision (7). Ex-
changing sequence quantity for sequence quality
is inherent in shotgun genome sequencing, where
redundant sequencing of genomes at 10× to 50×
coverage enables a far lower error rate than is
attainable from single reads alone. In general, to
redundantly sequence DNA fragments, it is nec-
essary to create a finite DNA pool that is smaller
than the amount of sequencing available (i.e., cre-
ate a bottleneck) and to have a method of labeling
the molecules in the pool (8–10). To adapt these
techniques to redundantly sequence PCR ampli-
cons, the initial template DNA could be diluted
to create a bottleneck. However, this dilution
would likely need to be empirically determined
for every input sample (e.g., using quantitative
PCR), and one would still need to label each tem-
plate molecule. As an alternative, we developed
a method called low-error amplicon sequencing
(LEA-Seq).
As outlined in Fig. 1A, LEA-Seq is based on
redundant sequencing of a set of linear PCR tem-
plate extensions of 16S rRNA genes to trade
sequence quantity for quality. In this method, we
create the bottleneck with a linear PCR extension
of the template DNA with a dilute, barcoded,
oligonucleotide primer solution. Each oligo-
nucleotide is labeled with a random barcode
positioned 5′ to the universal 16S rRNA primer
sequence (Fig. 1A and fig. S1). We then amplify
the labeled, bottlenecked linear PCR pool with
exponential PCR, using primers that specifically
amplify only the linear PCR molecules. During
the exponential PCR, an index primer is added to
the amplicons with a third primer to allow pool-
ing of multiple samples in the same sequencing
run (fig. S1). This exponential PCR pool is then
sequenced at sufficient depth to redundantly se-
quence (~20× coverage) the bottlenecked linear
amplicons. The resulting sequences are sepa-
rated by sample, using the index sequence, and
the amplicon sequences within each sample are
separated by the unique barcode; the multiple
reads for each barcode allow the generation of
an error-corrected consensus sequence for the
initial template molecule. In LEA-Seq, the linear
PCR primers are diluted to a concentration that
generates ~150,000 amplicon reads at 20× cov-
erage per amplicon on an Illumina HiSeq DNA
sequencer.
To empirically test LEA-Seq against existing
16S rRNA amplicon sequencing methods, we
first generated nine in vitro “mock” communities
composed of different proportions of strains from
a 48-member collection of phylogenetically di-
verse, cultured human gut bacteria whose ge-
nomes had been characterized (7) (table S1). To
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calculate precision, we compared amplicons gen-
erated using two sequencing platforms (Illumina
MiSeq and 454 FLX instruments), targeting dif-
ferent variable (V) regions of the 16S rRNA gene
with different PCR primers. We defined a true
positive sequence as 100% identical across 100%
of its length to the 16S rRNA gene sequence(s)
in the reference genome. We calculated precision
at different abundance thresholds by including
only those sequences representing at least a min-
imal portion of the total sequencing reads (0.5%,
0.1%, 0.05%, 0.01%, or 0.005%).
Relative to the existing standard approaches,
LEA-Seq produced amplicon sequences with
higher precision at lower abundance thresholds
(Fig. 1B). For 16S rRNA sequences representing
≥ 0.01% of the reads, LEA-Seq enabled a pre-
cision of 0.83 T 0.02 (V4) and 0.63 T 0.03
(V1V2) versus 0.08 T 0.064 and 0.09 T 0.005,
respectively, for the same regions with standard
amplicon sequencing (table S2). These perform-
ance improvements are dependent on generat-
ing the consensus sequence from the redundant
amplicon reads (table S2, method “LEA-Seq
without consensus”). LEA-Seq also produced
slower saturation in performance (precision of
>0.7 for reads representing 0.001% of the total;
fig. S2 and table S2). Similar results were ob-
tained using the several different mock com-
munities [see (7) for additional details of the
analysis, includingV1V2 versus V4 comparisons].
On the basis of this assessment of its attributes,
we used LEA-Seq to quantify the stability of
the gut microbiota within individuals as a func-
tion of time and change in body mass index
(BMI) while they consumed controlled monot-
onous or free diets.
Applying LEA-Seq to Define the Stability
of the Fecal Microbiota of 37 Healthy Adults
Stability of a Microbiota Best Fits
a Power-Law Function
We used LEA-Seq to characterize the microbiota
in 175 fecal samples obtained from 37 healthy
adults residing throughout the United States;
33 of these donors were sampled 2 to 13 times
up to 296 weeks apart (1, 11) (table S3). The
remaining four individuals were sampled on
average every 16 days for up to 32 weeks while
consuming a monotonous liquid diet as part of
a controlled in-patient weight loss study (see
methods) (12–14). None of the individuals took
antibiotics for at least 2 months before sam-
pling. All fecal samples were cooled to –20°C
immediately after they were produced and then
to –80°C within 24 hours. DNA was isolated
from all samples by bead beating in phenol and
chloroform.
Using an Illumina HiSeq 2000 instrument to
sequence amplicons from the V1V2 region of bac-
terial 16S rRNA genes, we generated 108,677 T
60,212 (mean T SD) LEA-Seq reads per fecal
DNA sample. Reads were then filtered using a
minimum sequence abundance threshold cutoff
of eight reads (i.e., to detect strains present in
the fecal microbiota at an average relative abun-
dance of 0.007%). On the basis of our mock
community data, the precision at this threshold
for the V1V2 region is 0.63. We defined the
number of strains in a sample as the number of
unique amplicon sequences, and the number of
species-level operational taxonomic units (OTUs)
in the sample as the number of clusters with 97%
shared sequence identity. To correct for false pos-
itives, we multiplied the number of strains by
the precision (i.e., if we detect 100 unique se-
quences, we expect 63 of them to be true). For
individuals sampled over multiple time points,
we calculated the number of species and strains
for each sample individually and averaged them.
The results indicated that individuals in this co-
hort harbored 195 T 48 bacterial strains in their
fecal gut microbiota, representing 101 T 27 species.
To study each individual’s microbiota over
time, we took all possible pairs of samples from
the time series of each individual (table S3) and
calculated the time in weeks between the sam-
ple dates as well as the fraction of shared strains
between them, as measured by the binary Jaccard
index (an unweighted metric of community
overlap):
Jaccard indexðsample A, sample BÞ ¼
sample A ∩ sample B
sample A ∪ sample B ð1Þ
Control experiments using mock communities
(table S1) established that LEA-Seq of V1V2
16S rRNA amplicons produced highly accu-
rate estimates of the Jaccard index [correlation
between known and measured Jaccard index =
0.996; see (7)]. To characterize the stability of
an individual’s microbiota, we binned fecal sam-
ples into intervals (<3 weeks, 3 to 6 weeks, 6 to
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Fig. 1. Multiplex bacterial 16S rRNA gene sequencing using LEA-Seq;
comparison with previous methods using mock communities com-
posed of sequenced gut bacterial species. (A) Schematic of how the LEA-
Seq method is used to redundantly sequence PCR amplicons from a set of
linear PCR template extensions of bacterial 16S rDNA. This approach results
in amplicon sequences with a higher precision than standard amplicon se-
quencing at lower abundance thresholds. (B) Performance of 16S rRNA
amplicon sequencing methods assayed as the precision obtained for
different sequence abundance thresholds. Standard methods for amplicon
sequencing using the 454 pyrosequencer and the Illumina MiSeq instrument
exhibit increased precision as less abundant reads are filtered out. By redun-
dantly sequencing each amplicon with LEA-Seq, the precision of amplicon
sequencing is increased at lower abundance thresholds for both the V1V2
region of the bacterial 16S rRNA gene (compare red and green lines) and the
V4 region (compare magenta and blue lines), thereby enabling detection of
lower-abundance bacterial taxa at high precision.
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9 weeks, 9 to 12 weeks, 12 to 32 weeks, 32 to 52
weeks, 52 to 104 weeks, 104 to 156 weeks,
156 to 208 weeks, 208 to 260 weeks, and
>260 weeks) and determined the average Jaccard
index values for each bin. The results disclosed
that the bacterial composition of each individ-
ual’s fecal microbiota changed over time, with
more strains shared between shorter sampling
intervals relative to long intervals (Fig. 2A).
Nonetheless, the set of microbial strains was re-
markably stable overall, with more than 70% of
the same strains remaining after 1 year and few
additional changes occurring over the following
4 years. The stability of a microbiota best fits a
power-law function (R2 = 0.96; Fig. 2A, blue
line, and table S4); large differences in commu-
nity composition occur on shorter time scales,
whereas a stable core set of strains persists at
longer time scales.
To define the stability of a given strain as a
function of its relative abundance in the micro-
biota, we used all pairwise combinations of
fecal samples obtained from each individual to
calculate (i) the mean abundance of the strains
shared by two or more samples, and (ii) the
mean abundance of strains that were not shared
between any two samples. Strains that were
shared across two time points were roughly 3
times as abundant as those that were not shared
[0.030 T 0.013 fraction of the community ver-
sus 0.011 T 0.011 (mean T SD); P = 2.2 × 10−9
(t test); fig. S3A]. We also binned the strain
abundances for each donor using five fractional
abundance thresholds of 0.1, 0.01, 0.001, 0.0001,
and <0.0001 (e.g., bin 0.01 contains all strains
≤0.1 and >0.01) and calculated the probability
that strains in a given bin were shared between
samples. We found that the higher the fractional
abundance of a strain, the more likely the strain
was shared between samples (r = 0.96, P < 0.0087;
fig. S3B). Together, these results suggest that
the more stable components of the microbiota
are also the most abundant members.
Effects of a Monotonous Low-Calorie
Diet and Associated Weight Loss on Diversity
To explore the role of weight loss on the micro-
biota, we applied LEA-Seq to the fecal micro-
biota of four individuals sampled over the course
of an 8- to 32-week period in a three-phase study
that used different caloric intakes of a defined
monotonous liquid diet to first stabilize initial
weight, then decrease weight by 10%, and fi-
nally maintain weight at the 10% reduced level
(Fig. 2B and table S3). Daily caloric intake was
2988 T 290 kcal, 800 kcal, and 2313 T 333 kcal
for the three phases of the study, respectively
(14, 15). While on this diet, these four indi-
viduals experienced significantly reduced sta-
bility of their microbiota, as measured by the
Jaccard index (Fig. 2B). For each individual,
we found no significant correlation between time
and diversity/richness (i.e., number of strains in
a sample; minimum P = 0.17). Additionally, we
found no significant correlation between the
change in composition of the microbiota (Jaccard
index between two samples) and the change in
diversity/richness (absolute difference in the num-
ber of species or strains between two samples)
(P = 0.09 and 0.44 for strains and species, re-
spectively). Considering family-level taxonomic
bins, there were several groups whose abundance
was strongly positively or negatively correlated
with time during the weight loss period, includ-
ing Clostridiaceae [average correlation (r) across
donors during weight loss = 0.60], Coriobacte-
riaceae (r = 0.53), Bifidobacteriaceae (r = 0.55),
Enterobacteriaceae (r = 0.58), Lachnospiraceae
(r = –0.65), Oscillospiraceae (r = –0.53), and
Oxalobacteraceae (r = –0.74).
Modeling the Relationship Among Time,
Body Composition, and Microbiota Stability
Given the correlation between weight loss and
changes in the microbiota of individuals con-
suming a monotonous 800 kcal/day diet, we
took a broader view across all 37 individuals in
our study to determine whether this correlation
was due to the monotonous diet that the four in-
dividuals had consumed, or if there is a gener-
alizable and quantifiable relationship between
weight stability and microbiota stability. To ex-
plore this question, we not only calculated the
time (Dtime) and Jaccard index between all pairs
of fecal samples collected from an individual
(Fig. 2), but also the absolute value of the change
in natural logarithm of the BMI value (abbreviated
DlnBMI) between all pairs. We found a signifi-
cant negative correlation between DlnBMI and
Jaccard index (Fig. 3A; r = –0.68, P = 2.98 ×
10−73) that was even greater than that between
Dtime and Jaccard index (Fig. 3B; r = –0.42, P =
1.45 × 10−43). These relationships held when we
removed the data generated from the four in-
dividuals on the monotonous diet (DlnBMI: r =
–0.69, P = 3.27 × 10−54; Dtime: r = –0.65, P =
9.05 × 10−46).
To quantify the relationship among Dtime,
DlnBMI, and the Jaccard index between pairs of
samples (Fig. 3C), we fit the following model:
Microbiota stability ¼ b0 þ blnBMIX lnBMI þ
btimeX time ð2Þ
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Fig. 2. Measuring the stability of an individual’s fecal microbiota over
time with LEA-Seq. (A) The Jaccard index (fraction of shared strains) was
calculated between all possible pairwise combinations of fecal samples
collected from each individual, where bacterial strains were considered
shared if the nucleotide sequence was 100% identical across 100% of
the length of the V1V2 region of their 16S rRNA genes. Jaccard indices
were binned into intervals of <3 weeks, 3 to 6 weeks, 6 to 9 weeks, 9 to
12 weeks, 12 to 32 weeks, 32 to 52 weeks, 52 to 104 weeks, 104 to
156 weeks, 156 to 208 weeks, 208 to 260 weeks, and >260 weeks apart
(mean T SE for each bin is shown). The decay in the Jaccard index as a
function of time between two samples best fits a power law (blue line). (B)
Four individuals losing 10% of their body weight in the study involving
consumption of a monotonous low-calorie liquid diet (magenta) had signif-
icantly less stable microbiota than the mean of the 33 remaining individuals
(blue). Means T SE for the Jaccard index are plotted. (C) At the phylum level,
Bacteroidetes (blue) and Actinobacteria (red) were more stable compo-
nents of the microbiota than Proteobacteria and Firmicutes (hypergeometric
distribution).
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where microbiota stability is the Jaccard index
between samples, XlnBMI is the change in lnBMI
between any two samples collected from the
individual (DlnBMI), Xtime is the time between
the two samples being compared (Dtime), b0 is
the estimated parameter for the intercept, and
blnBMI and btime are the linear regression esti-
mated parameters for DlnBMI and Dtime, re-
spectively. Remarkably, this model explained
46% of the variance in the stability of the micro-
biota (Jaccard index) within the individuals over
time (R2 = 0.46, P = 1.94 × 10−72; when the
monotonous dieters were excluded, R2 = 0.51, P =
1.40 × 10−58). Once again, the weight stability
of an individual [DlnBMI; analysis of variance
(ANOVA), P = 1.18 × 10−51] was a better pre-
dictor of fecal microbiota stability than the time
between samples (Dtime; ANOVA, P = 0.09),
with Dtime only being a significant predictor of
stability when the monotonous dieters were
excluded (ANOVA, P = 2.82 × 10−7). Together,
these relationships among time, BMI, and the
stability of an individual’s microbiota highlight
the role that longitudinal surveys of a microbiota
could play in health diagnostics.
Sequenced Collections of Fecal Bacteria
Obtained from Individuals over Time
As in previous studies (1, 16–19), we found that
each individual’s microbiota at a given time
point was most similar to their own at other time
points (Jaccard index, 0.82 T 0.022), followed
by their family members (Jaccard index, 0.38 T
0.020), and then unrelated individuals (Jaccard
index, 0.30 T 0.005). The Jaccard index estimates
with LEA-Seq suggest that on average any two
unrelated individuals share ~30% of the strains
in their microbiota. However, it is possible that
unrelated individuals on average share no strains
in their microbiota, and that this 30% represents
the lower resolving limit of 16S rRNA amplicon
sequencing of the targeted variable region (V1V2)
and currently available maximum read lengths
on the Illumina HiSeq 2000 instrument (paired-
end, 101 base pairs).
Whole-genome alignments between bacteria
isolated and sequenced from different samples
provide many orders of magnitude of additional
resolving power to determine which strains (now
defined at the level of whole-genome sequence
identity rather than 16S rRNA identity) remain
in an individual’s microbiota over time, or reside
in two unrelated individuals. Isolation and se-
quencing of extensive collections of organisms
from the human gut microbiota (20) can pro-
vide a practical method to look at the plasticity
and evolution of the gene content of microbial
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Fig. 3. Relationship among weight stability,
time, and fecal microbiota stability. (A) The
microbiota sampled from a given individual
during periods of weight loss or gain has de-
creased stability (lower Jaccard index). (B) The
Jaccard index decreased as the time between
samples increased (see also Fig. 2). (C) Across
samples from 37 individuals, a linear model of
microbiota stability as a function of changes in
lnBMI and changes in time explained 46% of
the variation in the stability of the microbiota
(Jaccard index). Note that changes in lnBMI
explained more of the variation in microbiota
stability than did the passage of time. Color
changes correspond to the Jaccard index values
in the color scale at right. Blue dots show the
change in Jaccard index, time, and lnBMI be-
tween two samples from a given individual.
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strains harbored in individuals’ intestines over
time. Therefore, adapting a high-throughput meth-
od we had developed for generating clonally
arrayed collections of anaerobic bacteria in mul-
tiwell format from frozen fecal samples (20), we
produced draft genome sequences for 444 bac-
terial isolates recovered from the frozen fecal
microbiota of five donors who had been sam-
pled across periods from 7 to 69 weeks apart (n =
1 to 4 time points per donor; 11 total samples;
mean coverage per microbial genome = 118×;
see tables S5 and S6) (7). These genomes span
a broad phylogenetic range within the four dom-
inant bacterial phyla that constitute the human
gut microbiota (Bacteroidetes, Firmicutes, Proteo-
bacteria, and Actinobacteria; table S6).
To look for changes in bacterial genome con-
tent across time in each individual, we performed
whole-genome alignment with nucmer (21) and
calculated the fraction of DNA sequence aligned
between each pair of genomes [coverage score =
(Xaln + Yaln)/(X + Y ), where X and Y are the
lengths of genome X and Y, respectively, and Xaln
and Yaln are the number of aligned bases of ge-
nomes X and Y, respectively] (7, 22). We found
that the shared genome content between isolates
from unrelated individuals was broadly distrib-
uted for taxa from the same genus (coverage
score = 0.30 T 0.20) or species (0.77 T 0.12), with
a maximum of 0.956 (Fig. 4A, blue; fig. S4). We
then compared the shared genome content be-
tween isolates within each fecal sample (i.e., self-
versus-self at a single time point) and found
isolates that shared a very high proportion of
their content (0.965 to 0.999) (Fig. 4A, red).
Remarkably, we found the same high propor-
tion of shared genome content between isolates
from a given donor between different time points
(i.e., self-versus-self over time; Fig. 4A, green),
which suggests that the same strains of bacteria
persisted in these individuals over the course of
the sampling period.
Defining replicate bacterial strains as those
with a coverage score of >0.96 and species as
those with a coverage score of >0.5 (fig. S4), we
subsequently clustered the genome isolates by
sample and by individual (table S5); this effort
yielded a total of 165 strains and 69 species
across the five donors (Table 1). Across the four
donors with multiple time points, on average
36% of an individual’s bacterial strains were
isolated from multiple time points. This fraction
of shared bacterial strains across time at the
level of the genome is lower than that measured
by LEA-Seq; however, this likely reflects the
increased sampling depth and culture indepen-
dence of LEA-Seq [detecting isolates at depths
of 1:10,000 to 1:100,000 (0.01 to 0.001%) com-
pared with 0.14 to 0.06% for high-throughput
culturing]. For the most deeply sampled indi-
vidual (F3T1 in table S3), where isolates were
sequenced from four samples taken over the
course of ~16 months, more than 60% of the
strains were isolated from multiple samples.
Stability Viewed from the Perspective
of Phylum-Level Membership
When we assigned phylum-level taxonomy to
all LEA-Seq 16S rRNA amplicons from each
of the 37 individuals in our study (23), we found
that members of the Bacteroidetes and Actino-
bacteria were significantly more stable compo-
nents of the microbiota relative to the population
average (hypergeometric distribution comparing
the total number of shared/not shared strains
within a given phylum for all samples versus the
total number of shared/not shared strains across
all phyla, except the phylum of interest; P =
7.54 × 10−28 and 0.0068, respectively), whereas
the Firmicutes and Proteobacteria were signifi-
cantly less stable (Fig. 2C; P = 1.83 × 10−11 and
0.0015, respectively). The cultured bacterial strains
manifested similar trends for the Bacteroidetes
and Firmicutes, where 52% and 21%, respec-
tively, of the strains were isolated and sequenced
across multiple time points (table S7), thus dem-
onstrating at a whole-genome level the strain
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Fig. 4. Comparison of genome stability in fecal bacterial isolates
recovered from individuals over time. The fraction of aligned nucleo-
tides between any two microbial genomes was calculated using the cov-
erage score (see text). (A) Histogram of the fraction of aligned genome
content between all sequenced bacterial isolates from unrelated indi-
viduals (blue; only coverage scores ≥ 0.01 are shown) shows that the
alignable genome content never exceeded 96% (dashed line). However,
highly conserved strains with coverage scores exceeding this threshold
were readily detected in the microbiota of individuals at a single time point
(red) or between samples from an individual taken up to 15 months apart
(green). Counts denote the number of times a sample fell into each cov-
erage score bin. (B and C) Sequencing the genomes of M. smithii strains (B)
and B. thetaiotaomicron strains (C) revealed that no two isolates from
unrelated individuals had more than 96% shared (alignable) gene content
(blue), whereas highly conserved strains above this threshold were found
between isolates obtained from a single individual’s fecal microbiota at a
single time point (red), as well as from isolates taken from different mem-
bers of the same family (brown).
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stability initially identified when only the 16S
rRNA gene was targeted for analysis.
Strains Shared Between Members
of Human Families
The power-law response of the Jaccard index
as a function of the sample collection interval
makes it possible to extrapolate beyond the sam-
pling time frame of the current study and sug-
gests that the majority of strains in the microbiota
represent a stable core that persists in an in-
dividual’s intestine for his or her entire adult
life, and could represent strains acquired during
childhood from parents or siblings (fig. S5).
Therefore, we used LEA-Seq to measure the
fraction of shared strains between family mem-
bers (sister-sister or mother-daughter). As in pre-
vious studies (1), we found the microbiota of
related individuals was more similar than unre-
lated ones, with a significantly larger proportion
of shared V1V2 16S rRNA sequences [Jaccard
index = 0.38 T 0.020 (related), 0.30 T 0.005 (un-
related); P = 0.00053].
To determine whether this increased simi-
larity between family members manifested itself
at the level of their gut microbial genome se-
quences, we used a targeted approach to look at
genome content differences in (i) two families
using previously sequenced Methanobrevibacter
smithii isolates (24) from two sets of twin pairs
and their mothers (six total donors, 19 genomes;
table S3), and (ii) five families where 26 Bacteroides
thetaiotaomicron strains were isolated with a
species-specific monoclonal antibody (7, 25) from
nine donors including sister-sister and mother-
daughter pairs (all isolates were from a single
sample from each donor; table S3). M. smithii, a
methanogen, is the dominant archaeon in the
human gut microbiota and facilitates fermenta-
tion of polysaccharides by saccharolytic bacteria
such as B. thetaiotaomicron by virtue of its abil-
ity to remove hydrogen (24). As with our untar-
geted large-scale genome sequencing of personal
bacterial culture collections described above, we
found that unrelated individuals had no pair of
isolates of either species that shared >96% of their
genome content. However, within an individual
we once again found replicate isolates of the same
strain (Fig. 4, B and C, blue and red). Strikingly,
we also found replicate strains of M. smithii or
B. thetaiotaomicron shared across family mem-
bers (Fig. 4, B and C, brown; table S3).
In contrast with the results obtained using
this taxon-targeted whole-genome sequencing ap-
proach, our untargeted sequencing of the clonally
arrayed personal bacterial culture collections
had only involved two related individuals (fe-
male dizygotic co-twins 1 and 2 from family 60;
F60T1 and F60T2, table S3) and had revealed
no strains with >96% of their genomes aligned.
Therefore, we isolated and sequenced an addi-
tional 89 genomes from two time points of the
dizygotic twin sister (F61T2) of subject F61T1
(yielding a total of 188 strains and 75 species
across the six donors). As with the previous do-
Table 1. Species composition of the sequenced arrayed culture collections from six donors.
Alternative names for species are in parentheses.
Species ID Species
Donor
F3T1 F58T1 F60T1 F60T2 F61T1 F61T2
1 Alistipes indistinctus + +
2 Anaerococcus vaginalis (A. hydrogenalis) + + + +
3 Anaerofustis stercorihominis + +
4 Anaerofustis stercorihominis +
5 Bacteroides +
6 Bacteroides caccae + + +
7 Bacteroides finegoldii + +
8 Bacteroides fragilis + +
9 Bacteroides intestinalis (B. cellulosilyticus) + + + +
10 Bacteroides massiliensis + +
11 Bacteroides ovatus + + + +
12 Bacteroides salyersiae +
13 Bacteroides thetaiotaomicron (B. faecis) + + + +
14 Bacteroides uniformis (B. acidifaciens) + + + +
15 Bacteroides vulgatus (B. dorei) + + + + + +
16 Barnesiella intestinihominis +
17 Bifidobacterium adolescentis + +
18 Bifidobacterium bifidum +
19 Bifidobacterium longum + + +
20 Bifidobacterium pseudocatenulatum + +
21 Blautia +
22 Blautia schinkii + +
23 Butyricimonas virosa + + + +
24 Clostridiales +
25 Clostridiales +
26 Clostridiales +
27 Clostridiales +
28 Clostridiales +
29 Clostridiales +
30 Clostridiales +
31 Clostridium + + +
32 Clostridium +
33 Clostridium bolteae +
34 Clostridium hylemonae +
35 Clostridium leptum + +
36 Clostridium scindens + +
37 Clostridium scindens +
38 Collinsella +
39 Collinsella aerofaciens + + +
40 Coprococcus comes + + +
41 Dorea formicigenerans + + + +
42 Dorea longicatena + + + +
43 Dorea longicatena +
44 Eggerthella lenta (Subdoligranulum variabile) +
45 Escherichia coli + + + + +
46 Eubacterium biforme +
47 Eubacterium callanderi +
48 Eubacterium contortum +
49 Eubacterium eligens +
50 Finegoldia magna (Dialister invisus) +
51 Lactobacillus +
52 Lactobacillus casei +
53 Megasphaera elsdenii +
54 Odoribacter splanchnicus + + +
55 Parabacteroides distasonis + + + + +
56 Parabacteroides goldsteinii + +
57 Parabacteroides merdae + +
58 Peptoniphilus harei + +
59 Roseburia intestinalis +
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nors, we were able to isolate numerous strains
shared across the two time points (8 of 25 =
32%). In addition, we were able to isolate two
strains (B. thetaiotaomicron and Escherichia
coli) in both of the sisters, showing that even
nontargeted genome isolation and sequencing
can retrieve the same strain across family mem-
bers. We did not explicitly sample members of
our cohort of females during significant physi-
ological transitions such as menarche and meno-
pause. However, the presence of the same bacterial
strain in mothers and their adult daughters who
had progressed through one or both of these life-
cycle milestones suggests that components of the
microbiota are retained during these events.
Prospectus
The objects we touch and consume during the
course of our lives are covered with diverse
microbial life. Despite this, LEA-Seq revealed
that on average 60% of the approximately 200
microbial strains harbored in each adult’s in-
testine were retained in their host over the course
of a 5-year sampling period. Our results are sup-
ported by a microarray-based profiling of fecal
microbiota collected from three males and two
females over ~8 years (19) but differ from those
of a similar analysis using standard 16S rRNA
amplicon sequencing, which found high variabil-
ity in microbiota composition in two individuals
sampled for up to 15 months (26). This differ-
ence likely reflects the fact that the sequenc-
ing depth and precision limitations of standard
16S rRNA amplicon sequencing are overcome
to some extent with microarrays where ampli-
cons are mapped and hybridized to a finite pool
of target sequences (i.e., sacrificing resolution
for precision). The differences could also be due
to true differences in the stabilities in microbiota
of the individuals, as both studies surveyed only
a small number of individuals. Our findings are
also supported by a recent report that mapped
deep shotgun sequencing data sets of the fecal
microbiome to a set of reference bacterial ge-
nomes (6) and found that the gut communities
of these individuals were more similar to each
other at the microbiome level than to unrelated
individuals (average maximum time between
samples = 32 weeks with two individuals sam-
pled over a period of >1 year). Applying LEA-
Seq to longitudinal surveys of the fecal microbiota
of 37 twins sampled for up to 5 years allowed
us to show that the stability of an individual’s
microbiota follows a power-law function. Using
this function, we could extrapolate the stability
of the microbiota over decades. The resolution
and accuracy of these predictions should improve
as advances in sequencing chemistry enable longer
regions of 16S rRNA genes to be characterized.
LEA-Seq itself can be generalized to any appli-
cation that requires deep amplicon sequencing
with high precision (e.g., the VDJ regions of im-
munoglobulin and T cell receptor genes, or tar-
geted searches for variants in candidate or known
disease-producing genes).
Our study also illustrates how a highly per-
sonalized analysis of the gut community at
strain-level microbial genome resolution can be
conducted using collections of cultured bacteria
(or archaea) generated from frozen fecal sam-
ples collected over time from a given subject.
This strain-level analysis can be part of a broad
phylogenetic survey, or it can target a particular
species.
The stability of the microbiota that we docu-
ment in healthy individuals has important im-
plications for future use of the microbiota (and
microbiome) as a diagnostic tool as well as a
therapeutic target for individuals of various ages.
Our findings suggest that obtaining a routine
fecal sample as part of a yearly physical exam-
ination designed to promote disease prevention
would be sufficient to monitor changes in the
composition and stability of an individual’s fecal
microbiota. For example, in the case of inflam-
matory bowel diseases, the concordance for
Crohn’s disease and ulcerative colitis among
monozygotic twin pairs is only 38% and 15%,
respectively (27). Our results suggest that these
twins likely share identifiable unique subsets of
their microbiota that represent long-term envi-
ronmental exposures for their immune systems
that should be considered when trying to predict
disease risk, or infer which species or strains
may have a causal role in disease initiation, pro-
gression, relapse, and treatment responses. More-
over, the effects of travel, changes in diet, weight
gain and loss, diarrheal disease, antibiotics, im-
munosuppressive therapy, or clinical trials de-
signed to deliberately manipulate the microbiota
(e.g., through administration of existing or new
prebiotics, probiotics, synbiotics, antibiotics, or
transplantation of microbiota from healthy indi-
viduals to those with various diseases attributed
to a dysfunctional microbiota) can be more ac-
curately quantified by applying the methods we
describe. Finally, the stability we document high-
lights the impact of early colonization events on
our microbiota in later life; earlier colonizers, such
as those acquired from our parents and siblings,
have the potential to provide their metabolic
products and exert their immunologic effects for
our entire lives.
Methods
Diet Studies
Four obese (BMI > 30 kg/m2) female subjects
with a mean (T SD) age of 26 T 3 years were
admitted to the General Clinical Research Center
at Columbia University Medical Center and re-
mained as in-patients throughout the study. The
protocol for recruitment and for the weight loss
study was approved by the Institutional Review
Board of New York Presbyterian Medical Center
and is consistent with guiding principles for re-
search involving humans. Written informed con-
sent was obtained from all subjects. The diet
protocol has been described in detail (12, 13).
Briefly, subjects were fed a liquid-formula diet
with 40% of energy as fat (corn oil), 45% as car-
bohydrate (glucose polymer), and 15% as protein
(casein hydrolysate). Diet composition but not
quantity was constant throughout the study. The
diet had a caloric density of 1.25 digestible kcal
of energy per gram and was supplemented with
vitamins and minerals in quantities sufficient to
maintain a stable weight, defined as an average
daily weight variation of <10 g/day for ≥2 weeks.
This weight plateau is designated as Wtinitial. The
four individuals in this study consumed 2600 to
3300 kcal/day of the diet to maintain Wtinitial.
After a brief period at Wtinitial, subjects were
provided 800 kcal/day of the same liquid-
formula diet until they had lost ~10% of Wtinitial.
The duration of the weight loss phase ranged
from 36 to 62 days (table S3). Once 10% weight
loss had been achieved, intake was adjusted
upward until subjects were again weight-stable.
Weight maintenance calories were dispropor-
tionately reduced (~22%) below those required to
Species
ID
Species
Donor
F3-
T1
F58-
T1
F60-
T1
F60-
T2
F61-
T1
F61-
T2
60 Ruminococcaceae +
61 Ruminococcus (Lachnospiraceae) + +
62 Ruminococcus albus +
63 Ruminococcus bromii + +
64 Ruminococcus gauvreauii +
65 Ruminococcus gnavus + + +
66 Ruminococcus obeum +
67 Ruminococcus sp. CCUG 37327 A + +
68 Ruminococcus sp. DJF VR70k1 +
69 Ruminococcus torques + +
70 Streptococcus +
71 Streptococcus gordonii +
72 Streptococcus parasanguinis +
73 Streptococcus thermophilus +
74 Subdoligranulum variabile + + + + +
75 Veillonella parvula +
Species ID Species
Donor
F3T1 F58T1 F60 F60T2 F61T1 F61T2
Table 1. (continued).
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maintain initial weight and ranged from 2050 to
2800 kcal/day for the four individuals. Subject
F72 also received triiodothyronine (25 mg/day)
during this second weight-stable period (table
S3). Fecal samples were obtained throughout
the study (table S3) and frozen at –80°C until
processed for DNA extraction (1).
Twin Participants
Twins were selected from a general population
cohort of female like-sex twin pairs, born in
Missouri to Missouri-resident parents between
1 July 1975 and 30 June 1985, and first assessed
at median age 15 with multiple waves of follow-
up (28, 29). Selected twins were drawn from (i)
a study, which included biological mothers where
available, contrasting stably concordant lean twin
pairs (both twins had BMIs in the range 18.5 to
24.9 by self-report at all completed assessments)
and concordant obese twin pairs (both twins had
BMIs ≥ 30, but with pairs prioritized where at
least one twin had BMI > 35, to maximize sep-
aration from the concordant lean pairs) (1); (ii) a
small-scale study of concordant lean monozy-
gotic twin pairs contrasting free diet with free
diet supplemented by twice-daily consumption
of a fermented milk product (11); and (iii) an
ongoing study of twin pairs selected for BMI
discordance (either discordant lean/obese or
quantitatively discordant).
Other Protocols
See (7) for procedures for (i) creating mock bac-
terial communities to benchmark standard meth-
ods for 16S rRNA sequencing and LEA-Seq, (ii)
generating robotically arrayed personal bacterial
culture collections from human fecal samples,
(iii) isolating B. thetaiotaomicron strains from
fecal samples collected over time from individ-
uals and family members, and (iv) sequencing
microbial genomes.
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